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Summary 
With the widespread installation of biomedical cyclotrons and positron 
emission tomography (PET) scanners around the world, scientists are 
increasingly recognizing PET as an accessible and valuable tool for the 
investigation of physiological or biological challenges in the pre-clinical 
and clinical setups. The continuous progress of nuclear imaging techniques 
demands for the development and implementation of efficient, clean and 
sustainable synthetic routes to manufacture novel radiotracers. This task is 
especially challenging for the synthesis of radiotracers labeled with short-
lived β+ emitters, which are extremely valuable since they substantially 
reduce the radiation burden on the subject under investigation. Hence, 
extremely rapid and selective synthetic schemes must be designed to 
access radiotracers radiolabeled with short half-lived positron emitters. 
Biocatalysis, although surprisingly underused in radiochemistry, 
constitutes an attractive alternative to conventional chemistry. Enzymes 
present an exquisite chemical selectivity and high turnover numbers; they 
also evolved to work under physiological conditions, where the 
concentration of the metabolites is tightly regulated and are rarely in 
excess. Furthermore, enzymes are also the most sophisticated chiral 
catalysts yielding enantiopure products in most of the cases. Hence, the 
use of enzymes can now be seen as an innovative approach to radiolabel 
biologically active molecules with short half-lived positron emitters, for 
their use in positron emission tomography. Although years 70´s and 80´s 
are considered the golden era of biocatalysis in radiochemistry, advances 
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in enzyme engineering during the last decade have significantly enhanced 
the toolbox of enzymes available for chemical reactions, which may find 
application in the context of radiochemistry. The biocatalytic approaches 
for the synthesis of PET radiotracers using Nitrogen-13, Carbon-11 and 
Fluorine-18 that have been reported during the last four decades are 
reviewed in Chapter 2.  
The main target of this PhD thesis was the development of new bio-
strategies in the context of nitrogen-13 radiochemistry, and mainly the 
preparation of 13N-labeled precursors and their incorporation in biological 
molecules with interest in preclinical application.  
In Chapter 4, the reduction of [13N]NO3- to [13N]NO2- using a 
heterogeneous biocatalyst is described. For the design and fabrication of a 
suitable heterogeneous biocatalyst, a eukaryotic nitrate reductase from 
Aspergillus niger was immobilized on different carriers. Optimal 
immobilization and recovered activities were obtained when this enzyme 
was immobilized on porous agarose beads activated with a positively 
charged tertiary amino group. This immobilized preparation was 12-fold 
more thermostable than the soluble enzyme and could be re-used in up to 
7 reaction cycles, preserving its initial activity. A pure preparation of 
[13N]NO2- was obtained after 4 min reaction at room temperature and it 
was successfully applied in a two-step chemo-enzymatic radiosynthesis of 
S-[13N]nitrosoglutathione. 
A one-pot, enzymatic and non-carrier-added synthesis of a variety of 13N-
labeled amino acids (L-[13N]alanine, [13N]glycine, and L-[13N]serine) is 
described in Chapter 5. To that aim, an L-alanine dehydrogenase from 
Bacillus subtilis was used, together with nicotinamide adenine 
dinucleotide (NADH) as the redox cofactor, and labeled ammonia as the 
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amine source. Moreover, the addition of formate dehydrogenase from 
Candida boidinii in the same reaction vessel allowed the in situ 
regeneration of NADH during the radiochemical synthesis of the amino 
acids. The enzymatically labeled amino acids have been used to analyze 
their in vivo biodistribution in healthy mice. Likewise, the capacity to 
selectively accumulate in the tumor has been assessed in a prostate cancer 
mouse model, by using dynamic PET-CT imaging.  
Lastly, Chapter 6 describes the immobilization of L-Alanine 
dehydrogenase from Bacillus subtillis on agarose microbeads, activated 
with glyoxyl groups (aliphatic aldehydes) and two other carriers. These 
immobilized enzyme preparations were extensively characterized towards 
temperature, pH and kinetic parameters. Finally, the optimal 
heterogeneous biocatalyst was applied in the synthesis of L-[13N]alanine 
using pyruvate and labeled ammonia as the substrates. 
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Resumen 
La instalación generalizada de ciclotrones biomédicos a nivel mundial ha 
suscitado un gran interés entre la comunidad científica, que ve la 
tomografía por emisión de positrones (PET, del inglés Positron Emission 
Tomography) como una herramienta accesible para abordar de manera no 
invasiva, longitudinal y traslacional determinados problemas biológicos, 
fisiológicos y/o médicos inabordables mediante otras técnicas. Sin 
embargo, la utilización de la PET exige el desarrollo e implementación de 
rutas sintéticas que permitan la preparación eficiente y robusta de 
radiotrazadores marcados con isótopos emisores de positrones. Esto 
resulta especialmente complicado en el caso de la síntesis de 
radiotrazadores marcados con emisores de positrones de vida media corta. 
Dichos emisores de positrones resultan extremadamente valiosos ya que 
permiten reducir de manera significativa la dosis de radiación efectiva 
recibida por el sujeto investigado. 
La biocatálisis, aunque ha sido sorprendentemente infrautilizada en el 
contexto de la radioquímica, constituye una alternativa atractiva a la 
química convencional. Las enzimas presentan una excelente selectividad 
química y una gran capacidad catalítica. Además, han evolucionado de 
manera natural para trabajar en condiciones fisiológicas, donde la 
concentración de los metabolitos está fuertemente regulada y raramente en 
exceso. Las enzimas son también los catalizadores quirales más 
sofisticados que se conocen ya que son capaces de producir productos 
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enantioméricamente puros incluso en esquemas de reacción muy 
complejos. 
En este contexto, la biocatálisis ha emergido como una estrategia 
altamente innovadora para marcar moléculas biológicamente activas con 
emisores de positrones de vida media corta, con el fin último de utilizar 
dichas moléculas marcadas (radiotrazadores) en estudios de imagen 
mediante PET.  
La edad de oro de la aplicación de la biocatálisis en radioquímica fueron 
las décadas de los 70 y 80. Sin embargo, los avances en ingeniería 
enzimática llevados a cabo durante la última década han mejorado 
significativamente la cantidad, calidad y versatilidad de las enzimas 
disponibles. Este hecho ha abierto nuevas perspectivas en la utilización de 
la catálisis enzimática en el contexto de la radioquímica.  
El primer objetivo de la presente tesis doctoral ha sido efectuar una 
revisión exhaustiva de los diferentes enfoques biocatalíticos utilizados 
para la preparación de radiotrazadores marcados con isótopos emisores de 
positrones. Todos los trabajos reportados en las últimas cuatro décadas en 
lo que se refiere a la síntesis de radiotrazadores PET utilizando Nitrógeno-
13, Carbono-11 y Flúor-18, así como las perspectivas de futuro que ofrece 
esta tecnología se describen y discuten en el Capítulo 2 del presente 
documento.  
Una vez superada la fase de documentación, se definió el principal 
objetivo de esta tesis doctoral, que consistía en el desarrollo de nuevas 
estrategias basadas en biocatálisis en el contexto de la radioquímica del 
nitrógeno-13, con el objetivo último de preparar precursores marcados con 
13N y su incorporación en moléculas biológicas con interés en la aplicación 
Resumen 
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preclínica, esto es, en la realización de estudios de imagen en animales de 
experimentación. 
El primer objetivo experimental concreto de la tesis doctoral fue abordar 
el desarrollo de un proceso enzimático para la reducción de [13N]NO3- a 
[13N]NO2-. Cabe destacar que la irradiación directa de agua ultrapura con 
protones acelerados permite la formación eficiente de nitrógeno-13 
mediante la reacción nuclear 16O(p,α)13N, siendo la especie química 
formada mayoritariamente el anión [13N]NO3-. Dicha especie no tiene gran 
aplicación como sintón radiactivo; sin embargo, su reducción a [13N]NO2- 
permite abordar la preparación de una gran variedad de moléculas 
marcadas, incluyendo nitrosaminas, nitrosotioles y azoderivados, entre 
otros. Hasta la fecha, la reducción mencionada arriba se llevaba a cabo de 
manera eficiente en una columna de cadmio. Sin embargo, la utilización 
de este metal podría conllevar problemas asociados a su toxicidad en el 
caso de pretenderse la aplicación en el entorno clínico, y se estimó muy 
oportuno desarrollar un proceso enzimático que permitiera evitar la 
utilización de cadmio. La consecución de este objetivo se planteó mediante 
la utilización de un biocatalizador heterogéneo. Para el diseño del 
biocatalizador heterogéneo se inmovilizó una nitrato reductasa eucariota 
de Aspergillus niger en diferentes soportes porosos. El rendimiento óptimo 
de inmovilización y actividades enzimáticas recuperadas se obtuvieron 
cuando esta enzima se inmovilizó en unidades porosas de agarosa, 
activadas con un grupo amino terciario cargado positivamente. Este 
soporte presentó los grupos funcionales óptimos en términos de densidad 
y reactividad para lograr una mayor actividad enzimática después del 
proceso de inmovilización. Con el estudio de los parámetros cinéticos 
aparentes de la nitrato reductasa inmovilizada en este tipo de soportes, 
pudimos observar que la inmovilización daba lugar a un aumento de la Km 
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aparente para el NADPH, este aumento parece ser debido a una serie de 
problemas difusionales que presenta el cofactor a la hora de alcanzar los 
centros activos de las enzimas inmovilizadas en el microambiente poroso.  
Además, esta preparación inmovilizada fue 12 veces más termoestable que 
la enzima soluble y pudo reutilizarse hasta 7 ciclos de reacción, 
preservando su actividad inicial. En condiciones óptimas (4 minutos, 
temperatura ambiente; estas condiciones son comparables a las utilizadas 
anteriormente en el proceso de reducción en presencia de cadmio), pudo 
obtenerse [13N]NO2- puro que posteriormente pudo utilizarse para abordar 
la síntesis de S-[13N]nitrosoglutationa (Figura R.1). De la realización de 
este trabajo resultó la primera de las publicaciones asociadas a la presente 
tesis doctoral (da Silva, E. S. et al., Catalysis Science & Technology, 2015, 
5, 2705-2713).  
 
 
Figura R.1. Síntesis de S-[13N]nitrosoglutathiona ([13N]GSNO) a partir de 
[13N]NO3- producido en el ciclotrón. 
 
Una vez desarrollado el método de reducción descrito en el capítulo 4, se 
planteó la posibilidad de emplear métodos biocatalíticos para la 
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preparación de compuestos biológicamente activos, concretamente 
aminoácidos. Para la selección de los aminoácidos a marcar se contó con 
la colaboración del profesor Arkaitz Carracedo, de CIC bioGUNE, que 
dispone de un modelo animal de cáncer de próstata y dedica parte de su 
investigación al estudio de aberraciones metabólicas en estos tumores. En 
este contexto, en el Capítulo 5 de la presente tesis doctoral se presenta la 
síntesis enzimática, en un solo paso y sin carrier añadido de diferentes 
aminoácidos marcados con nitrógeno-13, concretamente L-[13N]alanina, 
[13N]glicina y L-[13N]serina (Figura R.2a). Para ello, se usó una L-alanina 
deshidrogenase de Bacillus subtilis NADH–dependiente. Esta enzima es 
capaz de llevar a cabo la aminación reductiva de -cetoácidos mediante el 
uso de [13N]amoníaco como fuente de grupos amino. Sin embargo, esta 
enzima no fue capaz de sintetizar L-aminoácidos muy voluminosos como 
la L-fenilalanina y al L-norvalina, debido a que presenta unos valores de 
Km para el amonio demasiado altos en la síntesis de los aminoácidos 
voluminosos anteriormente descritos. Tras optimización de las 
condiciones experimentales (cantidad de catalizador, pH, etc) pudo 
conseguirse la preparación de los tres aminoácidos con rendimiento 
radioquímico suficiente para abordar estudios en los modelos animales 
proporcionados por el Prof. Carracedo. Además, el acoplamiento de este 
enzima con una formiato deshidrogenasa de Candida boidinii en el mismo 
medio de reacción permitió la regeneración in situ de NADH durante la 
radiosíntesis de los aminoácidos (Figura R.2b), de modo que pudo 
disminuirse hasta 50 veces la concentración del cofactor sin comprometer 
los rendimientos radioquímicos de la reacción. 
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Figura R.2. (a) preparación enzimática de L-[13N]alanina, [13N]glycina, y L-
[13N]serina utilizando L-alanina dehidrogenasa (L-AlaDH) obtenida de Bacillus 
subtilis; (b) Preparación de L-[13N]alanina con regeneración del cofactor NADH. 
 
Los aminoácidos marcados enzimáticamente se utilizaron en primer lugar 
para estudiar su biodistribución in vivo en ratones sanos (Figura R.3). 
Todos los aminoácidos mostraron acumulación en la zona abdominal, 
hecho que ya había sido observado para otros aminoácidos en estudios 
anteriores reportados en la literatura. Dos de los aminoácidos (L-
[13N]alanina y [13N]glycina) mostraron poca eliminación por orina, 
convirtiéndose en potenciales trazadores para la visualización in vivo de 
los tumores de próstata.  
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Figura R.3. Imágenes PET-CT representativas obtenidas a diferentes tiempos 
tras administración intravenosa de L-[13N]alanina en ratón. Se muestran 
proyecciones coronales corregistradas con cortes representativos de imágenes 
CT; 0-30 s (a); 31-70 s (b); 71-230 s (c); 231-740 s (d); 741-3020 s (e). 
 
Los estudios efectuados en animales con tumor mostraron que los 
aminoácidos se acumulaban selectivamente en la próstata, y que dicha 
acumulación aumentaba en presencia de tumor (Figura R4). Sin embargo, 
es necesario efectuar estudios más exhaustivos y a diferentes tiempos tras 
aparición de los tumores para obtener resultados más concluyentes. Los 
resultados derivados del capítulo 5 se recogen en la segunda publicación 
asociada a esta tesis doctoral (da Silva, E. S. et al., Chemistry – A 
European Journal, 2016, 22, 13619-13626). 
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Figure R.4. Imágenes PET-CT (proyecciones sagitales) de animales control y 
animales con tumor, obtenidas tras administración de los aminoácidos marcados 
con nitrógeno-13. La posición de la vejiga y de la próstata se indican con una 
fleche blanca y roja, respectivamente. Como puede observarse, tan solo el 
aminoácido L-[13N]serina muestra eliminación significativa por orina.  
 
El trabajo desarrollado en el capítulo 5 implicaba la utilización de enzimas 
en disolución. Sin embargo, con el fin de evitar la presencia de enzima en 
la disolución final, así como para posibilitar la realización de reacciones 
en flujo, se consideró conveniente explorar la posibilidad de inmovilizar 
las enzimas. Así pues, en el Capítulo 6 se describe la inmovilización de la 
enzima L-alanina deshidrogenase de Bacillus subtillis en microesferas de 
agarosa porosa, activadas con grupos de glioxal (aldehídos alifáticos), 
además de otros dos soportes. Estas preparaciones enzimáticas 
inmovilizadas se caracterizaron en términos de temperatura, pH y 
Resumen 
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parámetros cinéticos. En base a estudios físico-químicos de la superficie 
de esta enzima, se propouso una orientación óptima a través de la cuál la 
enzima era inmovilizada en soportes activados con grupos aldehídos, 
dando lugar a enzimas inmovilizadas con una gran estabilidad y una 
actividad suficiente para su aplicación en procesos biotecnológicos. 
Finalmente, se aplicó el biocatalizador heterogéneo óptimo para abordar 
la síntesis de L-[13N]alanina, usando piruvato y amoniaco marcado como 
sustratos. Los resultados demostraron que con las enzimas inmovilizadas 
podían obtenerse buenos rendimientos radioquímicos, equivalentes a los 
obtenidos utilizando las enzimas en disolución. Sin embargo, pudo 
reciclarse el catalizador hasta en 5 ciclos consecutivos, sin que esto 
afectara de manera significativa al rendimiento obtenido (Figura R5). De 
este trabajo, que  abre pues las puertas al desarrollo de reacciones en flujo, 
resultó la tercera de las publicaciones relacionadas con la presente tesis 
docotral (da Silva, E. S. et al., Process Biochemistry, in press).   
 
Figura R.5. Rendimiento cromatográfico obtenido al efectuar síntesis 
consecutivas de L-[13N]-alanina utilizando la enzima inmovilizada. La reacción 
se llevó a cabo con 45 g x mL-1 de enzima inmovilizada a 25 ºC, pH 8 y t= 20 
minutos. 
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En resumen, en esta tesis doctoral, hemos demostrado que la aplicación de 
métodos biosínteticos permite la radiosíntesis selectiva y eficiente de 
compuesto marcadas que serían muy díficiles de obtener mediante 
métodos químicos. Los excelentes resultados que hemos obtenido aquí han 
sido gracias a capacidad que tienen los enzimas para catalizar un amplia 
diversidad de reacciones químicas con una gran quimio- regio- y 
enantoselectividad. En esta tesis, hemos mostrado que las enzimas se 
pueden aplicacar en radioquímica tanto en su forma solúble como en su 
forma inmovilzada. Y por eso en este contexto, hemos sido capaces de 
desarrollar diferentes procesos sínteticos para la generación de 
radiotrazadores basados en Nitrogeno 13.  
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BIOCATALYSIS 
One of the principal functions of enzymes as natural biocatalysts is to 
enhance the rate of virtually all chemical reactions within a cell. They 
increase the rates of chemical reactions without being permanently altered 
or consumed. They also increase the reaction rates without changing the 
equilibrium between the reactants and the products. 
These unique catalytic properties shown by enzymes make them desirable 
in many chemical processes. Enzymes work under mild reaction 
conditions (physiological pH and temperature), and constitute 
biodegradable and environment-friendly catalysts with high activity and 
chemo-, regio- and stereoselectivity.1 Additionally, the use of enzymes 
does not require the time-consuming protection/deprotection/activation 
steps frequently used in synthetic chemistry. These advantages enable 
shorter synthetic routes with less generation of waste products, thus being 
both environmentally and economically more attractive than traditional 
organic syntheses. Furthermore, enzymes can catalyze a wide spectrum of 
chemical and biochemical reactions that can be readily assembled in 
sophisticated pathways to synthesize complex molecules. These complex 
pathways formed by multi-enzyme systems have naturally evolved to 
work within the cellular milieu; however, in the last decades chemists have 
isolated enzymes and make them work ex-vivo under non-natural 
conditions. Moreover, advances in protein engineering have allowed the 
application of enzymes to chemical processes different from the natural 
ones. Therefore, intrinsic features of enzymes together with the recent 
technologies have paved the way for the implementation of biocatalysis in 
industrial processes1,2 as well as in the medical and pharmaceutical fields, 
where enzymes have been successfully exploited for the chemical 
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synthesis of drugs and building blocks3-5 and for the treatment of a variety 
of diseases.1  
Enzymes also present some inherent drawbacks associated with their 
natural origin: (i) they are poorly stable either in the presence of non-polar 
solvents, under high temperatures or under extreme pH values; (ii) they 
show limited reactivity towards artificial substrates (non-natural 
reactions); and (iii) they are highly soluble in water, limiting thus their 
reusability in batch reactions or their applicability in continuous-flow 
processes.6 Fortunately, the significant advances in genomics and 
computational biology have resulted in novel experimental and 
computational protein engineering tools, which have significantly 
enhanced the toolbox of available enzymes.7 On the other hand, enzyme 
immobilization has addressed the solubility issue by heterogenization of 
the biocatalysts, which enables both reutilization in batch reactions and 
integration into flow reactors. In addition, immobilized enzymes show 
often increased stability, facilitate the product separation and avoid time-
consuming purification steps.8 All these facts open new avenues for the 
application of enzymatic chemistry to the preparation of radiolabeled 
compounds in multiple biomedical applications.1,9-12 
 
ENZYME IMMOBILIZATION: THE WORKHORSE OF 
HETEROGENEOUS BIOCATALYSIS 
Enzyme immobilization involves the fixation of an enzyme to an insoluble 
matrix (carrier); however, optimizing the immobilization of enzymes is 
challenging. In spite of the difficulties, this methodology has been 
accepted as one of the most successful methods to overcome the 
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limitations of free enzymes.13,14 There are several reasons to immobilize 
enzymes (Table 1.1): first, immobilized enzymes act as heterogeneous 
biocatalysts that can be easily manipulated and separated from the 
products once the reaction is completed, preventing the contamination of 
the product and facilitating the downstream processing; second, by using 
an optimal immobilization methodology, the immobilization may enhance 
both operational and storage stability, while denaturation by exposure to 
heat or organic solvents can be prevented; third, when the immobilized 
enzymes are highly stable, the resulting heterogeneous biocatalyst can be 
recycled for several operational cycles and directly integrated into 
continuous chemical processes.14 
The immobilization of enzymes has been intensively exploited since the 
70’s. However, no universal immobilization protocols to improve both 
activity and stability of the immobilized enzymes have been described. For 
this reason, enzyme immobilization is still an empirical approach where 
trial-and-error approximations are more common than rational approaches. 
However, the results obtained during more than 40 years of research in 
enzyme immobilization have demonstrated that the physic-chemical 
properties of the support material and the immobilization chemistry (the 
type of bonds between the enzyme and the solid surface) are essential to 
achieve active and stable heterogeneous biocatalysts. In theoretical terms, 
structural information about the enzyme can guide the selection of the best 
immobilization protocol; however, examples of rational enzyme 
immobilization are scarce because of the chemical and geometrical 
complexity of protein structures and the heterogeneity of the solid material 
surfaces. Mass transfer limitations need often to be addressed by selecting 
the proper microstructure of the solid carrier to favor the access of the 
substrates from the reaction media to the immobilized catalytic centers.15 
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The immobilization chemistry and the nature of the solid carrier are 
fundamental to control the protein orientation and the substrate/product 
diffusion, and both factors will be crucial to ensure high activity and 
stability of the final heterogeneous biocatalysts.16 
 
Table 1.1. Properties of immobilized enzymes: advantages and drawbacks. 
Adapted from the reference.17 
Advantages Drawbacks 
Reuse of the biocatalyst Loss in enzyme activity 
Easier reactor operation Mass transfer limitation 
Easier product separation Additional cost 
Stability of the enzyme  
 
Selection of a Suitable Carrier Material 
The properties of the selected carrier are essential for the performance of 
the heterogeneous biocatalyst. Ideal carrier properties include physical 
strength, hydrophilicity, inertness, ease of derivatization, biocompatibility, 
resistance to microbial attack, and availability at low cost.18 However, 
even though immobilization on solid carriers is an established technology, 
there are still no general rules for selecting the best carrier for a given 
application. Both the immobilization chemistry and the selection of the 
optimal carrier are usually based on trial-and-error.  
In general, the carriers can be classified as inorganic and organic, 
according to their chemical composition. In turn, the organic carriers can 
be subdivided into natural and synthetic polymers (Figure 1.1). Natural 
polymers such as chitin, chitosan and cellulose have many advantages over 
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many synthetic polymers in terms of biodegradability, non-toxicity, 
physiological inertness, hydrophilicity and remarkable affinity to proteins. 
The green properties of those materials make them attractive, especially in 
specific applications including food, pharmaceutical, medical and 
agricultural processing.14,16 However, membranes prepared from synthetic 
polymers have been largely preferred as enzyme carriers because of their 
low cost, easy surface modification, resistance to biodegradation and 
thermal and chemical stabilities. 
Inorganic materials can also be classified into natural and synthetic 
materials. Naturally occurring silica-based materials are the most suitable 
and versatile matrices for enzyme immobilization and have been widely 
used in industrial manufacturing of enzyme-processed products,19,20 as 
well as for research21 and medical purposes.22,23  Silica can be easily 
fabricated to provide desirable morphology, pore structures, and micro-
channels.24,25 Additionally, the surface of silica gel can be easily modified 
by chemical methods to provide different types of functional groups at the 
surface.19,26,27 Furthermore, silica is cheap, mechanically stable, 
chemically inert, and environmentally friendly. In the last decade, other 
synthetic inorganic materials such as metal oxides, metal phosphates, 
zeolites and metal organic framework (MOFs) are gaining relevance in the 
protein immobilization field.28 
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*Metal-organic-frameworks (MOFs) because they are kind of hybrid materials. 
Figure 1.1. General classification of the carriers used for enzyme immobilization. 
Adapted from the reference16.  
 
In addition to the nature of the carrier, physical characteristics such as 
particle diameter, swelling behavior, mechanical strength and compression 
behavior also affect the performance of the immobilized systems. Pore and 
particle size of the carrier determine the total surface area and critically 
affect the maximum amount of enzyme that can be bound. Here, we can 
also categorize the solid carriers as non-porous and porous. Non-porous 
carriers show less diffusional limitations, but microscopic particles 
(suitable for re-utilization) have low loading capacities. Nanoparticles 
have a much larger surface area per mass unit but they are laboriously 
manipulated in batch reactors and cause filter clogging during their 
reutilization. Hence, porous, micrometric particles are generally preferred 
because their high surface area enables higher enzyme loads, their 
manipulation during the operational cycles is much easier and finally the 
General classification of the carriers
Organic 
Natural materials
Polysaccharides: 
cellulose, dextrans, 
agar, agarose, chitin, 
alginate  
Proteins: collagen, 
albumin
Carbon
Synthetic materials
Polystyrene
Other polymers: 
polyacrylate, 
polymethacrylates, 
polyacrylamide, ...
Inorganic
Natural materials
Bentonite
Silica
Synthetic materials
Glass (non-porous 
and controlled pore)
Metals oxides
Zeolites and metal 
hydroxides*
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vast majority of the immobilized enzymes are physically protected by the 
porous microenvironment. In the context of this PhD thesis. As example, 
cross-linked agarose porous beads (agarose BCL) have been used. The 
material is hydrophilic and biocompatible, it can be manufactured in the 
micrometric size within a range of porosity and is commercially available 
at large scale.29,30 Its main limitation, the high cost, can be overcome by 
employing reversible methods that allow regeneration and re-use of the 
carrier once the immobilized enzymes become inactive.  
 
Selection of the optimal immobilization chemistry. The pathway to the 
enzyme stabilization 
In the last decades, a plethora of immobilization protocols has been 
reported in the literature.2,13,14,16,31 Depending on the enzyme and 
immobilization strategy, the final stability and activity of the enzyme may 
be significantly affected.  
The chemistries to immobilize enzymes onto solid carriers can be divided 
into two main groups based on the nature of the enzyme-carrier bonds: (i) 
reversible chemistries, where the enzyme-carrier interaction can be easily 
reverted by changing the media conditions, thus enabling the enzyme 
elution or lixiviation; and (ii) irreversible chemistries, where the enzymes 
are irreversibly attached to the carrier (Figure 1.2).6,14 Reversible 
immobilization can be achieved by physical adsorption of the enzyme 
based on ionic, van der Waals or hydrophobic interactions, on affinity 
interactions and on reversible covalent bonds. Irreversible immobilization 
mainly involves irreversible covalent bonds between the protein and the 
surface.  
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Figure 1.2. Schematic representation of the main different methods of enzyme 
immobilization. Adapted from the reference16. 
 
Methods of Reversible Immobilization 
Reversibly immobilized enzymes can be detached from the carrier under 
gentle conditions. The use of these enzymatic systems is highly attractive 
because when the enzymatic activity decays, the carrier can be regenerated 
and reloaded with the fresh enzyme. This methodology is particularly 
interesting when the cost of the carrier is high. Indeed, the cost of the 
carrier is often a primary factor in the overall cost of immobilized 
biocatalysts. In addition, the reversibility between the enzyme and the 
carrier surface has proven useful for processes where the enzymes must 
work at the boundary of insoluble substrates and then need to be recovered 
for subsequent operational cycles.32  
In 1916, one of the first immobilized enzymes prepared by adsorption was 
reported by Nelson and Griffin, who showed that invertase physically 
adsorbed on charcoal (solid powder) kept its catalytic activity.33 One 
hundred years later, physical adsorption still remains the oldest, simplest, 
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and most widely used method for protein immobilization.34 The 
phenomenon of physical adsorption can be driven by weak and non-
specific forces such as hydrogen bonding, by Van der Waals forces (alone 
or combined), by hydrophobic interactions or by stronger salt bridges 
(combination of hydrogen bonding and charge-charge interactions).16,35  
Immobilization by ionic adsorption (commonly named as ionic exchange) 
is vastly exploited in reversible protein immobilization because protein 
surfaces are rich in positively (basic residues) and negatively charged 
amino acids that can easily interact with negative and positive groups on 
the carrier surface, respectively.34 Protein-carrier interactions are strong 
enough to retain the protein attached to the solid phase during the operation 
but they can be mainly disrupted by ionic strength and high or low pH. 
This immobilization chemistry has revealed highly useful to stabilize the 
quaternary structure of multimeric proteins.  
Another classical method to reversibly immobilize protein is the affinity 
immobilization. Affinity binding is also included which relies on the 
creation of different (bio)affinity bonds between a functionalized 
(activated) carrier and a specific group present on the protein surface.14 In 
most cases, proteins are engineered with affinity tails that selectively react 
with affinity groups on the carrier surface.6,16,36 The most well-known 
genetically encoded affinity tag is the polyhistidine tag (Hist-tag) that is 
selectively bound to carriers activated with metal-chelates (Cu(II), Co(II), 
Zn(II), or Ni(II)); the metal determines the selectivity and the strength of 
the interaction.37-41 This immobilization is easily and selectively reverted 
by adding imidazole groups that compete with the histidines for the 
chelates. This chemistry provides a remarkable selectivity and an 
extraordinary control of protein orientation, and minimizes the 
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conformational changes suffered by the proteins, yielding highly active but 
poorly stabilized proteins upon the immobilization protocol.36 
Finally, the reversible immobilization based on disulfide bridges is the 
most representative method of reversible covalent immobilization. A thiol 
from the protein surface (from the cysteine) selectivity reacts with a 
disulfide group on the carrier surface. This immobilization is easily 
reverted by reducing agents such as dithiothreitol.16,42,43 The major 
advantage of this immobilization chemistry is the high selectivity for 
cysteine as unique natural amino acid able to participate in such thiol-
disulfide exchange. Since cysteine residues are rarely found in the protein 
surfaces, engineering proteins with unique cysteines is a powerful strategy 
to immobilize proteins on disulfide activated materials through any desired 
orientation.44,45  
 
Methods of Irreversible Immobilization 
The concept of irreversible immobilization means that once the enzyme is 
attached to the carrier, the enzyme cannot be physically separated from the 
solid material. Unlike reversible immobilization, when the enzymes are 
irreversibly bound to the carriers, the solid material cannot be regenerated 
once the enzyme becomes inactive. This is an important issue when using 
expensive materials. However, irreversible attachment avoids the enzyme 
lixiviation during the operational process and frequently improves the 
enzyme stability, resulting in increased operational life of the 
heterogeneous biocatalysts. Stabilization of proteins through 
immobilization mainly relies on multivalent attachments that rigidify 
protein structures. In other words, the greater the number of covalent 
linkages between the enzyme and the carrier, the more rigid the enzyme 
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structure becomes. This multivalent covalent attachment has been 
demonstrated as one of the main reasons to explain the higher stability of 
the immobilized proteins.18 Paradoxically, the rigidification of the protein 
structure may noticeably decrease the protein activity. This fact is 
particularly important for enzymes, where rigidification might reduce 
some fundamental flexibility required for the catalysis. For this reason, it 
is essential to reach a compromise between the stability (rigidification) and 
activity. 
Figure 1.2 shows the three main methodologies for irreversible 
immobilization: irreversible attachment to a pre-existing carrier, 
irreversible entrapment/microencapsulation of the enzyme into synthetic 
materials, and irreversible cross-linking of enzyme aggregates. 
Irreversible immobilization on the pre-existing carrier will be the only 
technique described in detail in this chapter because it was fundamental to 
the experimental work of this thesis. 
The vast majority of the irreversible immobilization chemistries are based 
on a nucleophilic attack of protein surface residues (Lys, Cys, His and even 
Tyr) to a battery of reactive groups (cyanogen bromide, vinyl groups, 
aldehyde and epoxide groups) present on the surface of the carrier. 
Glutaraldehyde has been exploited to activate aminated carriers to 
immobilize primary amine groups, i.e., the N-terminus and the -amino 
group of the lysines.16,46,47 This immobilization is highly efficient but its 
action mechanism is not fully understood. 
CNBr-activated carriers are highly versatile. A plethora of materials have 
been activated with this groups (membranes, surfaces, nanoparticles, etc.), 
and some of these materials are commercially available.48 Dozens of 
proteins have been immobilized through this immobilization chemistry 
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that requires very mild conditions and where the primary amines (mainly 
from the N-terminus) of proteins react with the cyanogen bromides to form 
cyanate esters or imidocarbonates.49-52 The major disadvantage of this 
immobilization chemistry is the low stability of cyanogen bromide groups 
under aqueous conditions that often limit the multivalency of the 
attachment and the protein load of the final immobilized preparation.  
Epoxide and glyoxyl groups are alternative groups for irreversible 
immobilization that present a much higher stability than the cyanogen 
bromides and whose immobilization mechanism is better understood and 
reliable that for the glutaraldehyde groups. Glyoxyl groups are small 
aliphatic aldehydes that form reversible imino bonds with the primary 
amino groups (-NH2 from Lys and N-terminus) in the enzyme forming 
reversible Schiff's bases. Finally, those imine bonds must be reduced to 
achieve irreversible secondary amine bonds between the protein and the 
carrier.53,54 Under alkaline conditions, glyoxyl groups establish a 
multivalent covalent attachment with those protein regions that display the 
highest amount of most reactive lysine residues, rigidifying such protein 
regions.55 The main drawbacks of this chemistry are the mandatory 
alkaline pH (around 10) needed to achieved the multivalent 
immobilization and the reduction step required to irreversibly immobilize 
the protein.56 In spite of such disadvantages, carriers activated with 
glyoxyl groups promote an intense multivalent protein immobilization that 
has stabilized a plethora of proteins by a factor of 100-1000.53,57  
Epoxide groups, unlike glyoxyl groups, can be attacked by a larger battery 
of protein nucleophiles such as Cys, His, Asp, Glu, Tyr and of course Lys. 
This nucleophilic attack yields irreversible secondary amine bonds without 
requiring any reduction step. Nevertheless, after the immobilization, the 
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remaining epoxy groups must be blocked by aminated or thiolated 
compounds to deactivate the surface in order to avoid undesired post-
immobilization interactions. Remarkably, the vast majority of 
economically viable carriers based on polymetacrylate are activated with 
epoxide groups which have allowed industrial exploitation of this 
chemistry.55,58 The biggest limitation of this immobilization chemistry is 
the low reactivity of the epoxy groups. Consequently, this chemistry 
promotes lower stabilization factors than the glyoxyl under comparable 
conditions (carrier activation degree and nature, enzyme orientation, etc.).  
 
Table 1.2. Characteristics, advantages and drawbacks of most common enzyme 
immobilization methods. 
Method Bonding type Advantages Drawbacks 
Adsorption/ 
Ionic 
bonding  
Hydrophobic, Van 
der Waals or ionic 
interactions 
Simple and economical 
Soft conformational 
change of the enzyme 
Can be recycled, 
regenerated and reused  
Desorption  
Non-specific 
adsorption 
Covalent 
binding  
Chemical binding 
between functional 
groups of the 
enzyme and carrier 
No enzyme release 
Potential for enzyme 
stabilization 
Matrix and enzyme 
are not regenerable 
Major loss of activity 
Entrapment  Occlusion of an 
enzyme within a 
polymeric network 
No chemical modification 
Wide applicability for 
multimeric enzymes 
Easy handling and reusage 
Mass transfer 
limitations  
Enzyme release 
Cross-
linking  
Covalent bonds 
between enzymes 
by a functional 
reactant 
Strong linkage – low 
enzyme release 
Biocatalyst stabilization 
Mass transfer 
limitations  
Loss of activity 
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MOLECULAR IMAGING 
Molecular imaging can be defined as a set of non-invasive techniques that 
allow the visualization of cell function and the monitoring of molecular 
processes in living organisms. Since the 90’s, molecular imaging has 
opened a wide range of possibilities for the investigation of biological, 
physiological and medical processes which cannot be studied using other 
techniques.59-61 Positron emission tomography (PET), single photon 
emission computerized tomography (SPECT) and optical/fluoresce 
imaging are considered molecular imaging techniques.  
The anatomical information provided by molecular imaging techniques is 
usually scarce. Thus, both in the clinical and in the preclinical settings, 
such techniques are combined with other modalities able to provide 
accurate anatomical information. The combination of the resulting images 
(multimodality) offers information at the anatomical and molecular levels. 
Anatomical modalities include magnetic resonance imaging (MRI) and 
computed tomography (CT). Under the administration of a contrast agent, 
these modalities can be also considered molecular imaging modalities. 
It is worth mentioning that each imaging modality has strengths and 
limitations. Thus, while nuclear imaging techniques (PET and SPECT) 
offer unparalleled sensitivity, they rarely reach a resolution below 1 mm 
in the preclinical setting and a few mm in the clinical systems. On the 
contrary, MRI can offer high resolution (up to a few micrometers) while 
its sensitivity is low (Table 1.3). Consequently, the application of one 
modality or another will depend on the problem under investigation and 
often the combination of two or more modalities will provide the most 
accurate data.  
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Table 1.3. Properties of most common clinical and pre-clinical imaging 
modalities.59,60,62-66 
Technique Energy used 
Common contrast 
agents 
Imaging 
agent 
mass 
Spatial 
resolution 
Temporal 
resolution 
Sensitivity 
of detection 
Penetration 
depth 
Quantification 
efficiency 
CT X rays I or Ba agents mg range 0.03-1 mm Minutes 0.1 mol.l-1 >300 mm --- 
SPECT ɣ rays ɣ emitters <1 ng 0.5-15 mm Minutes 10-11 mol.l-1 >300 mm High 
PET 
Annihilation 
photons 
β+ emitters <1 ng 1-10 mm 
Seconds-
minutes 
10-12 mol.l-1 >300 mm High 
MRI 
Radio frequency 
waves 
Gd3+ agents or 
Fe3O4 nanoparticles 
0.01-100mg 0.03-1mm Minutes-hours10-5 mol.l-1 >300 mm Medium 
Optical 
Visible to 
infrared light 
Fluorophores or 
lanthanides 
<1 ng-10mg 2-10 mm 
Seconds-
minutes 
10-11 mol.l-1 1-20 mm Medium 
 
Nuclear Imaging techniques 
Nuclear imaging techniques rely on the administration of a radiotracer, i.e., 
a molecule labeled with a radioactive isotope to enable external and non-
invasive detection. Gamma ray-emitters are appropriate radioisotopes 
because high-energy gamma rays can travel through biological tissues 
without suffering significant scatter or attenuation. These gamma rays can 
be detected using specific instrumentation, and the original concentration 
of radiotracer can be accurately quantified using tomographic 
reconstruction algorithms. As a result, a series of tomographic images 
conveying information on absolute radioisotope concentration can be 
obtained over time, in vivo and in a non- invasive way. Positron emission 
tomography (PET), single photon emission computed tomography 
(SPECT) and scintigraphy are nuclear imaging techniques. Nowadays, 
these techniques are available in combination with anatomical imaging 
such as CT or MRI (Figure 1.3).  
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Positron emission tomography will be the only technique described in 
detail in this chapter because it was the only modality used in the context 
of this PhD thesis. 
 
 
Figure 1.3. Fusion modalities of medicine nuclear techniques. 
 
Positron emission tomography (PET) 
Positron emission tomography relies on positrons (β+) emitted from 
radioisotopes. The positron, after travelling short distances (few 
millimeters) within the body annihilates with an electron in the 
surrounding matter. The combined mass of the positron and the electron is 
converted into two collinear ɣ photons with 511 keV each travelling in 
opposite directions (annihilation). These gamma rays can be detected by 
especial detectors displayed in a ring surrounding the object of study. By 
simultaneous detection of both 511 keV  rays, lines of response (LORs) 
are identified and used to locate the position in which the annihilation 
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event occurred. The detection of hundreds of thousands of photons enables 
the generation of an image (Figure 1.4).  
 
 
Figure 1.4. Key steps involved in the development of a molecular imaging study. 
 
PET allows whole body 3D scanning and is commonly associated with 
CT, or more recently with MRI. This improves the limitations of its poor 
anatomic correlation and allows the generation of an attenuation map for 
attenuation correction during image reconstruction. In the clinical field, 
PET is widely used to image cancer and inflammation states through a 
fluorinated analogue of glucose, 2-[18F]fluoro-2-deoxy-glucose 
([18F]FDG), that can identify changes in cellular glucose metabolism 
during inflammatory processes or related with the hyperactivity of cancer 
cells. PET can also be used to investigate more specific physiological and 
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molecular mechanisms of human disease through the use of appropriate 
radiolabeled imaging probes and to study the biodistribution of new drugs 
and the effectiveness of new therapies.60 
 
 
Figure 1.5. A simplified diagram illustrating the principles of PET scan. 
 
Fluorine-18 (18F) and carbon-11 (11C) are frequently used radionuclides in 
PET. Nitrogen-13 (13N) and oxygen-15 (15O) are also used to a lesser 
extent (see Table 1.4). This is, in part, due to the fact that they can be 
produced efficiently in biomedical cyclotrons and have a radioactive decay 
almost exclusively by β+ emission, but especially because they are isotopes 
of elements with low atomic mass that are highly prevalent in all organic 
molecules. Hence, any molecule of interest can a priori be radiolabeled 
with one of these positron emitters without modifying its biological 
activity. In the context of this PhD thesis, 13N was the PET isotope 
exploited.  
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Table 1.4. Features of most common radionuclides used in PET. Adapted from 
references 67 and 68. 
Radionuclide T1/2 Nuclear reaction Target 
Primary 
precursors 
Decay 
product 
15O 2.04 min 14N(d,n)15O N2(+O2) [15O]O2 15N 
13N 9,97 min 16O(p, α)13N H2O H2O+EtOH 
[13N]NO2/3 
[13N]NH3 
13C 
11C 20.4 min 14N(p,α)11C N2(+O2) N2(+H2) 
[11C]CO2 
[11C]CH4 
11B 
18F 109.8 min 
20Ne(d,α)18F 
18O(p,n)18F 
Ne(+F2) 
[18O]H2O 
[18F]F2 
[18F]F- 
18O 
 
Nitrogen-13 
Nitrogen-13 is the longest-lived radioisotope of nitrogen and has been used 
mostly under the chemical form [13N]NH3 or [13N]amino acids. Nitrogen-
13 with high specific activity can be generated by proton irradiation of 
pure water via the 16O(p,α)13N nuclear reaction. It decays by positron 
emission to its stable isotope carbon-13. The nitrogen-13 generated by 
irradiation of pure water is a mixture of radiolabeled nitrate ([13N]NO3-), 
nitrite ([13N]NO2-) and ammonia ([13N]NH3), being [13N]NO3- the major 
species (approx. 85% of total radioactivity).69 The [13N]NO3- can be 
reduced to [13N]NO2-, which can be used as labeling agent for the synthesis 
of a wide variety of labeled species, including nitrosothiols, nitrosamines, 
azo derivatives and triazoles.70-75 
Cyclotron produced [13N]NO3- can be also reduced to [13N]NH3 by 
classical or in-target reduction methods.76 Classical reduction methods 
include the treatment with titanium hydroxide,77 Raney-nickel catalyst,78 
or Devarda's alloy.79 More commonly, [13N]NH3 can be generated directly 
in the irradiated target by the addition of ethanol,80,81 hydrogen gas80 or 
methane82 to the pure water, which act as scavengers and prevent radiolytic 
oxidation of the ammonia. Ammonia can be also produced in-target using 
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cryogenic targets.83 Besides direct application as flow and perfusion 
marker,84-86 [13N]NH3 is the main precursor for the synthesis of natural 
amino acids.57,87-96  
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INTRODUCTION 
Biocatalysis, although surprisingly underutilized in radiochemistry, 
constitutes an attractive alternative to conventional chemistry. First, 
enzymes present an exquisite chemical selectivity and high turnover 
numbers; second, enzymes were evolved to work under physiological 
conditions, where the concentration of the metabolites is tightly regulated 
and are rarely in excess. This scenario resembles the conditions for 
radiochemical reactions where the concentration of the radioactive 
precursors is extremely low; third, enzymes are the most sophisticated 
chiral catalysts yielding enantiopure products in most of the cases. 
Therefore, by harnessing the enzyme properties in PET radiochemistry, 
chemists have the opportunity to synthesize radiotracers through fast and 
selective biosynthetic schemes, while minimizing the formation of side 
products and preventing the formation of racemic mixtures.  
Hitherto, enzymes have been employed to radiosynthesize [13N/11C]amino 
acids, [18F]nucleoside derivatives and [11C/18F]proteins. Additionally, 
enzymatic reactions have been employed to regio- and stereospecifically 
introduce radioactive precursors into a plethora of biological molecules.1,2 
Enzyme immobilization has also been utilized to achieve high 
radiochemical yields during repeated batch cycles.3-6 Most of the advances 
in the application of enzymatic reactions in radiochemistry occurred in the 
70´s-80´s, and were summarized by Gelbard in 1981.7 Since then, to the 
best of our knowledge, the role of biocatalysis in radiochemistry has never 
been reviewed again. The aim of this chapter is to provide an overview of 
the biocatalytic approaches that have been reported during the last four 
decades for the synthesis of PET radiotracers (see Figure 2.1) using 
nitrogen-13, carbon-11, and fluorine-18.  
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Figure 2.1. Number of scientific publications reporting the application of 
biocatalysis to radiochemistry since 1980. Data obtained using PubMed, 2015 
NLM and Web of Science, 2013 Thomson Reuters. 
 
Nitrogen-13 
Nitrogen-13 is the longest-lived radioisotope of nitrogen and has been used 
mostly under the chemical form [13N]NH3 or [13N]amino acids. Nitrogen-
13 with high specific activity can be generated by proton irradiation of 
pure water via the 16O(p,α)13N nuclear reaction. The nitrogen-13 generated 
is a mixture of radiolabeled nitrate ([13N]NO3-), nitrite ([13N]NO2-) and 
ammonia ([13N]NH3), being [13N]NO3- the major species (approx. 85% of 
total radioactivity). The [13N]NO3- can be reduced to [13N]NO2-, which can 
be used as labeling agent for the synthesis of a wide variety of labeled 
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species, including nitrosothiols, nitrosamines, azo derivatives and 
triazoles.8-13 This reduction can be easily performed by chemical methods 
using cadmium-copper activated columns.8,14  
As mentioned in the previous chapter, cyclotron produced [13N]NO3- can 
be also reduced to [13N]NH3 by classical or in-target reduction methods.15 
Besides direct application as flow and perfusion marker,16-18 [13N]NH3 is 
the main precursor for the synthesis of natural amino acids. In general, 
[13N]NH3 can be incorporated into amino acids through three main 
enzymatic routes (Figure 2.2): a) using amino acid dehydrogenases that 
catalyze the reductive amination of -ketoacids using nicotinamide 
adenine dinucleotide (NADH) as redox cofactor and [13N]NH3 as the 
amine source;1,2,19-26 b) using amino acid synthetases that catalyze the 
insertion of [13N]NH3 into the -carboxylic group of acidic amino acids 
by using adenosine triphosphate (ATP);2,22,23,27 and c) using a bi-
enzymatic system integrated by an amino acid dehydrogenase (usually 
glutamate dehydrogenase) that catalyzes the reductive amination of -
ketoglutarate to produce L-[13N]glutamate, that is concurrently used by a 
transaminase that transfers the radiolabeled amine group to the target -
ketoacid to form the desired L-[13N]amino acid.2,22 
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Figure 2.2. Examples of the main enzymatic routes to incorporate [13N]NH3 into 
amino acids. (A) Using amino acid dehydrogenases; (B) using amino acid 
synthetases and (C) using a bi-enzymatic system formed by an amino acid 
dehydrogenase and a transaminase. 
 
These synthetic strategies have been often applied by using soluble 
enzymes (Table 2.1). This, in turn, leads to the potential contamination of 
the final preparation with pyrogenic enzymes and poses difficulty in the 
purification process.7 This problem was smartly solved by immobilizing 
the enzymes on solid carriers through covalent and irreversible bonds. 
Several immobilized enzymes, including multi-enzyme systems, have 
been applied to the heterogeneous synthesis of 13N-labeled amino acids 
(e.g. glutamine22, glutamate1,19,20,22-24, asparagine27, citrulline2, 
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aspartate2,22, alanine1,20,22). These amino acids have been obtained with 
different radiochemical yields, ranging from 10% for L-[13N]asparagine 
using an asparagine synthetase,27 to 95% for L-[13N]glutamate using a 
glutamate dehydrogenase.23 The glutamate dehydrogenase proved 
versatile to synthesize a plethora of L-[13N]amino acids beyond glutamate 
(see Figure 2.2A).1,20 Some of the above-mentioned amino acids were 
investigated in vivo both in animals and humans in order to assess their 
biodistribution and metabolism.19,20 The preparation of L-[13N]glutamate 
was semi-automated in 1983 by Lambrecht et al.,23 who could synthesize 
this labeled amino acid with high purity and high specific activity (1.11 
GBq.µmol-1) using a glutamate dehydrogenase immobilized on porous 
glass beads in short times (10 minutes). Later on, the same group adapted 
this methodology to the fabrication of β-[13N]-nicotinamide adenine 
dinucleotide ([13N]NAD) and -[13N]aminobutyric acid ([13N]GABA).28,29 
Finally, this technology was optimized to manufacture pure L-
[13N]glutamate through a full automated system.24 
Besides amino acids, other biological molecules have been labeled with 
nitrogen-13 by using [13N]NH3 as the amine source and carbamyl 
phosphate synthase and carbamoyl transferases as the catalysts. Gelbard et 
al. synthesized [13N]carbamyl phosphate, L-[-13N]citrulline and  
[carbamyl-13N]-L-aspartate using carbamyl phosphate synthetase co-
immobilized with either aspartate transcarbamylase or ornithine 
transcarbamylase. These amino acid derivatives were obtained with 
radiochemical yields of around 15%. Labeled carbamyl phosphate could 
be obtained using carbamyl phosphate synthetase as the catalyst, [13N]NH3 
as the ammonia source, carbamic acid as substrate and ATP as the 
cofactor; in a concurrent reaction, the corresponding transcarbamylase 
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transferred the carbamyl group to the ornithine or the aspartate to achieve 
the corresponding amino acid derivative.2  
 
Table 2.1. Literature published on enzymatic reactions (functional group transfer 
and transformations) applied to nitrogen-13 chemistry since 1980. Entries are 
ordered chronologically. 
Radionuclide Biosynthetic route Enzyme family Reaction Compound Ref. 
[13N]Ammonia Asparagine synthetase EC 6.3.5.4 Acid amide hydrolysis L-[
13N]Asparagine 27 
[13N]Ammonia 
Glutamate 
Dehydrogenase 
(Immobilized) 
EC 1.4.1.2 Reductive amination L-[
13N]Glutamate 19,22 
[13N]Ammonia 
Glutamate 
Dehydrogenase EC 1.4.1.2 Reductive 
amination L-[
13N]Alanine 22 Glutamate-Pyruvate 
Transaminase 
(Immobilized) 
EC 2.6.1.2 
[13N]Ammonia Glutamine synthethase EC 6.3.1.2 Acid amide hydrolysis L-[
13N]Glutamine 22 
[13N]Ammonia Aspartate ammonia-lyase EC 4.3.1.1 Addition L-[13N]Aspartate 22 
[13N]Ammonia 
Glutamate 
Dehydrogenase 
(immobilized/ semi-
automated production 
method) 
EC 1.4.1.2 Reductive amination L-[
13N]Glutamate 23 
[13N]Ammonia 
Glutamate 
Dehydrogenase 
(immobilized) 
EC 1.4.1.3 Reductive amination 
L-[13N]Glutamate 
L-α-
[13N]Aminobutyrate 
L-[13N]Valine 
L-[13N]Methionine 
L-[13N]Leucine 
L-[13N]Alanine 
1,20 
[13N]Ammonia 
Carbamyl phosphate 
synthetase 
(Co-immobilized) 
EC 6.3.5.5 
 
Phosphorylat
ion/ 
Amination 
 
[13N]Carbamyl 
phosphate 
2 
[13N]Ammonia 
Ornithine 
transcarbamylase EC 2.1.3.3 
Carbamoylati
on 
L-[-13N]Citrulline 2 Carbamyl phosphate 
synthetase 
(Co-immobilized) 
EC 6.3.5.5 
Phosphorylat
ion/ 
Amination 
[13N]Ammonia 
Aspartate 
transcarbamylase EC 2.1.3.2 
Carbamoylati
on [Carbamyl-13N] 
Carbamyl-L-
aspartate 
2 Carbamyl phosphate 
synthetase 
(Co-immobilized) 
EC 6.3.5.5 
Phosphorylat
ion/ 
Amination 
[13N]Ammonia 
Glutamate dehydrogenase 
(Immobilized) EC 1.4.1.3 
Reductive 
amination 
Carbamyl-L-
[13N]Aspartate 
2 
Aspartate transaminase 
(Immobilized) 
 
EC 2.6.1.1 Transamination 
Aspartate 
transcarbamylase 
(Immobilized) 
EC 2.1.3.2 Carbamoylation 
[13N]Ammonia NAD synthetase (Immobilized) EC 6.3.1.5 
Amide group 
transfer [
13N]-NAD 28 
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Radionuclide Biosynthetic route Enzyme family Reaction Compound Ref. 
 
[13N]Ammonia 
 
N.D. 
(two subsequent 
enzymatic Reaction) 
 
N.D. 
 
N.D. 
 
[13N]-GABA 
 
29 
[13N]Ammonia 
(via L-
[13N]Glutamate) 
Aspartate 
aminotransferase 
(Immobilized) 
EC 2.6.1.1 Transamination L-[
13N]Tyrosine 25 
[13N]Ammonia 
Phenylalanine 
dehydrogenase 
(Immobilized) 
EC 1.4.1.20 Reductive amination 
L-
[13N]Phenylalanine 
L-[13N]Tyrosine 
25 
[13N]Ammonia 
Glutamate 
Dehydrogenase 
(automated production 
method) 
EC 1.4.1.2 Reductive amination L-[
13N]Glutamate 24 
[13N]Nitrate Nitrate reductase (Immobilized) EC 1.7.1.1 Reduction [
13N]Nitrite 30 
 
Carbon-11 
Over the last two decades of the 20th century, biocatalysis played an 
important role in the developments of carbon-11 radiochemistry. Carbon-
11 is an attractive and important β+ emitting radionuclide for the 
radiolabeling of molecules with biological activity due to the ubiquitous 
presence of carbon in natural products and drug-like compounds. The 
cyclotron production of carbon-11 is achieved by proton irradiation of 
nitrogen-14 via the 14N(p,α)11C nuclear reaction. By adding small amounts 
of O2 or H2 to the target, [11C]CO2 and [11C]CH4 are produced, 
respectively. One major drawback in [11C]CO2 production is the inevitable 
contamination of the cyclotron target and the gas lines with “cold” CO2, 
which leads to a contamination of up to 1000 atoms of stable carbon per 
one carbon-11 atom produced, and results in low specific activities. This 
effect is less significant in the case of [11C]CH4.31,32 Both [11C]CO2 and 
[11C]CH4 can be chemically derivatized to other 11C-labeled precursors 
such as [11C]hydrogen cyanide, [11C]acetate, [11C]methanol, [11C]methyl 
iodide, [11C]propionate and [11C]carbonate. In this context, biocatalysis 
has exploited those precursors to incorporate carbon-11 into more than 50 
biological targets (Table 2.2). In carbon-11 radiochemistry, as well as for 
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nitrogen-13, the use of immobilized enzymes is more popular than the use 
of their soluble counterparts, because the immobilized enzymes facilitate 
product purification and enzyme reutilization, as well as allow the enzyme 
integration into continuous flow reactions. 
In a pioneering work in the enzymatic synthesis of 11C-labeled 
radiotracers, a phosphoenolpyruvate carboxylase (EC4.1.1.31) and aspartate 
transaminase (EC2.6.1.1) were separately immobilized on sepharose 
activated with cyanogen bromide groups and applied for the synthesis of 
L-[4-11C]aspartic acid using [11C]CO2 as the 11C source.33 In brief, 
cyclotron-produced [11C]CO2 and the appropriate substrate 
(phosphoenolpyruvate) were flushed through a column packed with 
immobilized carboxylase, generating [4-11C]oxaloacetate that was 
subsequently contacted with L-glutamate and passed through a second 
packed column containing an immobilized aspartate transaminase, which 
enabled the amine transfer from L-glutamate to the [4-11C]oxaloacetic acid 
to yield L-[4-11C]aspartic acid (Figure 2.3). [11C]CO2 was also used as a 
radioactive precursor for the synthesis of several amino acid derivatives 
based on the coordinate action of carbamoyl phosphate synthetase and 
amino acid transaminases. This synthetic strategy has been very valuable 
for studying the L-glutamate metabolism in a variety of tissues.2,33,34 
 
 
Chapter 2 
55 
 
Figure 2.3. Schematic representation of the radiosynthesis of L-[4-11C]aspartic 
acid. This radiosynthesis was performed using a phosphoenolpyruvate 
carboxylase (EC4.1.1.31) and aspartate transaminase (EC2.6.1.1) separately 
immobilized on sepharose activated with cyanogen bromide groups and [11C]CO2 
as the 11C source. 
 
Enzymatic carbon-11 radiochemistry has also been applied to other 
carbon-11 precursors beyond [11C]CO2. For example, [11C]cyanide was 
used as a radioactive precursor to synthesize L-[11C]amino acids and other 
biological amines.35 In this reaction scheme, O-acetyl-L-serine 
sulfhydrylase and -cyano-α-aminobutyric acid synthase (EC2.5.1.49) 
catalyze the nitrilation of O-acetyl-L-serine and O-acetyl-L-homoserine to 
yield β-[11C]cyano-L-alanine and γ-[11C]cyano-α-amino-L-butyric acid, 
respectively. These intermediate nitriles were further converted into L-[4-
11C]aspartic acid and L-[5-11C]glutamate by alkaline hydrolysis with 50-
70% decay corrected radiochemical yields and radiochemical purities 
higher than 95% (Figure 2.4).36,37 The same chemo-enzymatic route was 
applied to the synthesis of L-[methyl-11C]methionine and its analogues 
[11C]ethionine and [11C]propionine using [11C]cyanide as radioactive 
precursor and their corresponding O-acetyl-protected amino acids.38  
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Figure 2.4. Schematic representation of the chemoenzymatic radiosynthesis of 
L-[4-11C]aspartic acid (1) and L-[5-11C]glutamate (2). The synthesis of these 
compounds was carried out using O-acetyl-L-serine sulfhydrylase and -cyano-
α-aminobutyric acid synthase to catalyze the nitrilation of O-acetyl-L-serine and 
O-acetyl-L-homoserine to yield their intermediates β-[11C]cyano-L-alanine and 
γ-[11C]cyano-α-amino-L-butyric acid, respectively. 
 
Another carbon-11 precursor that can be directly used by enzymes is 
[11C]acetate which can be labeled in two different positions (carboxylic 
and 2-position).39 [11C]acetate is the main precursor to synthesize 
[11C]acetyl-CoA,40,41 one of the main hubs in the central metabolism of 
cells. [11C]acetyl-CoA can be synthesized through two different enzymatic 
pathways; (i) a two-step cascade catalyzed by an acetate kinase (EC2.7.2.1) 
that phosphorylates [11C]acetate yielding [11C]acetyl-phosphate, and a 
phosphotransacetylase (EC2.3.1.8) that incorporates the coenzyme A into the 
phosphorylated intermediate yielding [11C]acetyl-CoA; and (ii) a single-
step reaction catalyzed by coenzyme A synthetase (EC6.2.1.1) that directly 
incorporates coenzyme A into [11C]acetate producing [11C]acetyl-CoA. 
Interestingly, [11C]acetyl-CoA has been used as a general acetylating agent 
to synthesize a variety of carbon-11 labeled molecules such as [11C]acetyl-
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L-carnitine,41 L-[11C]carnitine,41 [11C]acetyl-L-serotonin,42 and [11C]N-
acetyl-D-glucosamine43.  
[11C]methanol and [11C]propionate have also been employed sporadically 
for the enzymatic preparation of 11C-labeled radiotracers. For example, L-
[11C]serine can be synthesized by an alcohol oxidase co-immobilized with 
a catalase that oxidizes [11C]methanol to [11C]formaldehyde.44,45 This 
radioactive aldehyde is then chemically condensed to tetrahydrofolate 
forming a methyl-transfer cofactor that is sequentially used by a serine 
hydroxyl-methyltransferase (EC2.1.2.1) to transfer the radiolabeled methyl 
group to glycine yielding L-[11C]serine.44 Likewise, [11C]formaldehyde 
has been applied to the synthesis of nucleosides, by using an enzyme 
system integrated by thymidylate synthase and alkaline phosphatase co-
immobilized on membranes fabricated with hollow fibers to yield 
[11C]thymidine and 2´-Fluoro-5-[11C]-methyl-β-L-arabinofuranosyluracyl 
([11C]-FMAU).45,46 Also, [11C]propionate can be enzymatically 
incorporated into acyl-L-carnitine to form [carbomyl-11C]propionyl-L-
carnitine through two different multi-enzyme systems.47 
Unlike the above-mentioned precursors, [11C]methyl iodide cannot be 
directly utilized by enzymes but can be efficiently incorporated into L-
[11C]alanine48,49 and L-[11C]methionine38,50 through chemical methods. 
These amino acids can be subsequently utilized by different enzymes to 
synthesize radiotracers with biomedical interest. For example, L-
[11C]alanine can be enzymatically converted into [11C]pyruvic acid by the 
action of alanine racemase and D-amino acid oxidase, leading to 
quantitative deamination of the amino acid. The dynamic racemization of 
the amino acid mediated by the racemase allows the D-amino acid oxidase 
to access 100% of the amino acid in spite of its strict enantioselectivity 
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towards the D-isomer. The catalase is required in this reaction to in situ 
eliminate hydrogen peroxide, an undesired by-product generated by the 
oxidase. Alternatively, alanine racemase can be coupled with an alanine 
dehydrogenase to quantitatively transform L-[11C]alanine into 
[11C]pyruvic acid via a NAD+-dependent oxidative deamination catalyzed 
by an alanine dehydrogenase.51 The resulting [11C]pyruvic acid can be 
easily reduced to [11C]lactic acid by adding a NADH-dependent lactate 
dehydrogenase.60,62,64,65 From [11C]pyruvate, several aromatic L-
[11C]amino acids can also be synthesized. For example, by using a 
transaminase/tyrosinase enzymatic tandem, L-tyrosine derivatives such as 
L-[11C]tyrosine and 3,4-dihydroxy-L-[11C]phenylalanine (L-[11C]DOPA) 
can be synthesized. Alternatively, the labeled pyruvate can be converted 
into L-[11C]tryptophan or 5-hydroxy-L-[11C]tryptophan by using a 
tryptophanase.49,52-54 Interestingly, accurate selection of the enzymatic 
route and the 11C-labeled precursor ([11C]cyanide or [11C]methyl iodide) 
enables the preparation of L-[11C]tryptophan or L-[11C]tyrosine labeled in 
two different positions (carboxylic or β-position; see Figure 2.5).49,52,55-57 
The synthesis of these aromatic [11C]amino acids was refined by co-
immobilizing the multi-enzyme systems51 and by automating the 
procedure58,59. Using an automated system, L-[11C]DOPA and 5-hydroxy-
L-[11C]tryptophan could be synthesized with >99% radiochemical purity 
and 5.3 and 22.0 GBq.μmol-1 specific activities, respectively.58 Advances 
on the enzymatic routes have allowed the production of these aromatic 
[11C]amino acids in sufficient amounts to evaluate in vivo their 
biodistribution.53,60-62 
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Figure 2.5. Chemo-enzymatic synthesis of aromatic L-amino acids labeled with 
carbon-11 in two different positions. 
 
The chemical synthesis of L-[11C]methionine starting from [11C]methyl 
iodide provides a labeled compound that can be efficiently utilized by 
several enzymes to efficiently manufacture a plethora of interesting 
radiotracers. In one example, methionine adenosyltransferase was used to 
condense L-[ 11C]methionine with ATP to yield S-adenosyl-L-[11C]-
methionine, a methyl-donor cofactor used by methyltransferases in a 
variety of metabolic reactions.63 This 11C-labeled methyl-donor cofactor 
has been exploited to label [11C]epinephrine64 and [4-methoxy-
11C]daunorubicin50 by the action of different methyl transferases. A more 
advanced use of L-[11C]methionine is its incorporation into proteins by 
using cell-free protein translation systems. This extraordinary utilization 
of carbon-11 amino acids has been applied to the synthesis of 
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[11C]interleukin 8, a chemoattractant cytokine with promising application 
in chemo- and immunotherapy.65 The in vitro synthesis of labeled proteins 
is based on cell-free pure preparations of protein synthesis machinery from 
E.coli that contain all the elements required for the sequential transcription 
and translation of genes into proteins (Figure 2.6).66 With this system, 
[11C]interleukin 8 was synthesized with a 63% radiochemical yield in only 
20 minutes. The [11C]cytokine was further purified by cation exchange and 
ultrafiltration methods, with a resulting radiochemical purity >95%. This 
pioneering work opens a promising path to the synthesis of radiotracers 
based on peptides and biotechnology-derived antibodies, which are 
becoming increasingly important as a major source of bio-based drugs.67 
 
Figure 2.6. Schematic illustration of the proposed labeled protein preparation 
system using a cell-free translation system. 
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Table 2.2. Literature published on enzymatic reactions (carbon-carbon bond 
formation, functional group transfer and transformations) applied in the carbon-
11 chemistry since 1980. 
Radionuclide Biosynthetic route Enzyme family Reaction Compound Ref. 
[11C]Carbon 
dioxide 
Phosphoenolpyruvate 
carboxylase 
(Immobilized) 
EC 4.1.1.31 Decarboxylation 
L-[4-11C]Aspartic acid 33 
Aspartate transaminase 
(Immobilized) EC 2.6.1.1 Transamination 
[11C]Carbon 
dioxide 
Carbamyl phosphate 
synthetase 
(Immobilized) 
EC 6.3.5.5 Phosphorylation/ Amination 
[11C]Carbamyl 
phosphate 
2 
[11C]Carbon 
dioxide 
Ornithine 
transcarbamylase EC 2.1.3.3 Carbamoylation L-[ureido-
11C]Citrulline 
2 Carbamyl phosphate 
synthetase 
(Co-immobilized) 
EC 6.3.5.5 Phosphorylation/ Amination 
[11C]Carbon 
dioxide 
Aspartate 
transcarbamylase EC 2.1.3.2 Carbamoylation [Carbamyl-
11C]Carbamyl-L-
aspartate 
2 Carbamyl phosphate 
synthetase 
(Co-immobilized) 
EC 6.3.5.5 Phosphorylation/ Amination 
[11C]Carbon 
dioxide 
1) Phosphoenol 
pyruvate carboxylase 1) EC 4.1.1.31 1) Carboxylation 1) [
11C]Oxaloacetate 
34 
2) Citrate synthase 2) EC 2.3.3.1 2) Addition 2) [11C]Citrate 
3) Aconitase 3) EC 4.2.1.3 3) Elimination 3) [11C]Isocitrate 
4) Isocitrate 
dehydrogenase 4) EC 1.1.1.42 
4) Oxidative 
decarboxylation 4) [α-
11C]Ketoglutarate 
5) Glutamate-pyruvate 
Transaminase 5) EC 2.6.1.2 5) Transamination 5) L-[
11C]Glutamate 
[11C]Acetate 
1) Acetate kinase 1) EC 2.7.2.1 1) Phosphorylation 
1) 
[11C]Acetylphosphate 
34 
2) 
Phosphotransacetylase 2) EC 2.3.1.8 2) Acylation 2) [
11C]Acetyl-CoA 
3) Citrate synthase 3) EC 2.3.3.1 3) Addition 3) [11C]Citrate 
4) Aconitase 4) EC 4.2.1.3 4) Elimination 4) [11C]Isocitrate 
5) Isocitrate 
dehydrogenase 5) EC 1.1.1.42 
5) Oxidative 
decarboxylation 5) [-
11C]Ketoglutarate 
6) Glutamate-pyruvate 
Transaminase 6) EC 2.6.1.2 6) Transamination 6) L-[
11C]Glutamate 
Hydrogen 
11C]cyanide Mandelonitrile lyase EC 4.1.2.10 
Cyanohydrin 
formation 
[11C]Cyanohydrin 
intermediate for 
[11C]Octopamine 
35 
Hydrogen 
11C]cyanide 
L-3-cyanoalanine 
synthase EC 4.4.1.9 
Elimination (β – 
replacement) 
Intermediate compound 
for L-2,4-Dianino4-
11C]Butyric acid 
36 
Hydrogen 
11C]cyanide 
O-acetyl-  
L-serine sulfhydrylase EC 2.5.1.47 
Elimination (β – 
replacement) 
Intermediate compound 
for 4-11C]Aspartic acid 
37 
Hydrogen 
11C]cyanide 
-cyano-α-
aminobutyric acid 
synthase 
EC 2.5.1.49 Elimination (β – replacement) 
Intermediate compound 
for L-5-11C]Glutamate 
37 
[11C]Methyl 
iodide 
-cyano-α-
aminobutyric acid 
synthase 
(Immobilized) 
EC 2.5.1.49 Elimination L-[methyl-
11C] 
Methionine 
38 
[11C]Carbon 
dioxide Acetate kinase EC 2.7.2.1 
Quantification by 
phosphorylation [1−
11C]acetate 39 
[1-11C]Acetate Acetyl CoA synthetase (Immobilized) EC 6.2.1.1 Acid-thiol ligation 
[11C]Acetyl coenzyme 
A 
40 
[11C]Acetate Acetyl CoA synthetase EC 6.2.1.1 Acid-thiol ligation O-[11C]Acetyl CoA 41 
[11C]Acetate 
Acetyl CoA synthetase EC 6.2.1.1 Acid-thiol ligation 
O-[11C]Acetyl-L-
Carnitine 
41  Carnitine 
acetyltransferase 
EC 2.3.1.7 Acylation 
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Radionuclide Biosynthetic route Enzyme family Reaction Compound Ref. 
[11C]Acetate Carnitine acetyltransferase EC 2.3.1.7 Acylation L-[
11C]Carnitine 41 
 
[1-11C] acetate 
(via 
[11C]acetylCoA) 
 
Acetyl CoA synthetase 
 
EC 6.2.1.1 
 
Acid-thiol ligation [11C]N-acetylserotonin 42 Arylamine N-
acetyltransferase 
 
EC 2.3.1.5 
 
Acylation 
      
 
[1-11C]acetate 
 
(via 
[11C]acetylCoA) 
 
Acetyl CoA synthetase 
 
EC 6.2.1.1 
 
Acid-thiol ligation [11C]N-acetyl-D-
glucosamine 
43 Glucosamine N-
acetyltransferase EC 2.3.1.3 Acylation 
      
[11C]Methanol 
Alcohol oxidase EC 1.1.3.13 
Oxidation 
L-[3-11C]Serine 44 
Catalase 
(co-immobilized) EC 1.11.1.6 
Serine 
Hydroxyl-
methyltransferase 
EC 2.1.2.1 Hydroxymethylation 
      
[11C]Carbon 
dioxide 
Alcohol oxidase EC 1.1.3.13 
Oxidation 11C]Formaldehyde 45 Catalase 
(co-immobilized) EC 1.11.1.6 
[11C]Carbon 
dioxide (via 
11C]Formaldehy
de) 
Thymidylate synthase EC 2.1.1.45 Methylation 11C]Thymidine 
46 Alkaline phosphatase 
(immobilized) EC 3.1.3.1 
Dephosphorylatio
n 
11C]2'-Arabino-2'-
Fluoro-β-5-MethyI-
Urid (FMAU) 
      
[11C]Propionate 
Acetate kinase EC 2.7.2.1 Phosphorylation NCA [carbonyl- 
11C]Propionyl 
L-Carnitine 
47 Phosphotransacetylase EC 2.3.1.8 Acylation Carnitine 
acetyltransferase EC 2.3.1.7 Acylation 
[11C]Propionate 
Acetyl CoA synthetase  EC 6.2.1.1 Acid-thiol 
ligation 
Acylation 
NCA [carbonyl- 
11C]Propionyl 
L-Carnitine 
47 Carnitine 
acetyltransferase EC 2.3.1.7 
      
11C]Methyl 
iodide 
D-amino acid oxidase / 
Catalase 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
Resolution / 
Redox reaction [3-
11C]Pyruvic acid 
48 Glutamic-pyruvic 
Transaminase EC 2.6.1.2 Transamination L-[
11C]Alanine 
      
Hydrogen 
11C]cyanide 
D-amino acid oxidase / 
Catalase 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
Resolution / 
Redox reaction L- [carboxy-
11C]Tyrosine 49,53 Glutamic-pyruvic transaminase EC 2.6.1.2 Transamination 
β-Tyrosinase EC 4.1.99.2 β – replacement L- [carboxy -11C]DOPA 
Hydrogen 
11C]cyanide 
D-amino acid oxidase / 
Catalase 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
Resolution / 
Redox reaction L- [3-
11C]Tryptophan 
49,54 Glutamic-pyruvic 
transaminase EC 2.6.1.2 Transamination 5-Hydroxy-L- [3-11C]tryptophan Tryptophanase EC 4.1.99.1 β – replacement 
Hydrogen 
11C]cyanide 
D-amino acid oxidase / 
Catalase 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
Resolution / 
Redox reaction 
 
Transamination 
L-[1-11C]Alanine 49 Glutamic-pyruvic 
Transaminase EC 2.6.1.2 
      
[methyL-11C] 
Methionine 
L-methionine-S-
adenosine transferase EC 2.1.1.12 Methylation 
S-methyl-L-[methyl-
11C] Methionine 
50  
Carminomycin-4-O-
methyltransferase 
EC 2.1.1.292 Methylation [4-methoxy-11C]Daunorobicin 
      
11C]Methyl 
iodide 
(via [11C]Carbon 
dioxide) 
Alanine 
racemase/Alanine 
Dehydrogenase 
EC 5.1.1.1/ EC 
1.4.1.1 
Isomerization/ 
Oxidative 
deamination L-[3-11C]DOPA 51 
β-tyrosinase 
(Co-immobilized) EC 4.1.99.2 β – replacement 
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Radionuclide Biosynthetic route Enzyme family Reaction Compound Ref. 
11C]Methyl 
iodide 
(via [11C]Carbon 
dioxide) 
Alanine racemase/ 
Alanine 
Dehydrogenase 
 
 
Tryptophanase 
(Co-immobilized) 
EC 5.1.1.1/ EC 
1.4.1.1 
 
 
EC 4.1.99.1 
 
Isomerization/ 
Oxidative 
deamination 
 
β – replacement 
 
5-Hydroxy-L- 
[3-11C]tryptophan 
51 
      
 
11C]Methyl 
iodide 
(via [11C]Carbon 
dioxide) 
 
Alanine racemase/D-
amino acid oxidase 
 
EC 5.1.1.1/ EC 
1.4.3.3 
 
Isomerization/ 
Resolution L-[3-11C]DOPA 51,58,59 
β-tyrosinase 
(Co-immobilized) EC 4.1.99.2 β – replacement 
11C]Methyl 
iodide 
(via [11C]Carbon 
dioxide) 
Alanine racemase/D-
amino acid oxidase 
EC 5.1.1.1/ EC 
1.4.3.3 
Isomerization/ 
Resolution 5-Hydroxy-L- 
[3-11C]tryptophan 
51,58,59 Tryptophanase 
(Co-immobilized) EC 4.1.99.1 β – replacement 
      
[11C]Carbon 
dioxide 
D-amino acid oxidase / 
Catalase 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
Resolution / 
Redox reaction L- [3-11C]Tyrosine 52,53 Glutamic-pyruvic 
transaminase EC 2.6.1.2 Transamination 
β-Tyrosinase EC 4.1.99.2 β – replacement L- [3-11C]DOPA 
      
11C]Methyl 
iodide 
D-amino acid oxidase / 
Catalase 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
Resolution / 
Redox reaction L- [β-
11C]Tryptophan 
55 Glutamic-pyruvic   
Transaminase 
EC 2.6.1.2 Transamination 5-Hydroxy-L- 
[β-11C]tryptophan 
Tryptophanase EC 4.1.99.1 β – replacement 
[11C]Carbonate 
Mutant strain of the 
cyanobacterium 
Synechocystis PCC 
6803 
-- Photosynthesis L-[11C]Phenylalanine 56 
      
[11C]Carbon 
dioxide 
Aspartate transaminase 
(Immobilized) EC 2.6.1.1 Transamination [3-
11C]Phenylalanine 57 
      
[methyl-11C] 
Methionine 
Methionine 
adenosyltransferase EC 2.5.1.6 
Adenosyl group 
transfer 
[methyl-11C]Adenosyl-
methionine 
63 
      
[methyl-11C] 
Methionine 
L-methionine-S-
adenosine transferase EC 2.5.1.6 
Adenosyl group 
transfer [11C]-(-)-Epinephrine 64 Phenylethanolamine-N-
methyl transferase EC 2.1.1.28 Methylation 
      
L-[11C] 
Methionine Cell-free system PURESYSTEM Protein synthesis [
11C]interleukin 8 65 
[11C]Carbon 
dioxide 
Pyruvate: ferredoxin 2-
oxidoreductase  
 
L-Lactate 
dehydrogenase 
EC 1.2.7.1 
 
 
EC 1.1.1.27 
Oxidative 
decarboxylation 
 
Deamination 
[11C]Pyruvate acid 
 
 
L-[3-11C]Lactic acid 
68 
      
11C]Methyl 
iodide 
Glutamate-pyruvate 
transaminase 
EC 2.6.1.2 Transamination 
L-[3-11C]Lactic acid 
69 
L-Lactate 
dehydrogenase 
EC 1.1.1.27 Deamination 
 
[11C] Hydrogen 
Cyanide (NCA) 
D-amino acid oxidase 
(Immobilized) EC 1.4.3.3 Resolution L-[
11C]Leucine 70,71 
[11C]Carbon 
dioxide 
Green 
algae Scenedesmus 
obtuslusculus Chod. 
-- Photosynthesis [11C]Glucose 72 
[11C] Hydrogen 
Cyanide (NCA) 
D-amino acid oxidase / 
Catalase 
(Co-immobilized) 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
Resolution / 
Redox reaction L-[
11C]Alanine 73 
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Radionuclide Biosynthetic route Enzyme family Reaction Compound Ref. 
 
[11C] Hydrogen 
Cyanide (NCA) 
 
D-amino acid oxidase / 
Catalase 
(Co-immobilized) 
 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
 
Resolution / 
Redox reaction 
 
 
[1-11C]Pyruvic acid 
 
 
73 
L-Alanine 
dehydrogenase EC 1.4.1.1 
Oxidative 
deamination 
 
[11C] Hydrogen 
Cyanide (NCA) 
L-Lactate 
dehydrogenase EC 1.1.1.27 Reduction L-[1-
11C]Lactic Acid 73 
 
Hydrogen 
11C]cyanide 
D-amino acid oxidase / 
Catalase 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
Resolution / 
Redox reaction [1-
11C]pyruvic acid 74 
Hydrogen 
11C]cyanide 
 
D-amino acid oxidase / 
Catalase 
 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
 
Resolution / 
Redox reaction 
L-[1-11C]Lactic Acid 75 Glutamic-pyruvic 
transaminase EC 2.6.1.2 Transamination 
L-Lactic 
dehydrogenase EC 1.1.1.27 Reduction 
11C]Methyl 
iodide 
D-amino acid oxidase / 
Catalase 
EC 1.4.3.3 / 
E.C. 1.11.1.6 
Resolution / 
Redox reaction 
L-[3-11C]Lactic Acid 75 Glutamic-pyruvic transaminase EC 2.6.1.2 Transamination 
L-Lactic 
dehydrogenase EC 1.1.1.27 Reduction 
[11C]Methyl 
iodide 
D-mannitol 
dehydrogenase EC 1.1.1.67 Oxidation D-[16-
11C]Fructose 76 
11C]Methyl 
iodide 
(via [11C]Carbon 
dioxide) 
Alanine racemase/ 
Alanine 
Dehydrogenase 
EC 5.1.1.1/ EC 
1.4.1.1 Isomerization/ 
Oxidative 
deamination 
[3-11C]Pyruvic acid 77  
Alanine racemase/D-
amino acid oxidase 
(Co-immobilized) 
EC 5.1.1.1/ EC 
1.4.3.3 
 
Fluorine-18 
The number of enzymatic applications in fluorine-18 radiochemistry is 
much lower than in carbon-11 and nitrogen-13 radiochemistry (Table 2.3) 
because the repertoire of enzymatic reactions that use fluorine in nature is 
very limited. However, incorporation of fluorine-18 into biological 
molecules is priceless for PET radiochemistry since fluorine-18 has a very 
convenient half-life for in vivo studies, especially in the context of small 
molecules.78,79 [18F]fluoride ion ([18F]F-) is cyclotron-generated by 
irradiation of 18O-enriched water ([18O]H2O) with high-energy protons via 
the 18O(p, n)18F nuclear reaction. The presence of water molecules into the 
final radioactive solution affects [18F]F- reactivity, which limits direct use 
in nucleophilic substitution reactions. To overcome this drawback, 
[18F]Fluoride ions are captured in an anion-exchange resin and further 
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formulated using a phase transfer catalyst (e.g. Kryptofix [2.2.2]) a polar, 
non-protic solvents to favor the nucleophilic attack.  
Until XXst century, no enzymes capable to directly incorporate cyclotron-
produced [18F]F- had been reported. Hence, the first 18F-labeling 
enzymatic reactions reported in the 1980’s and 1990’s were based on the 
use of 18F-labeled precursors. For example, 2-deoxy-2-[18F]fluoro-D-
glucose ([18F]FDG) was purified from the chemical synthesis by using an 
hexokinase that selectively phosphorylates D-glucose, facilitating the 
purification of the radiolabeled sugar.80 In a more synthetic approach, 6-
[18F]fluorodopamine, 4-[18F]catechol and [18F]FDG-1-phosphate were 
used as substrates of dopamine β-hydroxylase81, β-tyrosinase82 and UDP-
glucose pyrophosphorylase83 to synthesize (−)-6-
[18F]fluoronorepinephrine, 6-[18F]fluoro-L-DOPA and uridine diphospho-
2-deoxy-2-[18F]fluoro-α-D-glucose (UDP-[18F]FDG), respectively 
(Figure 2.7). 
In 2002, the isolation of a fluorinase (adenosyl-fluoride synthase: 
EC2.5.1.63) from the soil bacterium Streptomyces cattleya meant a 
breakthrough in enzymatic synthesis of fluorinated compounds. The 
structural and biochemical characterization of this enzyme opened new 
prospects for the direct 18F-radiofluorination of biological molecules.84-87 
Nature has specialized fluorinases to convert S-adenosyl-L-methionine 
(SAM) to 5’-fluoro-5’-deoxyadenosine (FDA)86 through a nucleophilic 
attack of the fluorine ions on the methionine derivative. Since enzymes 
work by default under aqueous conditions, it was anticipated that 
cyclotron-produced [18F]F- could be used to directly form 18F−C bonds. 
Indeed, fluorinases have been later exploited to tackle the [18F]fluorination 
of several organic molecules.88,89 
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Figure 2.7. Schematic representation of the enzymatic reaction to synthesize 
(−)-6-[18F]fluoronorepinephrine (A), 6-[18F]fluoro-L-DOPA (B) and UDP-
[18F]FDG (C). The radiosynthesis of these molecules was achieved starting from 
the respective 18F-labeled substrates using dopamine β-hydroxylase, β-tyrosinase 
and UDP-glucose pyrophosphorylase, respectively. 
 
In a first attempt, the fluorinase purified from Streptomyces cattleya was 
applied to the preparation of [18F]FDA from SAM and [18F]F-, although 
poor yields could be achieved (approx. 1%).90 However, when this enzyme 
was recombinantly overexpressed in E.coli and coupled with a L-amino 
acid oxidase (L-AAO), the radiochemical yield was greatly increased.91 In 
this multi-enzyme system, the fluorinase catalyzes a nucleophilic attack of 
[18F]F- ion to SAM, with the release of one molecule of L-methionine. This 
molecule of L-methionine is concurrently deaminated by L-AAO, 
preventing the reversible reaction. By using this combination of enzymes, 
up to 95% radiochemical yield was achieved for the synthesis of [18F]FDA. 
Harnessing the benefits of the enzyme immobilization, fluorinase was 
Chapter 2 
67 
immobilized to perform the synthesis of [18F]FDA more efficiently.92 
Furthermore, Sergeev et al. have broadened the substrate scope of the 
fluorinase, which is able to accept SAM analogues to synthesize [18F]FDA 
with 32% radiochemical yield in 3h.93  
The high-yield synthesis of [18F]FDA accomplished by this two-enzyme 
system has paved the way for the enzymatic incorporation of fluorine-18 
to a plethora of molecules. For example, the deamination of [18F]FDA 
catalyzed by a 5′-adenylic acid deaminase results in the formation of 5'-
[18F]fluoro-5'-deoxyinosine (5’-[18F]FDI). By using bi-enzymatic systems 
comprising an immobilized purine nucleotide phosphorylase and phytase, 
the transfer of 18F-fluorinated adenine from [18F]FDA to the 5-deoxy-1-
phosphoribose and the concurrent dephosphorylation of the carbon-1 
yielding 5´-deoxy-5’-[18F]fluoro-D-ribose (5’-[18F]FDR) could be 
achieved. After 4 hours reaction, the different enzymatic routes resulted in 
75% and 45% radiochemical yields for 5’-[18F]FDI and 5’-[18F]FDR, 
respectively.91 Recently, the synthesis of 5’-[18F]FDR from [18F]F- through 
a four-enzyme/one-pot system (fluorinase, L-AAO, purine nucleotide 
phosphorylase and phytase) was significantly improved, resulting in 80% 
radiochemical conversion in 2 hours (see Figure 2.8). The amount of the 
radiolabeled monosaccharide was sufficient to be tested in PET imaging.93-
95 The multi-enzyme cascade was varied to synthesize 5’-deoxy-5’-
[18F]fluorouridines ([18F]FDU) from [18F]fluoride using [18F]FDA as 
intermediate. In the cascade, the phytase was replaced by a thymidine 
phosphorylase that incorporates one uracil nitrogen base into the carbon 1 
of the fluorinated sugar to yield fluorinated uridines. Using different uracil 
derivatives, the multi-enzyme system was used to synthesize the 
corresponding uridines with decent radiochemical conversions (13-33%) 
in 1-2h time. 
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Figure 2.8. Schematic representation of the reported fluorinase multi-coupled 
enzyme systems for the synthesis of 18F-labeled compounds. 
 
As in the case of carbon-11, enzymatic reactions have also been employed 
to the synthesis of 18F-labeled proteins using a cell-free approach.65 
Considering the slow pharmacokinetics of macromolecules, the 18F-
labeled proteins are more interesting than the 11C-labeled analogues since 
the longer half-life of 18F enables longer scanning times. By using pure 
transcription and translation machinery of Escherichia coli and 4-
[18F]fluoro-L-proline, Harada et al. have reported the synthesis of 
[18F]interleukin-8 in overall production time of 120 minutes with 1.5% 
radiochemical conversion with respect to the fluorinated amino acid.  
Radiochemical conversion is lower than that achieved with L-
[11C]methionine because the aminoacyl-tRNAs synthases are dramatically 
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less efficient using non-natural amino acids, limiting the pool of tRNAs 
loaded with 4-[18F]fluoro-L-proline. 
 
Table 2.3. Enzymatic radiofluorination and biotechnological developments of 
the fluorinase and other enzymatic transformations using in the fluorine-18 
chemistry reported since the 80’s. 
Radionuclide Biosynthetic route 
Enzyme 
family Reaction Compound Ref. 
18F]Fluoride ion Hexokinase EC 2.7.1.1 Purification 
 
2-Deoxy-2-
[18F]fluoroglucose 
 
80 
 
18F]Fluoride ion 
(via 6-
[18F]Fluorodopa
mine) 
Dopamine β-
hydroxylase EC 1.14.17.1 Reduction 
(−)-6-
[18F]Fluoronorepi
nephrine 
81 
18F]Fluoride ion 
UDP-glucose 
pyrophosphorylas
e 
EC 2.7.7.9 Nucleotidyl group transfer 
Uridine 
diphospho-2-
deoxy-2-
[18F]Fluoro-α-D-
glucose 
83,96 
18F]Fluoride ion 
(via 4-
[18F]Fuorocatech
ol) 
β-Tyrosinase EC 4.1.99.2 β – replacement 6-[
18F]Fuoro-L-
dopa 
82 
18F]Fluoride ion Fluorinase EC 2.5.1.63 Halogenation 
 
[18F]-5’-fluoro-5’- 
Deoxyadenosine 
 
90 
18F]Fluoride ion 
 
Fluorinase / L-
amino acid 
oxidase 
EC 2.5.1.63/ 
EC 1.4.3.2 
Halogenation / 
Oxidation 
[18F]-5’-fluoro-5’- 
Deoxyadenosine 
 
(Intermediate for 
[18F]-
fluoroacetate) 
91,97 
18F]Fluoride ion 
 
(via [18F]-5’-
fluoro-5’- 
Deoxyadenosine) 
5′-Adenylic Acid 
Deaminase 
(coupled with 
Fluorinase / L-
amino acid 
oxidase) 
EC 3.5.4.6 Deamination [
18F]-5'-Fluoro-5'-
deoxyinosine 
91 
18F]Fluoride ion 
 
(via [18F]-5’-
fluoro-5’- 
Deoxyadenosine) 
Fluorinase / L-
amino acid 
oxidase 
EC 2.5.1.63/ 
EC 1.4.3.2 
Halogenation / 
Oxidation 
5´-deoxy-5’-
[18F]Fluoro-D-
ribose 
91 
Purine nucleoside 
phosphorylase 
(Immobilized) 
EC 2.4.2.1 Pentosylation 
Phytase EC 3.1.3.1 
Hydrolysis of 
phosphoric 
ester 
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Radionuclide Biosynthetic route 
Enzyme 
family Reaction Compound Ref. 
18F]Fluoride ion 
Fluorinase / L-
amino acid 
oxidase 
EC 2.5.1.63 / 
EC 1.4.3.2 
Halogenation / 
Oxidation 5’-deoxy-5’-
18F]Fluorouridine
s 
98 Purine nucleoside 
phosphorylase EC 2.4.2.1 Pentosylation 
Thymidine 
phosphorylase EC 2.4.2.4 Pentosylation 
18F]Fluoride ion 
Fluorinase EC 2.5.1.63 Halogenation 5´-deoxy-5’-
[18F]Fluoro-D-
ribose 
94,95 Nucleoside 
Hydrolase (TvNH) EC 3.2.2.1 
Hydrolysis of 
N-glycosyl 
bond 
18F]Fluoride ion Fluorinase EC 2.5.1.63 Halogenation [
18F]-5’-fluoro-5’- 
deoxyadenosine 
93 
18F]Fluoride ion 
Fluorinase 
(Immobilized) EC 2.5.1.63 Halogenation 
18F]-5’-fluoro-5’-
deoxyadenosine 
92 L-amino acid 
oxidase EC 1.4.3.2 
4-18F]fluoro-L-
proline Cell-free system PURExpress 
Protein 
synthesis 
18F]interleukin 8 99 
 
SUMMARY AND FUTURE PERSPECTIVES  
The application of biosynthetic methods in radiosynthesis has proven 
efficient for the preparation of labeled compounds that would be difficult 
to label using chemical methods. Enzymes exhibit high regio-, chemo- and 
stereo-selectivity and high catalytic versatility, and can be used either in 
their free form (in solution) or immobilized on a solid carrier.  
The understanding of the precise mechanisms underlying biocatalytic 
reactions in radiochemistry opens new avenues for the preparation of 
radiolabeled compounds in multiple biomedical applications. Thanks to 
the advances in bioengineering, old approaches are finding new 
applications. Moreover, new approaches are currently being developed, as 
exemplified by the most recent work from O’Hagan et al. with enzymatic 
fluorination of sugar and nucleoside derivatives88,89 or the elegant strategy 
from Harada et al. for the preparation of 11C/18F-labeled proteins using 
cell-free translation systems.74,108 
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A recurrent apprehension regarding the use of biological catalysts for the 
preparation of injectable solutions is often mentioned as a drawback for 
the incorporation of PET radionuclides into molecules by enzymatic 
methods. However, several factors may open a second era in the enzymatic 
preparation of radiopharmaceuticals: first, a legislative evolution has 
occurred in the last decades; second, protein engineering and improvement 
of industrialized and commercial methods for the preparation of enzymes 
have brought a new safety paradigm compatible with GMP practices.100,101 
Unlike in the past, where these biomolecules were often synthesized and 
isolated in situ for further use, nowadays they can be purchased through 
certified companies that ensure biological safety and absence of pyrogens 
or cell-derived residues; third, improvements in immobilization techniques 
and the availability of a wide range of spin or membrane filters facilitate 
purification steps. In this context, it can be expected that enzymatic 
synthesis will progressively find more and more applications both in the 
pre-clinical and clinical settings. The execution of the experimental work 
reported in this PhD thesis (see chapters 4-6) has resulted in a significant 
contribution to the development of novel strategies for the radiosynthesis 
of 13N-labeled compounds using enzymatic catalysis.   
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BACKGROUND 
Emerging PET applications, together with the need for better, more 
efficient and even personalized diagnostic tools, have resulted in a boost 
in the demand for new molecular probes for biological targets currently 
inaccessible to this technique. The development of such molecular probes 
(radiotracers) requires a multidisciplinary vision and approach, which 
should start at target identification, structure design and 
development/implementation of radiolabeling strategies, followed by 
exhaustive in vitro and in vivo testing, ultimately leading to radiotracer 
validation. 
The radiochemistry associated with the synthesis of radiotracers is far from 
trivial, especially for short half-lived radionuclides. Because of the limited 
availability of training programs in this field, PET centres and 
(radio)pharmaceutical companies compete for a limited pool of talent. This 
gap was identified by Prof. V. Gouverneur (University of Oxford), 
coordinator of the Marie-Curie FP7-PEOPLE-ITN action RADIOMI 
(2012-2016). In this initiative, six academic and two industrial partners, 
all of them leading experts in the areas of chemistry and radiochemistry, 
pooled their expertises to implement a coordinated, first-class training 
program to produce new talent in PET radiochemistry, focused on the 
development of innovative radiolabeling strategies for the preparation of 
small molecules labeled with short-lived positron emitters, namely 
fluorine-18, carbon-11 and nitrogen-13, while spanning over a wide range 
of molecular formats. Besides establishing a cutting-edge, scientifically 
sound research program, this successful initiative aimed to provide 
transnational and cross-sectorial training to 15 ESRs and 3 ERs, covering 
different aspects of radiolabeling using positron emitters.  
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CIC biomaGUNE, a research institution located in San Sebastian and 
where the experimental part of the current PhD thesis was conducted, 
participated in such initiative. Due to the previous work and tracked 
experience of Dr. Llop’s group in the field of 13N-radiochemistry, the 
specific role of CIC biomaGUNE team within the project was to develop 
innovative labeling strategies using nitrogen-13. With that aim, two PhD 
students were selected. One of them, Sameer M. Joshi, was focused on the 
development of novel strategies for the preparation of 13N-labeled 
compounds using the labeling agent [13N]NO2-. The project for the second 
PhD student, myself, Eunice S. Da Silva, author of the work presented 
here, should focus on developing innovative enzymatic strategies for the 
preparation of radiolabeled amino acids. In the experimental work, I was 
able to merge radiochemistry and biocatalysis to access valuable 
radiotracers in a more efficient manner thanks to the close collaboration 
established with the group of Heterogeneous biocatalysis from CIC 
biomaGUNE and led by Dr. Fernando López Gallego, who is the co-
supervisor of this thesis together with Dr. Jordi Llop. This fruitful 
collaboration, which started at the beginning of the thesis and is still active 
nowadays, and aims to apply biocatalytic solutions in radiochemistry. This 
thesis is a clear example of how to succeed bringing together two different 
areas to develop a multi-disciplinary project.  
Besides conducting the experimental work and getting involved in a 
cutting-edge research program at the local level, participation in the 
RADIOMI initiative provided me with the opportunity to collaborate with 
other different fields such as cancer research in collaboration with Prof. 
Arkaitz Carracedo (Animal studies), and to attend periodic meetings and 
different workshops, schools and international conferences, which have 
contributed to my overall education.   
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In this context, the first goal of the current PhD was the investigation of 
the work published in the field of enzymatic catalysis applied to 
radiochemistry. This investigation was focused on the work published 
since 1980 when the last review describing the applications of enzymatic 
methods in radiochemistry for the synthesis of PET radionuclides was 
published. All the literature found in this area was reviewed and the 
manuscript has been submitted to a scientific peer-reviewed journal 
(Journal of Labelled Compounds and Radiopharmaceuticals). Hence, the 
state-of-art of the enzymatic methods in radiochemistry was the basis of 
the work presented in the previous Chapter 2. 
Considering the potential of the enzymes observed within this literature 
revision, the first experimental goal of the present PhD was to develop 
biocatalytic strategies for the preparation of pure 13N-nitrite, which can be 
used as suitable labeling precursor for the subsequent preparation of 13N-
labeled molecules of interest. The results obtained were published in 
Catalysis Science & Technology (Catal. Sci. Technol., 2015,5, 2705-2713 
DOI: 10.1039/C5CY00179J) and are the basis of Chapter 4 of this PhD 
thesis. 
The successful application of enzymes in nitrogen-13 radiochemistry 
obtained in the first experimental work aroused our interest in the 
development of other enzymatic strategies to label small biomolecules. For 
example, amino acids could be very interesting tracers for the detection of 
some types of cancer. Enantioselective chemical synthesis of amino acids 
is also problematic and very hard to achieve. The use of enzymes could 
help, thanks to their fast reaction rates and unique enantio- and chemo-
selectivity. L-alanine dehydrogenase from Bacillus subtilis was the 
selected enzyme for the synthesis of amino acids which use ammonia as 
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substrate. This biocatalyst was firstly tested and characterized under non-
radioactive conditions. After optimization of the experimental conditions, 
the experimental setup was then applied to the synthesis of a variety of 
13N-labeled amino acids (L-[13N]alanine, [13N]glycine, and L-[13N]serine). 
The enzymatically radiolabeled amino acids were further analyzed 
regarding their in vivo biodistribution in healthy (wild-type) mice. The 
capacity to selectively accumulate in the tumor was assessed in a prostate 
cancer mouse model kindly provided by Prof. Carracedo. This work, 
which is the basis of Chapter 5 of the current PhD thesis, was published 
in Chemistry - A European Journal (Chem. Eur. J. 2016, 22, 13619. DOI: 
10.1002/chem.201602471). 
The third experimental part of the PhD thesis consisted in the stabilization 
of L-Alanine dehydrogenase from Bacillus subtillis into a solid carrier. 
This enzyme has been intensively exploited in biocatalysis but its 
immobilized form is rarely used. The immobilization of L-Alanine 
dehydrogenase from Bacillus subtillis was essayed on three different 
agaroses. After optimization of the experimental conditions and selection 
of the best catalyst, the experimental set up was then applied to the 
synthesis of labeled amino acids. This work, which is described in 
Chapter 6 of the current PhD thesis, was published in Process 
Biochemistry (Proc. Biochemistry. 2017. DOI:         
10.1016/j.procbio.2017.03.005).  
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OBJECTIVES 
The general objective of this PhD thesis was the development of enzymatic 
strategies for the preparation of 13N-labeled of radiotracers. To achieve this 
goal, the following specific objectives were defined: 
1- To acquire a solid knowledge about the potential of the biocatalysis in 
radiochemistry in order to design enzymatic strategies for efficient 
synthetic routes of relevant radiotracers.  
2- To develop an immobilized biocatalyst-based on a NADPH-dependent 
nitrate reductase for the one-pot preparation and one-step purification 
of [13N]NO2-, to be used as a radioactive precursor for the subsequent 
chemical synthesis of S-[13N]nitrosoglutathione.  
3- To select and produce a suitable NADH-dependent L-amino acid 
dehydrogenase to synthesize enantiopure 13N-labeled amino acids 
using [13N]NH3 as the primary labeling agent and -ketoacids as 
starting materials.  
4- To integrate a recycling enzyme (formate dehydrogenase) to the 
synthetic process developed in objective 3, in order to in situ replenish 
the pool of NADH. 
5- To assess the biodistribution of the 13N-labeled amino acids 
synthesized in objective 3 in healthy mice; to evaluate the potential of 
these 13N-labeled amino acids as radiotracers for the diagnostic of 
prostate cancer in animals with Pten deletion. 
6- To stabilize the amino acid dehydrogenase selected in objective 3 by 
immobilizing this enzyme on solid carriers using different 
immobilization chemistries; to fabricate and characterise a robust 
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heterogenous biocatalysts in order to run consecutive cycles of 
radiochemical synthesis of 13N-labeled amino acids. 
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In the present chapter, an unprecedented strategy for the reduction of [13N]NO3- to 
[13N]NO2- using a heterogeneous biocatalyst will be presented. A eukaryotic nitrate 
reductase from Aspergillus niger was immobilized on different carriers. Optimal 
immobilization yield and recovered activities were obtained when this enzyme was 
immobilized on porous agarose beads activated with positively charged tertiary amino 
group (Ag-DEAE). The optimal immobilized preparation was 12-fold more thermostable 
than the soluble enzyme. Biochemical characterization of the immobilized enzyme 
showed an interesting thermal-induced hyperactivation driven by the interaction between 
the enzyme and the carrier. The best heterogeneous biocatalyst could be re-used up to 7 
reaction cycles preserving its initial activity. Finally, to demonstrate the potential of this 
heterogeneous biocatalyst in the context of radiochemistry, a chemo-enzymatic 
radiosynthesis of S-13N]nitrosoglutathione was approached using enzymatically 
produced [13N]NO2- as the labeling precursor.  
Efficient [13N]nitrate reduction catalyzed by a 
highly stable immobilized biocatalyst 
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INTRODUCTION 
As recently shown by our research group, the labeling agent 
[13N]NO2- is a useful precursor for the preparation of a wide range of 
labeled compounds such as S-[13N]nitrosothiols1,2, S-
[13N]nitrosamines3, 13N-labeled azo derivatives4,5, 13N-labeled 
azides6 and 13N-labeled triazoles7, and further applications are 
currently being investigated8. Unfortunately, direct production of 
[13N]NO2- in the cyclotron is not feasible and it is usually obtained 
by reduction of [13N]NO3- to [13N]NO2- using a typical column 
containing activated cadmium.9 Besides the inherent toxicity of 
cadmium, which may hamper the translation of the technology to the 
clinical field, this experimental setting presents several technological 
pitfalls.  
Inspired by the biological cycle of nitrogen10, we reasoned that 
eukaryotic nitrate reductase (eNR)11 may efficiently catalyze the 
reduction of [13N]NO3- to the more convenient labeling agent 
[13N]NO2-. The enzyme eNR is a homodimer which contains three 
different domains per monomer: one N-terminus domain that binds 
NADPH and FAD+ as redox cofactors (NADPH-domain), a second 
cytochrome b domain containing a Fe-heme cofactor (heme-domain) 
and a third C-terminus domain that binds a molybdopterin cofactor 
(MOCO-domain). All these cofactors are required during the 
catalytic cycle; while FAD+, heme and MOCO cofactors are stably 
bound to the enzymes, NADPH must be exogenously added to the 
reaction media. The enzyme mechanism relies on the large 
conformational change that approaches the NADPH/FAD+ and heme 
domains to the MOCO domain, allowing the electron transfer from 
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NADPH to molybdenum via the heme group to reduce nitrate to 
nitrite (Figure 4.1).12 
 
 
Figure 4.1. Hypothetical reaction cycle of nitrate reduction by NR. The 
reaction starts with the reduced MoIV form (1). Then, nitrate binds to the 
active site (2) and replaces the equatorial hydroxo/water ligand, forming an 
intermediate (3). The bond between the nitrate oxygen and nitrogen is 
broken and nitrite is released (4); consequently, the Mo center is oxidized 
to MoVI (5). After completion of the reductive half-reaction, the Mo is 
regenerated [Mo(IV)] for the next cycle. Adapted from the reference12. 
 
Nitrate reductase has been mainly applied for the detection and 
determination of nitrate in different sources. Nitrate is a typical inorganic 
pollutant in environmental, food, industrial and physiological systems13,14, 
therefore, various methods for detection and determination of nitrate have 
been reported, involving spectroscopic, chromatographic, electrochemical 
detection methods, etc.15,16 Although, spectroscopic and chromatographic 
methods are accurate and reliable, they require bulky, delicate and 
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expensive equipment which is not suitable for in situ applications. Over 
the past decades, the immobilization of nitrate reductase has been quite 
exploited in biosensors based on immobilization methods, consisting of 
another option for optical17 and electrochemical18-21 biosensing 
applications. However, the immobilization of this enzyme is rather 
challenging since restrictions in the conformational flexibility 
required for the catalysis may compromise the reducing capacity. 
This structural complexity may explain the low recovered activity of 
immobilized eNRs reported elsewhere.22 In our work, we pretend to 
stabilize and make use of the nitrate reductase not for nitrate 
detection but to incorporate it in radiochemical synthetic routes. To 
the extent of our knowledge, the nitrate reductase has been not tested 
in any synthetic approaches. 
In the present chapter, we will present the unprecedented use of eNR 
as an efficient heterogeneous biocatalyst for the reduction of 
[13N]NO3- to [13N]NO2-. The immobilization chemistry was 
optimized to yield active and stable preparations of immobilized eNR 
on porous agarose beads. As a proof of concept of the applicability 
of the experimental set up to the preparation of PET tracers, the 13N-
labeled nitrosothiol S-[13N]nitrosoglutathione ([13N]GSNO) was 
prepared with an excellent radiochemical conversion. 
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EXPERIMENTAL SECTION 
Materials 
Agarose beads activated with a primary amine group (Ag-MANAE)23, 
coated with 25 KDa polyethyleneimine (Ag-PEI)24 and coated with 
dextran-sulphate (Ag-DS)25 were prepared as described elsewhere. 
Cyanogen bromide-activated-Sepharose® 4B (Ag-CB) was purchased 
from Sigma-Aldrich Química S.A. (Madrid, Spain) and diethyl-
aminoethyl Sepharose (Ag-DEAE) was purchased from GE healthcare 
(Pittsburgh, USA). Nitrate reductase from Aspergillus niger and reduced 
β-Nicotinamide adenine dinucleotide 2′-phosphate tetrasodium salt (β-
NADPH; purity >97%) were purchased from Roche Life Science 
(Barcelona, Spain). Sodium nitrite (NaNO2, ACS reagent, Ph. Eur.), 
sodium nitrate (NaNO3, ACS reagent), sodium phosphate dibasic 
(Na2HPO4, for molecular biology, purity  ≥98.5%), sodium phosphate 
monobasic (NaH2PO4, purity ≥99.0%), glutathione (GSH, purity  ≥99%), 
S-nitrosoglutathione (GSNO, purity  ≥97%), hydrochloric acid (HCl, 1 M 
standard solution), sodium hydroxide (NaOH, ACS reagent), 
trifluoroacetic acid (CF3COOH, HPLC grade) and acetonitrile (CH3CN, 
HPLC grade) were purchased from Sigma-Aldrich Química S.A. (Madrid, 
Spain) and used without further purification. Bio-Rad Protein Assay Dye 
Reagent Concentrate was purchased from BIO-RAD (Madrid, Spain). 
Additive for ionic chromatography mobile phase (P/N 5062-2480) was 
purchased from Agilent Technologies (Madrid, Spain). All others reagents 
were of analytical grade unless otherwise specified. 
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METHODS 
Structural modeling of nitrate reductase from Aspergillus niger. 
Structural homology models complexed with molybdenum, NADPH, 
FAD+ and heme cofactors were built by using different structural 
templates and aided by the homology-modeling server from Expasy.26 The 
modeling server selected the nitrate reductase from Pichia pastoris (2BIH) 
complexed with molybdopterin as template to model the molybdenum 
binding domain with 56% identity (Figure 4.2A). However, the server 
modeled both cytochrome and NADPH/FAD+ domains by using NADH-
dependent cytochrome B5 reductase from rat (1IB0) complexed with both 
FAD+ and NAD+ as a template showing 39% identity (Figure 4.2B).  
 
 
Figure 4.2. Plot showing predicted local similarity for the MOCO domain (A) 
and the NADPH binding domain (B) of eNR enzyme model by the homology-
modeling server from Expasy (predicted local similarity versus residue number). 
 
Structures are validated by comparison of an atomic model with their 
amino acid sequences and assignment from 1 (high reliability) to 0 ( poor 
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reliability) for each amino acid positions. The model for the domain that 
binds NADPH, FAD+ and heme has a very good compatibility score, while 
the model for the molybdenum binding domain presented very low score 
mainly due to the low compatibility of its N-terminus that was highly 
flexible and consequently hard to model. Protein models were visualized 
and aligned with their template structure by using PyMol 0.99 developed 
by DeLano Scientific LLC (San Francisco, CA). The electrostatic potential 
was calculated by using Bluues server.27 
Determination of the enzyme activity and protein concentration. The 
activities of both free and immobilized nitrate reductase from Aspergillus 
niger were determined by measuring the decrease in absorbance at 340 
nm, resulting from NADPH oxidation during the enzymatic conversion of 
nitrate to nitrite. A sample of enzyme solution of 10 L was incubated in 
a multi-well plate with 190 L reaction mixture with a final concentration 
of 10 mM sodium phosphate buffer, 0.21 mM NADPH and 4.25 mM 
NaNO3 at 25°C and pH 7.5 under mild shaking. When indicated, different 
temperatures and pH values were used. One activity unit was defined as 
the amount of enzyme required to oxidize 1 μmol of NADPH under the 
above-described conditions. The protein concentration of all soluble eNR 
samples was measured by using Bradford’s method28 and bovine serum 
albumin (BSA) as a protein standard. 
Kinetic parameters. The kinetic parameters were calculated from the 
initial rate values determined with different concentrations of NADPH (0-
2 mM) and nitrate (0-20 mM). Results were fitted to Michaelis-Menten 
equation by non-linear regression and Km and kcat were calculated using 
OriginPro 8.0 software.  
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Enzyme Immobilization. The eNR was immobilized on agarose beads 
activated with cyanogen bromide groups (Ag-CB), on agarose beads 
activated with either positively charged mono-aminoethyl groups (Ag-
MANAE) or diethyl-aminoethyl groups (Ag-DEAE) and coated with 
positively charged poly-ethylenimine (Ag-PEI), and on agarose beads 
coated with negatively charged dextran-sulphate (Ag-DS). 
Generally, all the immobilizations were carried out by adding 200mg of 
the corresponding carrier (Ag-CB, Ag-DEAE, Ag-MANAE, Ag-PEI and 
Ag-DS) to 1mL of soluble eNR (1-5U/mL) in 10 mM sodium phosphate 
at pH 7.5. The suspension was kept under mild stirring at 25°C. 
Periodically, samples of the supernatants and the carrier-enzyme 
suspensions were withdrawn and analyzed to evaluate the progress of the 
immobilization process. In parallel, a blank of the soluble enzyme (without 
a carrier) was also analyzed. After immobilization, enzyme preparations 
were washed with an excess of distilled water and immobilization buffer 
to eliminate any non-bound protein molecule.  
The immobilization on Ag-CB requires a pre-activation of the carrier; 
thus, 0.2 g of the lyophilized carrier was washed and swell with 10mL HCl 
1 mM during 30 min, followed by gentle filtration between successive 
additions of water. Then, the washed carrier was equilibrated with 100 mM 
NaHCO3 in 0.5 M NaCl, pH 8.3. eNR was incubated with the support 
under mild stirring at room temperature. The support containing the 
immobilized eNR was washed with Tris–HCl using 0.1 M HCl, pH 8.0, 
followed by 0.1 M acetic acid/sodium acetate containing 0.5 M NaCl, pH 
4.0 (3 cycles of alternating pH buffers) to block any remaining active 
groups. 
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Thermal stability of soluble and immobilized eNR. All enzyme 
preparations (both soluble and immobilized), were incubated in 10mM 
sodium phosphate buffer (pH 7.5) at different temperatures (25-55°C) for 
15 min. As previously described, the eNR activities were assayed at 25 ºC. 
In a different experiment, soluble and immobilized preparations were 
incubated at 40ºC, and samples were withdrawn at different times and 
assayed at 25ºC to determine the residual activity. The inactivation 
constant is calculated by fitting the thermal inactivation curve to first-order 
kinetics equation (A/Ao=e-k*t) considering that the enzyme becomes 
completely inactivated after a certain time. The fitting was carried out by 
using OriginPro 8.  
Loading capacity. For the best immobilization chemistry, Ag-DEAE, 
loading capacity studies were carried out. Different amounts of Aspergillus 
niger eNR preparation (0.0075; 0.0107; 0.0143; 0.0255; 0.0349 mg 
protein) were offered to 200 mg of Ag-DEAE suspended in 1 mL of 10 
mM sodium phosphate buffer at pH 7.5. The amount of protein bound to 
the carrier was determined as the difference between the initial and the 
residual protein concentration in the supernatants. This loading capacity 
was also monitored by analyzing both initial and residual enzyme activity 
in the supernatant. For each enzyme load, recovered activity of the 
immobilized eNR was measured upon the immobilization process.  
Fluorescence Spectroscopy studies. Fluorescence measurements were 
carried out in a Varioskan Flash fluorescence spectrophotometer (Thermo 
Scientific), monitoring the intrinsic fluorescence of soluble and 
immobilized Aspergillus niger eNR on Ag-DEAE, using an excitation 
wavelength of 280nm with excitation and emission bandwidths of 5 nm 
and recording fluorescence emission spectrum between 300 and 600nm. 
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All spectroscopic measurements were made in 10 mM sodium phosphate 
at pH 7.5 and 25ºC. 
Activity-pH profile of eNR soluble and immobilized on Ag-DEAE. The 
effect of pH on the activity of the enzyme preparations was determined by 
measuring the residual activities of eNR at the different pH values 
(5<pH<10) and 25°C. The expressed activity was measured as described 
before. Different 10 mM buffer solutions were used to set the right pH 
value; acetate buffer was used for pH 5-6; sodium phosphate buffer for pH 
7-8 and sodium bicarbonate buffer for pH 9-10. 
Production of the radioactive precursor [13N]NO2- by enzyme 
catalysis: general procedure 
Nitrogen-13 was produced in an IBA Cyclone 18/9 cyclotron via the 
16O(p,α)13N nuclear reaction. The target system consisted of an aluminum 
insert (2 mL) covered with havar foil (thickness 25 μm, ∅ 29 mm) and with 
an aluminum vacuum foil (thickness 25 μm, ∅ 23 mm). The target 
(containing 1.75 mL of ultrapure water, Type I water, ISO 3696) was 
irradiated with 18MeV protons. The beam current was maintained at 20 
μA (pressure in the range 5–10 bar into the target during bombardment) to 
reach the desired integrated currents (0.1-0.5 μAh). The resulting solution 
was transferred to a 10mL vial and the activity was measured in a dose 
calibrator (Capintec CRC®-25 PET, New Jersey, USA). The final 
activities (corrected to the end of irradiation) were in the range 333-1110 
MBq (9-30 mCi).   
Enzymatic reduction of [13N]NO3- to [13N]NO2- was carried out with 6.72 
mU of immobilized eNR packed into a plastic column. This insoluble 
preparation was incubated with 90 L of cyclotron produced 13N solution 
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(which contained [13N]NO3-) in the presence of 10L of 2.1 mM NADPH 
(0.21 mM final concentration) in 500 mM sodium phosphate buffer (50 
mM final concentration; pH 7.5) under mild conditions (25°C and pH 7.5) 
for 4 min. Relative amounts of [13N]NH4+, [13N]NO2- and [13N]NO3- were 
measured by radio-HPLC. An Agilent 1200 series HPLC equipped with a 
quaternary pump, a multiple wavelength detector and a radiometric 
detector (Gabi, Raytest) was used. An HP Asahipak ODP-50 (5 µm, 125x4 
mm, Teknokroma, Spain) was used as stationary phase, and a solution 
containing additive for ionic chromatography (15 mL) in 1L of a mixture 
water/acetonitrile (86:14) basified to pH 8.6 with 1M sodium hydroxide 
solution was used as the mobile phase at a flow rate of 1 mL/min. 
Simultaneous UV (λ = 254 nm) and isotopic detection were used. 
Recycling of eNR immobilized on Ag-DEAE. Reusability of eNR 
immobilized on Ag-DEAE was evaluated by performing consecutive 
catalytic cycles at 25°C using nitrate (both non-radioactive and 
radioactive) and NADPH as substrates. In some experiments, the 
immobilized enzyme was incubated with a solution 1.0 mM NADPH and 
the nitrate reduction was carried out without adding exogeneous NADPH. 
After each cycle, the immobilized preparation was washed and the 
enzymatic activity towards non-radioactive nitrate was determined by 
spectrophotometry, while the final yield towards radioactive nitrate was 
determined by radio-HPLC. 
Two-step chemo-enzymatic synthesis of S-[13N]nitrosoglutathione 
([13N]GSNO) 
The preparation of [13N]GSNO followed the synthetic protocol previously 
reported,2 but the [13N]NO2- used as the labeling agent was enzymatically 
synthesized. A radioactive solution (300 µL) containing cyclotron 
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produced [13N]NO3- was incubated in a packed column equilibrated with 
1 mM NADPH loaded with 175µg eNR per g of carrier (22mU of 
immobilized eNR determined as previously described) for 4 min; the 
resulting supernatant containing [13N]NO2- was diluted with 1 mL of 10 
mM sodium phosphate buffer (pH=7.5) and then flushed through an anion 
exchange cartridge (Sep-Pak® Accell Plus QMA, Waters) to selectively 
retain [13N]NO2-. The column was further washed with distilled water (2 
mL) and the QMA cartridge was dried with nitrogen gas for 15s. An acidic 
solution of the precursor glutathione (0.5 mL; 1 mM) was loaded into the 
cartridge and the nitrosation reaction was allowed to occur; the reaction 
mixture was finally eluted directly into a collection vial. The identification 
of [13N]GSNO was performed by co-elution with reference standard using 
the same HPLC system described above; in this case, a Mediterranean 
SeaRP-18 column (5µm, 150 x 4.6mm, Teknokroma, Spain) was used as 
stationary phase and aqueous TFA solution/acetonitrile (95:5) was used as 
the mobile phase at a flow rate of 1 mL/min. Simultaneous UV (λ = 220 
nm) and isotopic detection were used. 
 
RESULTS AND DISCUSSION 
Immobilization of eNR on functionalized porous agarose beads 
Eukaryotic nitrate reductase from Aspergillus niger was immobilized 
through different immobilization chemistries on a survey of agarose-
based matrixes: i) irreversibly immobilized through its N-terminus on 
agarose beads activated with cyanogen bromide groups (Ag-CB); ii) 
reversibly immobilized through its acid amino acid richest regions on 
agarose beads activated with either positively charged mono aminoethyl 
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groups (Ag-MANAE) or diethyl aminoethyl groups (Ag-DEAE) and 
coated with positively charged polyethylenimine (Ag-PEI); and iii) 
through its basic amino acid-richest regions on agarose beads coated with 
negatively charged dextran sulphate (Ag-DS), see Table 3.1. 
 
Table 4.1. Parameters of Aspergillus niger nitrate reductase immobilization onto 
agarose carrier via different chemistries. 
CARRIER Reactive group 
μmol of 
amines 
per gram 
of carrier 
Immobilization 
chemistry 
Immobilized 
Activity 
Ai (mU/g)a 
Immobilization 
yield  (%)b 
Expressed 
Activity 
Ae (mU/g)c/ 
(%)d 
Ag-CB Cyanogen Bromide 
 
- 
Covalent bond 
through the 
eNR Nt 
964±32 96±3 26±4 / (3) 
Ag-
DEAE 
Diethyl-
aminoethyl 150 Ionic 
adsorption 
through the 
most acid eNR 
regions 
995±10 99±1 210±60 / (21) 
Ag-PEI 
 
Poly-
ethylenimine 
3448 982±12 98±1 155±25 / (16) 
Ag-
MANAE 
 
Mono-
aminoethyl 
5 820±24 82±2 192±41 / (23) 
Ag-DS Dextran-sulphate 
 
- 
Ionic 
adsorption 
through the 
most basic 
eNR regions 
750 75 58 / (8) 
The initial offered activity was always 1000mU per gram. aAi=The activity immobilized on 1 gram of carrier after 
the immobilization process. This activity was calculated as the difference between the offered activity and the 
activity in the supernatant after incubation with the carrier for 1h. bImmobilization yield () = (immobilized 
activity/offered activity) x 100. cThe expressed activity (Ae) is defined as the measured activity of the immobilized 
enzyme after washing. dRelative expressed activity (Ae) = (expressed activity/immobilized activity) x 100. 
 
As it can be seen at Table 4.1, all carriers were able to efficiently 
immobilize eNR (immobilization yields >75% in all cases), although low 
values of expressed activity were achieved after immobilization when 
compared to the free enzyme. Irreversible immobilization and cationic 
exchange on Ag-CB and Ag-DS led to a dramatic decrease in the 
expressed activity (26±4 and 58 mU/g, respectively). On the other hand, 
ionic immobilization of eNR on positively charged carriers yielded values 
of expressed activity in the range 155-210 mU/g, resulting in up to 23% of 
Chapter 4 
103 
relative expressed activity. Noteworthy, although the chemistry that drove 
the immobilization on Ag-MANAE, Ag-DEAE and Ag-PEI was the same, 
Ag-MANAE offered lower immobilization yields (82±2%) than Ag-
DEAE (99±1%) and Ag-PEI (98±1%). This fact may be explained because 
Ag-MANAE surface presents a lower density of positively charged groups 
than Ag-DEAE and Ag-PEI surfaces, see Table 4.1.  
In order to explain the functional discrepancies obtained with the different 
immobilized preparations, we further studied the eNR surface to 
understand how the protein orientation on the carrier surface may affect its 
functionality. Unfortunately, X-ray structure of eNR from A. niger has not 
been solved yet, and hence its 3D-structural homology model containing 
the NADPH-domain, the heme-domain and the MOCO-domain was built 
(Figure 4.3A) and the electrostatic surface potential was calculated in 
order to determine the spatial charge distribution across the enzyme 
surface (Figure 4.3B and 4.3C). The analysis of this structural model 
reveals an acidic belt on the MOCO-domain located at the opposite face 
regarding the active site. The model also shows that heme, FAD+, NAD+ 
and molybdenum binding sites are surrounded by basic amino acids 
(Figure 4.3C).  
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Figure 4.3. Structural model of a monomer of eNR from Aspergillus niger. (A) 
Cartoon representation of 3D-structural homology model by using the X-ray 
structures of eNR from Pichia pastoris and cytochrome B5 from rat complexed 
with both FAD+ and NAD+ as templates for molybdenum domain (N-terminus) 
(orange) and cytochrome domain (C-terminus) (purple) respectively. The sphere 
representation colored in cyan depicts the dimerization domain of the eNR. Green 
sticks represent the cofactors NAD+, FAD+ and molydopterin. (B) Surface 
electrostatic potential of eNR calculated by Bluues server (back face of active 
site) and (C) proposed orientation of eNR monomer on porous Ag-DEAE 
surface. The blue circles represent the tertiary amine groups located on the carrier 
surface. The surface electrostatic potential is depicted with a red-blue gradient 
that corresponds to the acid-basic gradient. All the images were prepared by using 
Pymol 0.99v.  
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These structural observations suggest that eNR immobilized on Ag-DS is 
oriented through its active site (basic region), hampering the accessibility 
of both NADPH and nitrate to the catalytic pocket with a consequent 
decrease in catalytic efficiency. Nevertheless, the eNR orientation onto 
positively charged carriers seems to occur through one acidic region 
located far away from the binding pockets. Therefore, active centres 
remain fairly accessible for the substrates, resulting in significantly higher 
relative expressed activity values for such immobilized preparations 
(Figure 4.3C). Moreover, such orientation seems to negligibly affect 
dimmer stability because the dimerization domain is not involved in the 
protein-carrier interaction. In fact, when eNR immobilized on Ag-DEAE 
was incubated under high ionic strength conditions, the enzyme was 
quantitatively eluted to the supernatant, demonstrating the ionic character 
and the reversibility of this immobilization chemistry. 
The values of expressed activity shown in Table 4.1 have been determined 
by using NADPH as a cofactor; such values are relatively high when 
compared with previous results obtained using immobilization protocols 
based on porous hydrogels. For example, eNR from Aspergillus niger 
immobilized on a porous vinyl polymeric matrix expressed less than 2% 
of its expressed activity by using NADPH as cofactor.22 The high 
structural complexity of eNR might be the main reason for the low 
expressed activity achieved in this previous work. This enzyme requires 
enough structural flexibility for efficient electron transfer between both the 
cytochrome and the molybdenum domains. Hence, immobilization 
chemistries that highly rigidify the 3D structure of eNR (covalent 
immobilization), may hinder the catalytic conformational changes or 
promote wrong protein orientations that limit either the electron transfer 
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or the substrate accessibility, resulting in a low expressed activity of the 
immobilized preparation.  
 
Effects of the temperature on both activity and stability of soluble and 
immobilized eNR 
The thermal stabilities of immobilized and soluble eNR were tested at 
different temperatures. Figure 4.4A shows the inactivation courses of the 
three different immobilized preparations incubated at pH 7.5 and 25°C. 
The half-life time of eNR immobilized on Ag-DEAE was estimated 30-
fold and 6-fold higher than eNR immobilized on Ag-MANAE and Ag-
PEI, respectively, suggesting that the thermal stability of the immobilized 
enzymes relies on the chemical nature and density of the amine groups 
located on the surface of the carrier. The surface of Ag-DEAE containing 
150 μmol/g of tertiary amine groups seems to establish more favourable 
interactions with the acidic protein regions than the Ag-MANAE surface, 
which presents low density of primary amine groups (5 μmol/g), and the 
Ag-PEI surface coated by a polymeric bed with a high density of primary, 
secondary and tertiary amine groups (3448 μmol/g). Ag-PEI has been 
suggested as an excellent carrier to stabilize multimeric enzymes, because 
the basic polymeric bed establishes 3D-protein-polymer interactions24 that 
attach all the subunits to the carrier, resulting in a stabilization of the 
quaternary structure of the protein. Unexpectedly, in this study, eNR 
immobilized on Ag-PEI was less stable than eNR immobilized on Ag-
DEAE. This unexpected result may be explained because the flexibility of 
the polymer may generate additional interactions with the protein over 
time. Such enhancement of the spatial reactivity may lead to undesired 
interactions between both cytochrome and molybdenum domains and the 
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polymeric brushes, reducing the enzyme flexibility required for the 
electron transfer, and consequently decreasing the nitrate reduction 
activity over time. Those negative interactions would not be possible to 
the much less flexible Ag-DEAE surface formed by a 2D-monolayer of 
tertiary amine groups. Hence, our results suggest that the interaction 
between eNR and the positively charged carriers must be strong enough to 
guarantee the stabilizing immobilization effect and flexible enough to 
enable the conformation changes required for the catalysis. 
 
 
Figure 4.4. Stability of eNR. (A) Inactivation course of different eNR 
immobilized preparations at 25°C and pH 7.5. eNR was immobilized on Ag-
DEAE (●); Ag-PEI (▲); Ag-MANAE (■). Values are normalized to starting the 
activity. (B) Inactivation of eNR soluble (white bars) and immobilized on Ag-
DEAE (black bars) at different temperatures. Soluble and immobilized 
preparations were incubated 15 minutes at different temperatures and then 
activities were assayed at 25 ºC. 
 
As it can be seen in the Figure 4.4B, the enzyme immobilized on Ag-
DEAE was much more stable than its soluble counterpart under a broad 
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range of temperatures, between 30-55°C. Surprisingly, when such 
immobilized biocatalyst was incubated for only 15 minutes in the range of 
40-45°C, a 2-fold activity enhancement (hyperactivation) was observed 
with respect to the non-thermally treated enzyme. 
 
 
Figure 4.5. Activity/temperature profile of both soluble and immobilized eNR. 
Reductase activity of eNR immobilized on Ag-DEAE (white bars) and soluble 
eNR (black bars) was assayed at different temperatures at pH 7.5. 
 
Such hyperactivation effect was not observed with the soluble enzyme, 
which decreased its initial activity after incubation at temperatures higher 
than 25°C due to thermal inactivation. Interestingly, both the soluble and 
immobilized enzymes showed similar activity/temperature profiles. 
Figure 4.5 displays that the activity of soluble and immobilized enzymes 
at different temperatures is very similar: both preparations showed a 
maximum of activity in the range of 25-50. These results point out that the 
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temperature does have a differential effect on the conformational stability 
of the immobilized enzyme compared to the soluble one, but it does 
similarly affect their catalytic properties under different reaction 
temperatures. The optimal temperature of eNR, both for its soluble and 
immobilized forms, ranges 25-30ºC, which agrees with the optimal 
temperature of other mesophilic enzymes. Hence, these results suggest that 
the aforementioned hyperactivation effect can only be attributed to the 
carrier and that is not related to the effect of the temperature on the 
catalysis itself. 
Inactivation kinetics studies of the hyperactivated immobilized enzyme at 
conditions of pH 7.5 and 40°C proved an enhanced stability with respect 
to its soluble counterpart under the same conditions (Figure 4.6). The 
inactivation courses for both soluble and immobilized enzyme follow first-
order kinetics where the inactivation rate depends on the inactivation 
constant. The immobilized enzyme showed a thermal inactivation constant 
(ki) of (1.31±0.63)x10-5 (s-1) at 40°C, while the ki value of the soluble 
enzyme was (15.3±2.3)x10-5 (s-1). These findings confirm that the 
immobilization process results in an increased half-life time (t1/2) of eNR 
up to 883 minutes; 12 times longer than the t1/2 of the soluble enzyme. 
The thermal-hyperactivation and thermal-stabilization effects observed for 
eNR immobilized on Ag-DEAE may be explained by some beneficial 
enzyme-carrier interactions triggered by the temperature and that drive to 
some local structural re-organization in the enzyme, resulting in a more 
efficient electron transfer between the NADPH and the MOCO domains. 
Those interactions may stabilize a more beneficial conformation for eNR, 
which explains the 2-fold more active and 12-fold more stable enzyme 
compared to its soluble counterpart. These carrier- and temperature-
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assisted conformational changes were further investigated by fluorescence 
studies. 
 
 
Figure 4.6. Thermal inactivation courses of Aspergillus niger nitrate reductase 
immobilized onto Ag-DEAE at 40°C. The preparation of A. niger eNR insoluble 
derivative was carried out as described in Section Material and Methods. Each 
insoluble and soluble preparations were incubated in 10mM sodium phosphate at 
pH 7.5 and 40ºC. The A. niger eNR preparations used to perform these studies 
were: immobilized on Ag-DEAE (●) and soluble (♦). 
 
Fluorescence spectrum analyzed at 25 ºC was obtained for soluble eNR 
and immobilized eNR on Ag-DEAE with or without incubation at 40ºC 
during 15 minutes. 
As can be observed in Figure 4.7, the fluorescence spectrum of the soluble 
enzyme remained unaltered after the thermal incubation at 40ºC in spite of 
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the activity decay induced by the thermal treatment. However, a deep 
change in the fluorescence spectrum of the thermal incubated eNR 
immobilized on Ag-DEAE was observed. The temperature-incubated 
immobilized enzyme showed higher fluorescence intensity at 314 nm; λmax 
(maximum emission wavelength) for the tryptophan (Trp), and lower 
fluorescence intensity at 532 nm; λmax for FAD than the non-incubated and 
immobilized enzyme. Additionally, the enzyme immobilized on Ag-
DEAE presented a 10 nm-shift of the Trp- λmax (324 nm) with respect to 
the soluble enzyme (314 nm), but when incubated at 40º C, such Trp- λmax 
shifted back 10 nm to the UV, showing the same value than the soluble 
enzyme. These results point out that the immobilization of eNR promotes 
some conformational changes where the tryptophan residues are 
surrounded by a less polar environment than that one in their native 
conformation in solution. After a temperature-induced conformational 
change, the local environment of the tryptophan in the immobilized 
enzyme changes its polarity, becoming more polar as indicated by the 
observed red-shifting of Trp-λmax after thermal incubation.29 Moreover, the 
thermal incubation seems to trigger the shielding of the FAD cofactor 
because its fluorescence was quenched after thermal incubation. 
Therefore, the shift of Trp- λmax and the differences in the Trp and FAD+ 
fluorescence intensities reveal that the immobilization itself causes some 
structural rearrangement; interestingly, the temperature also induces 
further structural reorganization in the immobilized enzyme that can 
explain the enhancement in both activity and stability of the immobilized 
eNR incubated at 40ºC. Hereby, the temperature seems to act as an 
external stimulus that induces an optimal fitting between the surfaces of 
the enzyme and the carrier, resulting in a suitable geometric congruence 
for the catalysis. Despite the nature of this thermally-induced more active 
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conformation is not clear at present, it is worth mentioning that similar 
effects have been described for other soluble enzymes30-32. In any case, we 
put forth one of the few experimental demonstrations of thermal 
hyperactivation and stabilization assisted by the carrier surface, which is 
not only acting as a scaffold to stabilize eNR but also as an active surface 
that induces temperature-triggered positive conformational changes on the 
enzyme. 
 
 
Figure 4.7. Emission fluorescence spectra of A. niger eNR (soluble and 
insoluble). (A) Fluorescence spectra of A. niger eNR soluble. The fluorescence 
spectrum of soluble enzyme incubated 15 minutes at 40º C perfectly overlapped 
to the non-incubated enzyme. (B) The fluorescence spectra of A. niger eNR 
immobilized on Ag-DEAE activated (dash black) and no-activated (dash grey). 
The preparation of A. niger eNR insoluble derivative was carried out as described 
in Section Material and Methods. Both insoluble and soluble preparations were 
incubated in 10mM sodium phosphate at pH 7.5 and 25ºC and 40ºC. 
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Kinetic parameters and loading capacity of eNR immobilized on Ag-
DEAE 
Considering the high stability and satisfactory catalytic efficiency of eNR 
immobilized on Ag-DEAE, we selected this heterogeneous biocatalyst to 
carry out the sustainable reduction of [13N]NO3- to [13N]NO2- in aqueous 
media under mild conditions. Nevertheless, before applying this 
biocatalyst to radiochemistry, we carried out its kinetic characterization. 
To this aim, Michaelis-Menten parameters were determined for soluble 
and the immobilized eNRs towards the substrates: nitrate and NADPH. 
 
Table 4.2. Kinetic characterization of free and immobilized Aspergillus niger 
eNRs. 
 Km (mM) kcat (s-1) Kcat/Km (s-1 • mM-1) 
NaNO3 
NR soluble 0.27±0.07 30.33 111.23 
NR Ag-DEAE 0.06±0.03 11.97 199.44 
NADPH 
NR free 0.07±0.03 27.93 399.05 
NR Ag-DEAE 1.86±0.82 N.D. N.D. 
The steady-state kinetics parameters were measured at pH 7.5 and 25°C (see Section Material and Methods). 
 
As it can be seen in Table 4.2, the kinetic studies provided interesting data 
that helped us to understand the activity decrease resulting from the 
immobilization process. In a first glance, the immobilized preparation 
showed a 26-fold Km[NADPH] higher than the soluble enzyme. Contrarily, 
Km[NO3] was 4.5 times smaller for the immobilized eNR than for the soluble 
preparation. These results confirm that immobilization of eNR on Ag-
DEAE negatively affected the enzyme binding towards NADPH, which 
explains the low expressed activity after the immobilization process. The 
high Km[NADPH] values for the immobilized preparation may due to two 
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main reasons: i) Conformational changes induced by the carrier during the 
immobilization process that diminishes the enzyme affinity towards 
NADPH, or ii) mass transfer issues that hamper NADPH diffusivity from 
the bulk solution to the active sites of the immobilized eNR molecules.  
 
 
Figure 4.8. Enzyme-loading capacity of Ag-DEAE. The experiment was carried 
out offering different protein concentrations to 200mg of the carrier at pH 7.5 and 
25°C. Immobilization yield (full square) and relative expressed activity (open 
square) were determined for each enzyme load. Immobilization yield and 
expressed activity were calculated as was previously described. 
 
In order to elucidate which reason has more contribution to the low 
expressed activity, the effect of the enzyme loading on both 
immobilization yield and expressed activity after the immobilization was 
tested. Figure 4.8 shows that the immobilization was always quantitative 
regardless the enzyme load. However, the relative expressed activity 
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presented a strong negative logarithmic correlation with the enzyme load. 
Under very low enzyme loads (37.5 μgeNR/g carrier) the relative expressed 
activity was 85%, while the value decreased to approximately 20% at loads 
higher than 75 μgeNR/gcarrier.  
This experiment demonstrates that immobilization chemistry does not 
promote inactive enzyme conformations that intrinsically diminish its 
specific activity after the immobilization process. In such scenario, the 
expressed activity should be always low regardless of the enzyme load. 
So, it is plausible to think that mass transfer limitations of substrate and 
cofactors are the main reason to explain the low expressed activity of the 
immobilized eNR. Contextualizing these results together with the high 
Km[NADPH] values for the immobilized preparation, we suggest that the 
cofactor undergoes severe mass transfer limitations to diffuse across the 
Ag-DEAE microstructure to reach the enzyme active sites. Under high 
enzyme loads, NADPH does not efficiently diffuse into the porous 
microstructure of the carrier to saturate all active sites immobilized on 
such carrier. On the contrary, under very low enzyme loads, the vast 
majority of the eNR molecules are saturated with the NADPH. These 
results are in good agreement with previous data18, which showed that eNR 
from A. niger covalently immobilized on non-porous particles expresses 
more than 90% of its specific activity after immobilization. Moreover, 
these data strongly suggest that low specific activity of eNR immobilized 
on positively charged agarose beads is due to limited NADPH diffusion 
rather than inaccurate protein orientation, because positively charged 
porous carrier seem to immobilize eNR through an optimal orientation 
according to the protein surface analysis (see Figure 4.3C).  
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pH-profile of soluble and immobilized eNR on Ag-DEAE 
It is well-known that the immobilization can improve the pH tolerance of 
enzymes. Here, the activities of soluble and immobilized eNR on Ag-
DEAE under different pH conditions were also evaluated (Figure 4.9). 
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Figure 4.9. Effects of pH on NR immobilized onto Ag-DEAE activity. The NR 
preparations used to perform these studies were: immobilized on Ag-DEAE 
(open symbols) and soluble (filled symbols). The 10mM buffer solutions used in 
this essay were: sodium acetate pH 5 (circles); sodium phosphate pH 6, 7 and 8 
(squares) and bicarbonate pH 9 and 10 (triangles). 
 
The soluble and immobilized preparation showed optimal activity at pH 
value of 7 (Figure 4.9); such activity significantly decreased at pH lower 
than 7 for the immobilized enzyme. However, the effect of the acidic pH 
on the activity of the soluble enzyme was more dramatic reducing close to 
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50% of its initial activity. Under basic conditions, the soluble enzyme 
undergoes a dramatic inactivation as reflected in its activity-pH profile; 
such inactivation can be moderated by immobilizing eNR on Ag-DEAE. 
This data demonstrated that immobilized eNR performs more efficiently 
in a wider pH range (5 to 10) than the soluble enzyme. 
 
Reduction of radiolabeled nitrate catalyzed by eNR immobilized on 
Ag-DEAE. Reusability of the immobilized biocatalyst 
eNR immobilized on Ag-DEAE was used to reduce [13N]NO3- to 
[13N]NO2-. The reaction was carried out in batch mode and the 
immobilized biocatalyst was re-used for several reaction cycles. As it can 
be seen in Figure 4.10, the immobilized enzyme only yielded 60% of 
[13N]NO2- in 4 minutes in the first cycle, while the soluble enzyme reduced 
96% of [13N]NO3- to [13N]NO2-. Surprisingly, in the second cycle, the 
immobilized enzyme reduced up to 93% of [13N]NO3- to[13N]NO2-. We 
suggest that differences in NADPH effective concentration inside the 
carrier pores might cause that intriguing effect. 
We hypothesize that during the first reaction cycle some negatively 
charged NADPH molecules are ionically absorbed to the positively 
charged carrier surface. However, such molecules would present an 
association/dissociation equilibrium that would simultaneously provide 
one fraction of soluble NADPH available for the enzyme catalysis and the 
second fraction of NADPH trapped into the intra-pore space of the carrier 
surface that would be available for consecutive cycles. In this scenario, the 
effective concentration of NADPH in the second and successive cycles 
will be higher, explaining the higher yield observed in the second cycle 
compared to the first one. In order to demonstrate this ionic interaction 
 118 
between NADPH and Ag-DEAE, we equilibrated the eNR immobilized 
on Ag-DEAE with NADPH (same concentration and time as a typical 
reaction) in solution before triggering the first reaction cycle. 
 
 
Figure 4. 10. Reusability of eNR immobilized on Ag-DEAE. Soluble eNR (white 
bar), eNR immobilized on Ag-DEAE without NADPH equilibration (black bars) 
and eNR immobilized on Ag-DEAE equilibrated with NADPH (stripped bars) 
were used to catalyze the reduction from [13N]NO3- to [13N]NO2- at 25º C, pH 7.5. 
Reactions catalyzed by soluble and non-equilibrated immobilized eNR were 
carried out by adding exogenous NADPH, while the reactions catalyzed by 
equilibrated immobilized eNR were carried out without exogenous NADPH. 
 
The equilibrated heterogeneous biocatalyst was able to reduce 96% of 
[13N]NO3- to [13N]NO2- from the first cycle (Figure 4.10). This finding 
confirms that a fraction of NADPH is ionically trapped into the carrier 
surface, increasing the internal concentration of NADPH that results in 
higher reduction yields. In fact, we also confirmed that when the 
radiochemical reduction was carried out with the NADPH-equilibrated 
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immobilized enzyme, the heterogeneous biocatalyst was able to catalyze 
the radiolabeled nitrate reduction for 5 cycles with more than 30% yield 
without exogenous addition of NADPH (Figure 4.10). This experiment 
provides evidence that NADPH molecules are reversibly bound to the 
carrier surface providing an internal cofactor concentration that was 
sufficient for the immobilized eNR to catalyze the radiochemical reduction 
with the maximum yield during the first cycle, and proportionally lower 
yields with the consecutive cycles. The lower reduction yield along the 
cycles agrees with the fact that NADPH is oxidized to NADP+ decreasing 
the pool of NADPH trapped into the carrier porous structure. Therefore, 
along the consecutive cycles, immobilized eNR suffers from a lower 
availability of the reduced NADPH, explaining the lower yields along the 
operational cycles. Contrarily, when reduction was carried out by adding 
exogenous NADPH in each reaction cycle, the maximum yield was 
maintained during 7 cycles, demonstrating the excellent operational 
stability of the immobilized biocatalyst (Figure 4.10). To the best of our 
knowledge, this is the first evidence of a heterogeneous biocatalyst where 
the carrier plays an important role in supplying the corresponding cofactor 
to the enzyme. Furthermore, it was confirmed by SDS-page with silver 
staining (Figure 4.11) that this optimal heterogeneous biocatalyst, offers 
a clean final product without any significant protein contamination, even 
during the recycling process, confirming once again that ionic interactions 
between eNR and Ag-DEAE are quite strong in spite of their reversible 
nature. 
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Figure 4.11. SDS-PAGE/silver staining of Aspergillus niger nitrate reductase. 
Lane M: molecular weight marker; Lane 1: eNR soluble; lane 2: eNR 
immobilized before any reaction; lane 3: non-bound protein after immobilization; 
lane 4: cycle 1; lane 5: cycle 2; lane 6: cycle 3; lane 7: cycle 4; lane 8: cycle 5; 
and lane 9: eNR immobilized after 5 reaction cycles. 
 
Two step chemo-enzymatic solid-phase synthesis of S-[13N]GSNO 
To proof the concept that the enzymatically synthesized [13N]NO2- can be 
directly integrated into a radiochemical synthetic cascade, we coupled the 
optimal eNR immobilized on Ag-DEAE to the two-step chemo-enzymatic 
synthesis of S-[13N]GSNO (Figure 4.12). 
[13N]NO3- was enzymatically reduced to [13N]NO2- in the presence of 
NADPH. The supernatant of such reaction was passed through an anion 
exchange cartridge in order to trap the enzymatically produced  [13N]NO2-
. Then, an acidic solution of S-glutathione (1 mM) was also passed through 
the same anion exchange cartridge enabling the solid-phase S-nitrosation 
of glutathione. The resulting product was finally desorbed from the resin 
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by elution with distilled water. 95% of the enzymatically yielded 
[13N]NO2- was converted to S-[13N]GSNO, similar to the radiochemical 
conversion obtained in previous works conducted in our research group 
using Cd-reduced [13N]NO2-.1 This result confirms that the redox cofactor 
needed for the enzymatic reactions does not interfere with the next 
chemical step. Therefore, the radioactive nitrite produced by this 
heterogeneous biocatalyst is suitable to be used in radiochemical reactions. 
 
 
Figure 4.12. [13N]GSNO synthesis using [13ܰሿܱܰଶି produced by enzymatic 
catalysis. 
 
CONCLUSION 
In this chapter, an unprecedented strategy for the reduction of [13N]NO3- 
to [13N]NO2- using an efficient heterogeneous biocatalyst was successfully 
applied. The use of one eukaryotic nitrate reductase immobilized on a solid 
carrier to a radiochemical process is for the first time published. This 
immobilized enzyme has been able to selectively reduce [13N]NO3- to 
[13N]NO2- aided by NADPH as redox cofactor. Likewise, by controlling 
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the immobilization chemistry and physicochemical properties of the 
carrier, optimal heterogeneous biocatalysts with high potential in synthetic 
chemistry were achieved. Noteworthy, this work is one of the few 
examples where an immobilized enzyme has been applied for a 
radiochemical process and the first report so far of a two-step chemo-
enzymatic route to synthesize model radiotracers starting from a precursor 
([13N]NO3-) directly produced in the cyclotron. 
From this experimental work, we can also conclude that immobilized 
enzymes are highly active and stable, and simplify the process work-up, 
and have great potential to be applied in radiochemistry to yield pure 
radiotracers that can be directly used for biomedical purposes. Hence, they 
can be anticipated as ideal tools for the preparation of radiotracers labeled 
with short-lived radionuclides. Moreover, we have faced the challenge to 
immobilize an enzyme whose catalytic mechanism depends on several 
cofactors and conformational changes recovering enough activity and 
increasing its stability to catalyze several reaction cycles.  
The success of this work will so far open the doors to a new application of 
enzymes in radiochemistry and will potentiate the use of other chemo-
enzymatic designs for the synthesis of novel radiotracers, even using short-
lived isotopes. Successful enzyme immobilization will contribute to 
develop in flow radiochemical processes as well as to integrate 
radiochemical synthesis on-chip.33-36 
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In the present chapter, the one-pot, enzymatic and non-carrier-added synthesis of a variety 
of 13N-labeled amino acids (L-[13N]alanine, [13N]glycine, and L-[13N]serine) is presented. 
To this aim, L-alanine dehydrogenase from Bacillus subtilis, an enzyme that catalyzes the 
reductive amination of α-keto acids has been assayed, using nicotinamide adenine 
dinucleotide (NADH) as the redox cofactor and ammonia as the amine source. In 
addition, the integration of both L-alanine dehydrogenase and formate dehydrogenase 
from Candida boidinii in the same reaction vessel allows the in situ regeneration of 
NADH during the radiochemical synthesis of the amino acids. The enzymatically labeled 
amino acids have been used to analyze their in vivo biodistribution in healthy (wild-type) 
mice. The capacity to selectively accumulate in the tumor has been assessed in a prostate 
cancer mouse model (prostate-specific Pten deletion) by using dynamic PET-CT 
imaging. 
Enzymatic preparation of 13N-labeled amino acids 
and their Biological assessment in prostate tumor
models 
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INTRODUCTION 
Amino acids labeled with nitrogen-13 are attractive because these are very 
difficult to label using other isotopes. Additionally, amino acids could be 
very interesting tracers for the detection of some types of cancer when 
[18F]FDG does not work. Enantioselective chemical synthesis of amino 
acids is also very hard. The use of enzymes can help, thanks to their fast 
reaction rates and unique enantio- and chemo-selectivity.  
As already mentioned before (Chapter 2), the utilization of enzymes for 
the preparation of 13N-labeled amino acids was first described in the 70’s.1 
For example, L-[13N]glutamate was synthesized by incubation of α-
ketoglutarate (α-KG) with [13N]NH3 in the presence of the enzyme L-
glutamate dehydrogenase and NADH as the redox cofactor.2,3 Likewise, 
L-[13N]glutamine was synthesized by glutamine synthethase using 
glutamic acid as the substrate and adenosine triphosphate (ATP) as the 
cofactor.3,4 These two amino acids were synthesized with incorporation 
values close to 90% in 15 minutes of incubation. Other amino acids such 
as L-[13N]valine, L-[13N]methionine, L-[13N]leucine and L-[13N]alanine 
have been produced by a one-pot/two-step or two-pot/two-step processes 
by coupling glutamate dehydrogenase and transaminases. These 
methodologies have allowed 16-90% chromatographic yields of the 
corresponding L-[13N]amino acid.5,6 
Amino acid dehydrogenases (AADH) are a class of enzymes which have 
been extensively used in biocatalysis as main enzymes for the production 
of enantiomerically pure -amino acids,7,8 as cofactor recycling enzymes 
to replenish the NADH or NAD+ pool utilized by alcohol dehydrogenases9 
and as donor enzymes to provide ω-transaminases with the suitable amine 
donors using ammonia as the amine source.10 Interestingly, L-alanine 
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amine dehydrogenases (L-AlaDHs) are a special type of AADH that have 
low sequence similarities with other AADH (glutamate dehydrogenase, 
leucine dehydrogenases, phenylalanine dehydrogenases…) and some 
important mechanistic differences.11,12 L-Alanine dehydrogenase, L-
AlaDH, is an oxidoreductase (EC1.4.1.1) which catalyzes the reversible 
deamination of L-alanine yielding pyruvate and ammonia. In this reaction, 
the alanine is oxidized at the enzyme active site with concomitant 
reduction of NAD+ to NADH by hydride transfer.11,13 The kinetic 
properties of L-AlaDHs from different microbial sources have been 
extensively investigated, and some of these enzymes have been cloned in 
heterologous hosts.14 Although the physiological role of L-AlaDH remains 
controversial, it has been reported that this enzyme is involved in the 
utilization of alanine as an energy source during the germination process 
of Bacillus species.15,16 
In continuation of our previous work related to the application of enzyme-
mediated reactions to 13N-radiochemistry,17 we describe in this chapter a 
one-pot/one-step radiosynthesis of L-[13N]alanine, [13N]glycine, and L-
[13N]serine catalyzed by a versatile L-alanine dehydrogenase (L-AlaDH) 
from Bacillus subtilis (Figure 5.1a). In contrast with the well reported 
glutamate dehydrogenase that needs to be coupled to transaminase, L-
AlaDH is self-sufficient to incorporate [13N]NH3 into a broad scope of 
organic precursors to yield the corresponding L-[13N]amino acids with an 
exquisite selectivity.  
One of the major drawbacks of utilizing amino acid dehydrogenase is the 
necessity of adding an exogenous redox cofactor to the reaction mixture. 
This may require the product purification before administration in order to 
avoid toxicological or side effects. In biocatalysis, the recycling of the 
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redox cofactor has been elegantly solved by using secondary enzymes, 
whose mission is to replenish the pool of the cofactors during the reaction. 
In this scenario, a lower amount of cofactor can be used, with the 
consequent positive impact in the process-costs.   There are different 
enzymes that have been exploited to regenerate the cofactor.18,19 Glucose 
dehydrogenase,20,21 sulfite dehydrogenase,22,23 and formate dehydrogenase 
(FDH)24 are some examples. 
 
 
Figure 5.1. Schematic representation of: (a) Enzyme-mediated preparation of L-
[13N]alanine, [13N]glycine, and L-[13N]serine using L-alanine dehydrogenase (L-
AlaDH) from Bacillus subtilis as the enzyme; (b) one-pot, multi-enzyme reaction 
for the preparation of  L-[13N]alanine with regeneration of NADH. 
 
In the current work, coupling L-AlaDH with FDH from Candida boidinii 
has allowed us in situ recycling of NADH by using formate buffer as the 
substrate without compromising reaction rates (Figure 5.1b). Since FDH 
can be recombinantly produced in the laboratory obtaining high yields, and 
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it uses a soluble and low-cost substrate - formic acid - which is oxidized 
to carbon dioxide as product (which is easily evaporated shifting the 
equilibrium towards the oxidation reaction), this enzyme was designated 
for the regeneration of NADH in our experiment.24  
The present synthetic strategy resulted in ready-to-inject 13N-labeled 
amino acids in sufficient amount to approach in vivo studies in small 
healthy and diseased rodents, and paves the way towards future solid-
supported, multi-purpose, in flow synthetic processes.  
 
EXPERIMENTAL SECTION 
Materials 
The genes of L-alanine dehydrogenase (L-AlaDH) from Bacillus subtilis 
(L-alanine: NAD oxidoreductase, EC1.4.1.1) and formate dehydrogenase 
(FDH) from Candida boidinii (Formate: NAD+ oxidoreductase, EC1.2.1.2) 
were synthesized and cloned into pET28b by GenScript company 
(Piscataway, USA). β-Nicotinamide adenine dinucleotide, reduced 
disodium salt hydrate (β-NADH; purity >97%), pyruvic acid 
(CH3COCOOH, purity 98%), ammonium chloride (NH4Cl, for 
molecular biology, purity ≥99.5%), sodium phosphate dibasic (Na2HPO4, 
for molecular biology, purity ≥98.5%), sodium phosphate monobasic 
(NaH2PO4, purity ≥99.0%), L-alanine (purity ≥98%), D-alanine (purity 
≥98%), glycine (purity ≥99%), L-serine (purity ≥99.5%), D-serine (purity 
≥98%), L-phenylalanine (purity ≥98%), D-phenylalanine (purity ≥98%), 
L-norvaline, and D-norvaline (purity ≥99%) were purchased from Sigma 
Chemical Co. (St. Louis, IL, USA) and used without further purification. 
TALON resin was purchased from Clontech (Saint-Germain-en-Laye, 
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France). Bio-Rad Protein Assay Dye Reagent Concentrate was purchased 
from Bio-Rad Laboratories (Madrid, Spain). All other reagents were of 
analytical grade. 
Production of L-AlaDH and FDH in E. Coli. Expression. A total of 1ml 
of an overnight culture of E. coli BL21 transformed with the corresponding 
plasmid (pET28b-BsL-AlaDH or pET28b-CbFDH) was inoculated in a 
50ml of Luria-Bertani (LB) broth containing kanamycin (final 
concentration of 30 μg mL-1). To overexpress L-AlaDH, the resulting 
culture was incubated at 37°C with energetic shaking until the OD600nm 
reached 0.6. Then, 1-thio-β-d-galactorpyranoside (IPTG) was added to the 
culture to a final concentration of 1 mM to induce protein synthesis. Cells 
were grown at 37 °C for 3h and then harvested by centrifugation at 1290g 
for 30 min. To overexpress FDH, the culture was incubated at 21°C with 
energetic shaking until the OD600nm reached 0.6. Then, 1-thio-β-d-
galactorpyranoside (IPTG) was added to the culture to a final 
concentration of 1 mM to induce protein synthesis. Cells were grown at 
21°C for 18h and then harvested by centrifugation at 1290g for 30 min. 
Purification. Both FDH and L-AlaDH were purified as follows: the 
resulting pellet from 50 mL culture was resuspended in 5 mL of binding 
buffer (25 mM sodium phosphate buffer solution, pH 7). Cells were 
broken by sonication (LABSONIC P, Sartorius Stedim biotech) at 
amplitude 30% for 5min. The resulting suspensions were centrifuged at 
10528g for 30min. The supernatant containing the enzyme was collected 
and passed through a TALON resin equilibrated with binding buffer. 
Following the protein binding to the column, the flow through was 
discarded and the resin was washed three times with binding buffer prior 
to the protein elution with elution buffer (binding buffer supplemented 
with 300 mM imidazole). The eluted protein was gel-filtered by using a 
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centrifugal filter of 10KDa (Millipore, Merck) to remove the imidazole 
and exchange the enzyme buffer to 25 mM sodium phosphate 7, and the 
enzyme was stored under such conditions at 4 ºC. Samples were analyzed 
by 12 % SDS-PAGE (Sodium dodecyl sulphate-Polyacrylamide gel 
electrophoresis) (Coomassie Blue staining) after each protein production 
to determine the purity of the enzymes. The studies of the oligomeric state 
of this protein were carried out through a gel filtration process performed 
by Fast protein liquid chromatography (FLPC) using a Superdex TM 200, 
10/300 GL. 
Protein and enzyme colorimetric assays. Determination of the protein 
concentration. The protein concentration of soluble L-AlaDH and FDH 
were measured as described in Chapter 4 for eNR. Determination of 
enzyme activity. The enzymatic activities were spectrophotometrically 
measured in 96-well plates by monitoring the absorbance at 340 nm, which 
varied depending on the concomitant production or consumption of 
NADH. L-AlaDH: The reductive amination was assayed using 10µL of L-
AlaDH, 190 µL of 0.5mM NADH, and 75 mM pyruvic acid (or other α-
keto acids) which were incubated in 450 mM ammonium chloride at pH 
5-10 and 25ºC. On the other hand, for the oxidative deamination (inverse 
reaction) 10 µL of L-AlaDH, 200 µL of 1mM NAD+ and 10 mM L/D 
amino acids (alanine, glycine, serine, norvaline and phenylalanine) were 
incubated in 300 mM sodium phosphate buffer at pH 8 and 25ºC.  FDH: 
To measure the enzyme activity of FDH, 200 μL of 1 mM NAD+ and 100 
mM formic acid in 25 mM sodium phosphate buffer at pH 7 were 
incubated with 5 μL of the enzymatic solution at 25ºC. One unit of activity 
was defined as the amount of enzyme that was needed to either reduce or 
oxidize 1 μmol of the corresponding nicotinamide cofactor at 25ºC and the 
corresponding pH.  
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Enzyme kinetic parameters. The kinetic parameters, Michaelis constant 
value (Km) and maximum rate (Vmax), were determined by activity 
colorimetric assay at pH 8 (pH 9 for serine) and 25ºC following the method 
described above for L-AlaDH, using 0-1.8M ammonium chloride as amine 
source. 
Production of the radiolabeling agent [13N]NH3. Nitrogen-13 (13N) was 
produced in an IBA Cyclone 18/9 cyclotron via the 16O(p,α)13N nuclear 
reaction as explained in chapter 4, but 5 mM EtOH solution in pure water 
was irradiated. Integrated currents in the range 0.1-1 μAh were used. The 
resulting solution was transferred to a 10 mL vial and the activity was 
measured in a dose calibrator (Capintec CRC®-25 PET, New Jersey, 
USA). 
Synthesis of L-[13N]amino acids. General procedure. Radioactive 
enzymatic reactions of the amino acids were carried out by adding 100µL 
of a mixture containing 0.5 mM NADH, 75mM α-keto acid and 300 mM 
sodium phosphate buffer solution at pH 8 to a solution of 20 μL containing 
L-AlaDH (15-300 µg/mL in reaction) and 100µL of [13N]NH3 (20-450 
MBq). Reactions were conducted in tubes with 50 KDa cut-off 
membranes. For the preparation of L-[13N]serine, sodium bicarbonate 
buffer (300 mM, pH 9) was used instead. The mixture was incubated at 
25ºC under mild stirring for 2.5-20 min, and subsequently filtered under 
centrifugation to separate the enzyme from the radiolabeled products.  
Enzymatic cascade reactions for regeneration of the cofactor. The 
reactions were conducted as above, but FDH at 5:1 (FDH:L-AlaDH) molar 
ratio and formic acid (100 mM) were added. 100µL of this soluble 
preparation were incubated with cyclotron produced [13N]NH3 solution 
(100 μL). All the reactions were carried out in tubes with 50 KDa cut-off 
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membranes to easily separate the enzymes from the final products by fast 
centrifugation. 
HPLC and radio-HPLC analysis. The determination of all 
radioactive/non-radioactive compounds was carried out by HPLC using an 
Agilent 1100 Series system equipped with a quaternary pump and a 
variable wavelength UV detector connected in series with a radiometric 
detector (Gabi, Raytest, Straubenhardt, Germany). A chiral column, 
(Phenomenex Chirex®3126 column, 50 x 4.6mm; Micron Phenomenex, 
Madrid, Spain) was used as stationary phase. As the mobile phase, 1 mM 
CuSO4 solution at 1 ml min-1 was used for alanine, glycine and norvaline; 
2mM CuSO4 solution at 0.2 ml min-1 was used for serine; and 2mM 
CuSO4/methanol solution (70:30) at 1 ml min-1 was used for 
phenylalanine. Pure commercial enantiomers were used as standards. 
For the determination of the specific activity of L-[13N]alanine, the 
concentration of amino acid in the purified fraction was carried out by 
HPLC-MS, using an AQUITY UPLC separation module coupled to a LCT 
TOF Premier XE mass spectrometer (Waters, Manchester, UK). An 
Acquity UPLC Glycan BEH amide column (1.7 µm, 50 mm, 2.1 mm) was 
used as stationary phase. The elution buffers were A (acetonitrile) and B 
(0.1 M ammonium formate). The column was eluted with a linear gradient 
of B: t=0 min, 95%; t=3 min, 50%; t=3.5 min, 95%; t=5 min, 95%. Total 
run was 5 min, injection volume was 10 µL and the flow rate 0.5 mL/min. 
The detection was carried out in positive ion mode, monitoring the most 
abundant isotope peaks from the mass spectra. Alanine was detected as 
protonated molecule (m/z = 90) with a retention time of 1.81 min. 
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Animal experimentation 
General considerations. Animals were maintained in a temperature and 
humidity-controlled room with a 12 h light-dark cycle. Food and water 
were available ad libitum. Animals were cared for and handled in 
accordance with the Guidelines for Accommodation and Care of Animals 
(European Convention for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes), and ethical protocols were 
approved by the internal Ethical Committee and by regional authorities. 
In vivo studies. PET studies were performed using an eXploreVista-CT 
small animal PET-CT system (GE Healthcare). Healthy mice (20-22 g, 
C57BL/6JRJ, Janvier, France; n=2 per amino acid) were used to assess the 
biodistribution of the labeled amino acids. Prostate cancer mice (22-26 g, 
prostate-specific Pten deletion; n=2 per amino acid) kindly provided by 
Prof. Arkaitz Carracedo (CIC bioGUNE, Bilbao, Spain) were used to 
evaluate tumor uptake. In all cases, mice were anesthetized with a mixture 
of 3-4% isoflurane in O2 for induction, and reduced to 1-1.5% for 
maintenance. A nose cone was used to facilitate regular breathing, 
monitored by a SA Instrument Inc. (NY, USA) pressure sensor. 
Respiration and body temperature were monitored throughout the scan. 
The temperature, measured rectally, was maintained at 37±1ºC using a 
water heating blanket (Homeothermic Blanket Control Unit; Bruker, 
Germany). For administration of 13N-labeled amino acids, the tail vein was 
catheterized with a C10SS-MTV1301 29-gauge catheter (Instech, 
Laboratories Inc., Plymouth Meeting, PA, USA) and 16.5±3.1 MBq 
(approximately 100 μL) were injected in tandem with the start of a PET 
dynamic acquisition. The cannula was then rinsed with a physiologic 
saline solution (50µL) and dynamic images (33 frames: 8x5 s, 6x15 s, 6x30 
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s, 6x60 s, 7x120 s) were acquired in 2-bed positions in the 400-700 keV 
energy window, with a total acquisition time of 50min and 20s. After each 
PET scan, CT acquisitions were also performed, providing anatomical 
information as well as the attenuation map for later image reconstruction. 
Dynamic acquisitions were reconstructed (decay, random and CT-based 
attenuation corrected) with OSEM-2D (2 iterations, 16 subsets). PET 
images were visually analyzed using PMOD image analysis software 
(PMOD Technologies Ltd, Zürich, Switzerland). 
 
RESULTS AND DISCUSSION 
The aim of this chapter was to develop an efficient synthetic procedure for 
the preparation of 13N-labeled amino acids for the in vivo assessment of 
tumor uptake in a mouse model of prostate cancer. The natural amino acids 
L-alanine, L-serine and glycine are biosynthetically linked and together 
provide the essential precursors for the synthesis of proteins, nucleic acids, 
and lipids that are crucial to cancer cell growth.26,27 Hence, these three 
amino acids were identified as the priority target compounds.  
 
Selection, expression and purification of an active L-AlaDH in E. coli 
The inspection of different data bases (BRENDA, KEEGG, MetaCyc) 
suggests that L-AlaDH from Bacillus subtilis and Bacillus sphaericus may 
enable the preparation of different 13N-labeled amino acids since they 
present a broad substrates scope for the reductive amination of α-keto 
acids. Among L-AlaDHs, the L-AlaDH from Bacillus subtilis was selected 
here due to its better kinetic properties for a wider variety of amino acids. 
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The enzyme was expressed in E. coli BL21 and purified by affinity 
chromatography based on the histidine tag inserted at its N-terminus 
(Figure 5.2). According to the literature,14,28 the pure L-AlaDH is a 
hexamer with a subunit mass of 44 KDa which results in a total mass of 
264 KDa (Figure 5.2). This result was confirmed by SDS-PAGE gel and 
gel filtration analysis. The pure L-AlaDH showed a specific enzyme 
activity of 106±5 U/mg towards pyruvate. 
 
Synthesis of amino acids under non-radioactive conditions 
The amination activity towards α-keto acids with different side chains was 
first tested in non-radioactive conditions. With that aim, the synthesis of 
L-alanine, glycine, and L-serine was approached by incubating the 
appropriate substrates with ammonium chloride in the presence of NADH 
as cofactor and L-AlaDH from Bacillus subtilis as a biocatalyst. Despite 
this work was focused in these three amino acids, two more amino acids 
(L-phenylalanine and L-norvaline) were tested just to evaluate the scope 
of the application of our method. 
Expectedly, the highest activity was observed towards pyruvic acid, but 
the enzyme also catalyzed the reductive amination of other α-keto acids 
such as glycolic acid, 3-hydroxypyruvic acid, 2-oxopentanoic acid and 2-
phenylpyruvic acid to yield glycine, serine, norvaline and phenylalanine, 
respectively (Table 5.1). The specific enzyme activity towards these α-
keto acids ranged from 17 to 32% of the maximum specific enzyme 
activity measured with pyruvic acid. Generally, bulky α-keto acids were 
worse substrates than small ones, as previously observed for the vast 
majority of the previously studied L-AlaDHs.29-31  
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Figure 5.2. (Left) SDS-PAGE analysis of expression and purification of L-
AlaDH from Bacillus subtillis in BL21 E.coli. Lane M shows molecular weight 
references. Lane 1 represents a crude extract of after sonication. Lane 2 represents 
soluble protein fraction after sonication and removal of cell debris and membrane 
fraction. Lane 3 represents the flow-through fraction of the purification step. Lane 
4 represents pure L-AlaDH after elution with 300 mM imidazole. The different 
protein fractions were analyzed by 12% SDS-PAGE and stained with Coomassie 
Blue. The purified enzyme resulted in a band corresponding to 44 kDa. (Right) 
Gel filtration chromatogram of the pure enzyme L-AlaDH. The gel filtration was 
performed by flow protein liquid chromatography (FPLC) using a Superdex TM 
200, 10/300 GL. Reference markers (dotted line): 440 kDa, ferritin; 158 kDa, 
aldolase; 75 kDa, conalbumin and 43 kDa, ovalbumin. The purified enzyme 
obtained (black line) eluted as a major peak around 264 kDa corresponding to the 
total molecular weight of L-AlaDH indicating that the multimer is formed by 6 
subunits (44 KDa/subunit). 
 
As just mentioned, L-AlaDH from Bacillus subtilis presented a broad 
substrates scope for the reductive amination towards different α-keto 
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acids. On the contrary, such substrate versatility was not observed in the 
oxidative deamination of L-amino acids (Table 5.1). The enzyme did not 
oxidize glycine and phenylalanine and poorly oxidized serine and 
norvaline. These findings are in accordance with those previously reported 
for the recombinant and native enzymes purified from E. coli and B. 
subtilis, respectively.14,28 
 
Table 5.1. Specific activity (SA) values of L-Alanine Dehydrogenase for 
amination and deamination reactions under non-radioactive conditions. 
Amino acid 
SAdeamination 
(µmol x min-1 x mg-1) 
SAamination 
(µmol x min-1 x mg-1) 
Alanine 5.4±0.1 (L)  106±5 
Glycine N.D. 34.3±1.6 
Serine[b] 
 
0.039±0.001 (L)  
 22.5±3.1 
0.003±0.001 (D)  
Norvaline 0.002±0.001 (L)  18.6±1.2 
Phenylalanine N.D. 21.4±2.1 
pH = 8; N.D. = non-detected 
 
The effect of the pH on the reductive amination activity of L-AlaDH 
towards different α-keto acids was subsequently investigated (Figure 5.3). 
Optimal specific enzyme activity values for the biosynthesis of all tested 
amino acids, except L-serine, were observed at pH 8. For L-serine, optimal 
values were achieved at pH 9. Noteworthy, the specific enzyme activity of 
L-AlaDH towards 3-hydroxypyruvic acid at pH 9 was only 1.24 times 
lower than the activity towards pyruvic acid at pH 8. The activity-pH 
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profile of L-AlaDH for the reductive amination of pyruvic acid was wider 
than for other amino acid dehydrogenases.32 
 
 
Figure 5.3. Activity-pH profile of L-AlaDH for the biosynthesis of L-alanine, 
glycine, L-serine, L-phenylalaline and L-norvaline. The reactions were carried 
out in the presence of 0.5 mM NADH, 450 mM ammonium chloride and 10 mM 
of the corresponding α-keto acid in 300 mM buffer solution at 25ºC. Acetate 
buffer was used for pH 5-6; sodium phosphate buffer for pH 7-8 and sodium 
bicarbonate buffer for pH 9-10. Enzyme activity measurements were carried out 
for 2 minutes and blank experiments (without L-AlaDH) were performed to 
discard any stability issues of NADH that may lead to underestimation of the 
enzyme activity. Data are expressed as the mean ± standard deviation (n=3); (*) 
means the optimal pH value for the synthesis of the corresponding amino acid. 
 
Synthesis of L-[13N]amino acids 
A complete translation of the reaction parameters to radioactivity 
conditions is often not straightforward. If the carrier-free radioactive 
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precursor is used (in our case [13N]NH3), the concentration of this species 
is extremely low (around 15 µM in typical experiments conducted in our 
set up). Hence, the kinetics of the reaction might be significantly altered 
and careful refinement of the experimental conditions is usually required. 
In this work, we first attempted the synthesis of L-[13N]alanine. With this 
purpose, 75 mM of pyruvic acid was incubated with cyclotron-produced 
[13N]NH3 (aqueous solution, 20-25 MBq, 100 µL) and L-AlaDH in the 
presence of NADH as the cofactor (0.5 mM) in a buffered solution at pH 
8.0±0.1. The reactions were carried out in tubes with 50 KDa cut-off 
membranes to easily separate the enzymes from the final products by fast 
centrifugation. Chromatographic yields were monitored over time (Figure 
5.4, solid line) and values were then corrected by radioactive decay at 
different reaction times (Figure 5.4, dotted line).  
 
 
Figure 5.4. Chromatographic yields (solid line) and chromatographic yields 
corrected by taking into consideration the radioactive decay of the radionuclide 
(dotted line) at different reaction times obtained for the production of L-
[13N]alanine. The reactions were carried out in the presence of 20-25 MBq of 
[13N]NH4OH, 15 ug/mL of L-AlaDH, 0.5 mM of NADH, and 75 mM of pyruvic 
acid in 300 mM sodium phosphate buffer solution pH 8 at 25ºC. 
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Despite the low concentration of [13N]NH3, chromatographic yields of 
68±5% were obtained after 5 minutes reaction; this value increased to 
95±1% when the reaction was carried out for 20 min. Taking into account 
the short half-life of 13N, incubation times of 10, 15 and 20 minutes proved 
to be less desirable than the 5 min period, because the gain in yield was 
negligible compared to the decay of nitrogen-13 (Figure 5.4, dotted line). 
Noteworthy, when the reaction time was set to 20 min, the amount of 
radiochemical impurities (mainly unreacted [13N]NH3) was <5%, enabling 
putative in vivo studies without the need of a purification step to remove 
unreacted [13N]NH3. 
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Figure 5.5. Effect of the amount of enzyme in the radiochemical synthesis of L-
13N]alanine. The reactions were performed using a range of concentrations of L-
AlaDH between (7.5-60 µg/mL) in the presence of 45-50 MBq of [13N]NH3, 
0.5mM NADH, 75 mM pyruvic acid in 300 mM sodium phosphate buffer pH 8 
at 25ºC. In all cases, the reaction time was 5 minutes. Results are expressed as a 
mean ± standard deviation, n3. Chromatographic yields were calculated from 
chromatographic profiles. 
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In order to gain further knowledge on the reaction kinetics, the 
radiochemical synthesis of L-[13N]alanine was performed at different 
enzyme concentrations (Figure 5.5). As expected, fixing the optimal 
reaction time of 5 min, higher enzyme concentrations led to higher yields. 
Values of 68±5%, 78±4%, 85±9% and 98±1% were achieved when 
concentrations of enzyme of 15, 30, 45 and 60 µg/mL were used, 
respectively. 
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Figure 5.6. Effect of the amount of enzyme in the radiochemical synthesis of L-
13N]alanine. The reactions were performed using a range of concentrations of L-
AlaDH between (7.5-60 µg/mL) in the presence of 45-50 MBq of [13N]NH3, 
0.5mM NADH, 75 mM pyruvic acid in 300 mM sodium phosphate buffer pH 8 
at 25ºC. In all cases, the reaction time was 5 minutes. Results are expressed as a 
mean ± standard deviation, n3. Chromatographic yields were calculated from 
chromatographic profiles. 
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One of the major goals of the current work was to develop a versatile 
synthetic process, suitable for the efficient production of different amino 
acids. Additionally to L-[13N]alanine, the preparation of [13N]glycine and 
L-[13N]serine was a priority for future use in animal studies. Hence, and in 
order to investigate the versatility of our approach, the synthesis of other 
two amino acids L-[13N]phenylalaline and L-[13N]norvaline were assayed 
using the same experimental set up as for L-[13N]alanine. In all cases, the 
reactions were carried out for 5 minutes (optimal reaction time, Figure 
5.4), using 60-300 µg/mL of L-AlaDH and under saturating concentration 
of the corresponding α-keto acid at the optimal pH values. Reactions of 
20min were also investigated for the synthesis of [13N]glycine and L-
[13N]serine. Table 5.2 summarizes all the chromatographic yields 
obtained from the chromatographic profiles of the radiosynthesis of the 
above-mentioned amino acids. 
 
Table 5.2. Chromatographic yields (CY) for the synthesis of different 13N-labeled 
amino acids. 
Amino acid pH CY (%) 
Alanine 8 98±1[a] 
Glycine 8 49±3[a] / 98±1[b]  
Serine 
8 7[a]  
9 42±5[a] / 99±1[c] 
Norvaline 8 N.D. [a] 
Phenylalanine 8 N.D. [a] 
[a] 60 µg/mL of protein; [b] 180 µg/mL of protein; [c] 300 µg/mL of protein; N.D. = non-detected 
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Chromatographic yields of 49±3% and 42±5% were obtained for 
[13N]glycine and L-[13N]serine at short reaction times (5 min), 
respectively. These values increased up to >95% when the enzyme 
concentration was raised up to 180 and 300 µg/mL for the synthesis of 
[13N]glycine and L-[13N]serine, respectively (Table 5.2). The 
radiochemical synthesis of glycine and serine required higher enzyme 
concentrations because the specific enzyme activity of L-AlaDH was 
significantly lower towards glycolic acid and 3-hydroxypyruvic acid than 
towards pyruvic acid (Table 5.1). These findings are in accordance with 
our experiments under non-radioactive conditions, and confirm that L-
AlaDH from Bacillus subtilis can catalyze the reductive amination of 
glycolic acid and 3-hydroxypyruvic acid, although reaction rates were 
lower than those observed for pyruvic acid. Interestingly, the synthesis of 
L-[13N]serine at pH 8 resulted in chromatographic yields of 7% (Table 
5.2). The results corroborate that the synthesis of L-serine is both 
kinetically and thermodynamically favored under alkaline conditions, as 
observed under non-radioactive conditions.  
Unexpected results were obtained for the preparation of L-
[13N]phenylalaline and L-[13N]norvaline. Although the enzyme was active 
towards the corresponding α-keto acids under non-radioactive conditions, 
no conversion was observed under radioactive conditions, regardless the 
reaction time. The absence of formation of L-[13N]phenylalaline and L-
[13N]norvaline and the relatively low reaction rates obtained for 
[13N]glycine and L-[13N]serine could be initially attributed to an 
equilibrium between amination and deamination reactions. Nevertheless, 
the low specific activity of this enzyme for the deamination reactions using 
the different aminoacids as substrates discarded this hypothesis and 
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confirmed that the reductive amination is thermodynamically favoured at 
pH 8, as previously reported (Table 5.1).31  
In an attempt to completely understand these low reaction rates, further 
investigation of the enzyme kinetics was performed. Steady-state kinetic 
parameters for ammonia were determined for the reductive amination of 
the different α-keto acids under non-radioactive conditions (see Table 
5.3). 
 
Table 5.3. Kinetic parameters by Michaelis-Menten model for ammonia, for the 
different amino acids. 
Amino acid[a] Vmax (U/mg) Km (mM) 
Alanine 100.46±4.30 47.0±11.4[a] 
Glycine 51.96±6.05 527±149 [a] 
Serine 74.63±1.26 2810±613[a]  150±21[b] 
Norvaline 114.29±9.86 2231±544 
Phenylalanine ND ND 
[a] pH 8; [b] pH 9; N.D. = non-detected 
 
All Vmax values fell in the range 50-120 U/mg; however, Km values for 
ammonia varied significantly from one amino acid to the next. Km values 
for the synthesis of L-alanine and glycine at pH 8 were 47.0±11.4 and 
527±149, respectively, while the Km value for L-serine at pH 9 was 150±21 
mM.  However, the Km[ammonia] value for the synthesis of L-norvaline was 
2231±544 mM, while the same parameter could not be determined for the 
synthesis of L-phenylalanine because the steady-state was never reached, 
regardless the concentration of ammonia. These values suggest that the 
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activity of the L-AlaDH is very sensitive to the concentration of ammonia, 
and such sensitivity strongly depends on the nature of the α-keto acid.33 
The Km[ammonia] values explain that high radiochemical yields are difficult 
to achieve with low enzyme concentrations at short reaction times both for 
[13N]glycine and L-[13N]serine. In the case of L-norvaline and L-
phenylalanine, high concentration of ammonia is required for the reaction 
to occur at reasonable reaction rates; consequently, no formation of the 
amino acid can be observed under radioactive (no-carrier added) 
conditions, due to the low concentration of [13N]NH3 in the reaction media, 
even when a large excess of enzyme was used in the reaction mixture.  
A similar effect was observed for the synthesis of L-serine at pH 8, which 
resulted in a Km[ammonia] as high as the one found for L-Norvaline, 
supporting the fact that, unlike L-[13N]alanine, L-[13N]serine was poorly 
synthesized at pH 8. The different Km[ammonia] values of L-AlaDH using 
different α-keto acids as amine acceptors suggest that the affinity of L-
AlaDH for ammonia depends on the positioning of the α-keto acid into the 
active site. This fact is crucial to the success of the radiochemical 
synthesis, where extremely low concentrations of ammonia are used. In 
the light of these results, we point out that those enzymes or those 
substrates that facilitate the binding of the labeling agent to the active site 
(low Km values), will lead to the best results in radiochemistry.  
In sum, we have herein described a one-pot methodology that is clearly 
superior to previously published enzymatic methods,34 and enables the 
preparation of L-[13N]alanine, [13N]glycine and L-[13N]serine with 
chromatographic yields >95% in short reaction times. Specific activity 
values were in the range 15-35 GBq/µmol.  
Synthesis of L-[13N]alanine with in situ NADH regeneration 
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With the aim of simplifying the purification process, we envisioned the 
possibility to use lower concentrations of the cofactor by introducing a 
second enzyme in the reaction media capable to in situ regenerate NADH. 
The selected enzyme was formate dehydrogenase (FDH) from Candida 
boidinii, which is known to catalyze the oxidation of formate to carbon 
dioxide, by donating the electrons to a second substrate, such as NAD+, 
regenerating thus NADH (see Figure 5.1b).  
 
 
Figure 5.7. Chromatographic yields for the production of L-[13N]alanine at 
different concentrations of NADH (black bars). Grey bars correspond to values 
under identical experimental conditions in the absence of FDH. Values are 
expressed as the mean ± standard deviation (n=3). The reactions were carried out 
in the presence of 20-25 MBq of [13N]NH3, 60 μg/mL of L-AlaDH, 0.01 to 
0.5mM of NADH, and 75 mM of pyruvic acid in 300 mM sodium phosphate 
buffer at 25ºC and pH 8. 
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The one-pot, bi-enzymatic reaction offered exceptional results. The 
concentration of NADH in the starting solution could be decreased by 50-
fold without a significant impact on chromatographic yields (Figure 5.6). 
The simultaneous addition of L-AlaDH and FDH led to the formation of 
L-[13N]alanine with chromatographic yields of 95±2% by using NADH 
concentrations as low as 10 μM. These values are three times higher than 
those observed without FDH under identical experimental conditions. The 
FDH is fundamental to replenish the pool of NADH by consuming formate 
as sacrificing substrate; in this manner, the reduced form remains available 
for the L-AlaDH to catalyze consecutive cycles of the pyruvate reductive 
amination. These results substantially improve the synthetic scheme 
described by Baumgartner et al.34 With our configuration, similar yields 
can be obtained but the concentration of cofactor is 100-fold lower.  
 
In vivo experiments 
Prostate cancer is the fourth cause of death by cancer worldwide, the 
second in the male population according to data published by the World 
Health Organization (WHO).35,36 Notably, prostate cancer incidence is 
dramatically increasing in western societies in the past decades, suggesting 
that this type of tumor is intrinsically sensitive to lifestyle changes.37 
Despite the good response to standard therapies, a high number of patients 
exhibit recurrence and develop metastatic disease after the failure of 
subsequent therapeutic regimens. Hence, the molecular aspects related to 
disease progression and therapy response remain unclear. Phosphatase and 
tensin homolog (Pten) is one of the most commonly deleted/mutated tumor 
suppressor genes in human prostate cancer.38,39 As a lipid phosphatase and 
a negative regulator of the PI3K/AKT/mTOR pathway, Pten controls 
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several cellular processes, including survival, growth, proliferation, 
metabolism, migration, and cellular architecture.40 On the other hand, 
cancer cells have altered metabolism and have well-known metabolic 
abnormalities. Cancer cells need a continuous supply of nutrients that 
maintain abnormal growth and rapid division during cancer progression 
and depend on a high rate of aerobic glycolysis for continued growth and 
survival. Recent advances in cancer biology and cellular immunity reveal 
that not only glucose but also amino acids are essential to support the high 
metabolic demands of the tumor.41,42 Because amino acids are the most 
highly consumed nutrients by cancer cells and biosynthetic pathways, they 
are always in demand for different cancer subtypes.43,44 These processes 
of differentiation, proliferation and metabolism of cancer cells can be 
understood by using PET imaging technique and metabolic radiotracers, 
specifically radiolabeled glucose and amino acids.45-48 The information 
obtained about metabolic alterations may aid the development of new 
therapies and tools for the early detection of cancer lesions.  
In this study, and taking advantage of a collaboration with Prof. Carracedo, 
we decided to explore the in vivo behavior of three enzymatically labeled 
amino acids (L-[13N]alanine, L-[13N]serine, [13N]glycine) in a mouse 
model of prostate cancer, created by depletion of the Pten which resembles 
the behavior of human prostate cancer. Before that, we explored the 
pharmacokinetics (PK) properties (mainly biodistribution) in healthy 
animals. [18F]FDG and [11C]Choline, typically used in the clinical setting 
for the detection of prostate cancer, were also used in the study with 
diseased animals for comparison. 
Starting from 225±25 MBq of cyclotron produced [13N]NH4OH (Volume 
of 100µL), 85±6 MBq of pure L-[13N]alanine, [13N]glycine and L-
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[13N]serine could be obtained using the enzymatic approach previously 
described. The labeled amino acids were obtained with >98% purity, with 
decay-corrected radiochemical yields close to 70% in overall production 
times of 10 min. Specific activity values ranging 15-35 GBq/µmol were 
achieved. 
PET studies were conducted also with [18F]FDG, a glucose analogue in 
which the hydroxyl group at the 2-position is substituted with an 18F atom; 
and [11C]choline, an 11C-labeled amino acid methyl typically used in the 
clinical setting for the detection of prostate cancer.49 These tracers are 
widely used in the clinical diagnostic field for the early diagnose of 
prostate tumors, as well as for the evaluation of the response to 
treatment.50-52 The basis behind accumulation of [18F]FDG in tumor tissues 
is well known (Figure 5.7). [18F]FDG is taken up and phosphorylated by 
cells through the same pathways as glucose, and finally trapped within the 
cells since the fluorinated and phosphorylated glucose cannot be 
metabolized in the glycolysis. As a result, [18F]FDG concentration 
increases proportionally with the utilization rate of glucose and 
consequently with the cell growth, and therefore it can be used as an 
indirect proliferation marker. On the other hand, [11C]choline incorporates 
into tumor cells through an active, carrier-mediated transport mechanism 
for choline and then is phosphorylated intracellularly by choline kinase, an 
enzyme frequently upregulated in human tumors, yielding phosphoryl 
[11C]choline (Figure 5.7).53 In turn, this phosphoryl [11C]choline is 
integrated into phospholipids in the cell membrane as part of 
phosphatidyl[11C]choline. As the proliferation of cancer cells is much 
higher than normal cells, tumor cells exhibit an increased rate of 
[11C]choline uptake and incorporation, allowing tumor imaging with PET. 
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Figure 5.8. Intracellular metabolism of [11C]choline and [18F]FDG. Both are 
taken up by cells by means of membrane transporters. Once into the cell, they are 
phosphorylated to phosphoryl[11C]choline  and [18F]glucose-6-phosphate, 
respectively. Then, phosphoryl[11C]choline is integrated into phospholipids in the 
cell membrane as part of phosphatidyl[11C]choline; [18F]glucose-6-phosphate 
does not undergo further metabolism and is trapped in the cell. 
 
In vivo biodistribution studies in wild-type mice 
Biodistribution of L-[13N]alanine, [13N]glycine and L-[13N]serine was first 
investigated in healthy animals. After image acquisition, volumes of 
interest (VOIs) were manually defined in the main organs on CT images 
and translated to the PET images for quantification, which resulted in time-
activity curves (TACs) as represented by L-[13N]alanine in Figure 5.8. In 
this case, only those organs clearly visualized on the CT images (lung, 
heart, kidney, liver, brain and bladder) were delineated. Very similar 
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biodistribution patterns were obtained for all the labeled amino acids. The 
presence of radioactivity was detected in the heart at short times after 
administration, confirming the presence of radioactivity in the blood. The 
values rapidly decreased from  ̴30 %ID/cm3 immediately after injection to 
approximately 2%ID/cm3, value that was maintained for a long period of 
time. The presence of radioactivity in heart suggests the long residence 
time of the labeled species in the blood-pool. At longer time points, a 
progressive accumulation of radioactivity in the liver was observed, 
consistent with the anabolic function of this organ, with values below 5% 
ID/cm3 for the case of L-[13N]alanine. The highest accumulation of 
radioactivity was found in the abdominal region, especially in the intestine, 
as already reported in previous biodistribution studies for other amino 
acids.45 Low accumulation of radioactivity was found in the brain, which 
may facilitate the potential localization of tumors in this organ. Normally, 
only the aromatic amino acids are presumed to influence brain function. 
The aromatic amino acids (e.g. tryptophan, tyrosine, phenylalanine) are 
the biosynthetic precursors for the neurotransmitters serotonin, dopamine, 
and norepinephrine. However, small neutral amino acids like alanine and 
glycine appear to be actively pumped out of the brain.54 
Elimination via urine was negligible in the time window of the study for 
[13N]alanine, with average accumulation around 1.5 ID%/cm3 (Figure 5.8 
and 5.9). A slow progressive elimination by urine was found to 
[13N]glycine. However, for L-[13N]serine, elimination via urine was 
preferential showing a high uptake in the bladder. This fact may limit 
application of this tracer to investigate the uptake in the prostate or prostate 
cancer. 
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Figure 5.9. Accumulation of [13N]alanine into the different organs after 
intravenous administration. Time-activity-curves are expressed as the percentage 
of the injected dose (%ID) per cm3 of tissue. [13N]alanine biodistribution in 
organs indicated above each panel. The Y axis scale is different in every graph.  
 
In vivo studies: Prostate-specific Pten deletion cancer model 
It is very well known that the amino acid transport is generally increased 
in malignant tumor cells.43 This enhanced transport may be associated with 
specific cell surface changes in cancer cells.44,55 Generally, the process of 
malignant transformation requires that cells acquire and use nutrients 
(glucose and amino acids) efficiently for energy, protein synthesis, and 
cell division. In this context, the amino acids transport is likely enhanced 
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in tumor cells to supply the upregulated amino acid metabolism and 
protein biosynthesis.  
 
 
Figure 5.10. Representative PET-CT images obtained after intravenous 
administration of L-[13N]alanine in mice. Coronal projections of PET images 
have been co-registered with representative CT slices for co-localization of the 
radioactive signal. Images correspond to data averaged in the following time 
frames: 0-30 s (a); 31-70 s (b); 71-230 s (c); 231-740 s (d); and 741-3020 s (e).  
 
The three amino acids (L-[13N]alanine, [13N]glycine and L-[13N]serine) 
labeled with nitrogen-13 by the action of L-AlaDH were tested in a 
prostate cancer mouse model, as potential imaging PET agents. Likewise 
[11C]choline and [18F]FDG, typically used in the clinical setting for the 
detection of prostate cancer, were also used in the study with comparison 
purposes. 
Upon intravenous administration, accumulation of radioactivity in the 
tumor could be observed for L-[13N]alanine and [13N]glycine (see Figure 
5.10). Visualization of the prostate after administration of L-[13N]serine 
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was not possible due to the abovementioned accumulation of radioactivity 
in the bladder. 
Precise quantification of the amount of radioactivity in the prostate was 
extremely challenging because the prostate could not be clearly visualized 
on the CT images. Hence, the images were only evaluated from a 
qualitative point of view. Visual inspection of PET images acquired after 
administration of L-[13N]alanine and [13N]glycine suggests a progressive 
accumulation of radioactivity in the prostate over time, regardless the 
presence of the tumour. However, such accumulation seems to be more 
significant in animals with tumour. Despite these promising preliminary 
results, further investigation is required in the future to assess the potential 
of the 13N-labeled amino acids as metabolic markers in this tumour type. 
The involvement of these two amino acids in the metabolism and 
proliferation of cancer cells is already known and studied by several 
investigators. Alanine has been already identified as an important non-
invasive biomarker for prostate cancer detection and characterization in 
magnetic resonance imaging and 1H high-resolution magic angle spinning 
(HR-MAS) spectroscopy.56,57 Likewise, glycine metabolism in cancer 
cells has been associated with cancer cell proliferation. It has been recently 
shown that glycine uptake and catabolism can promote tumorigenesis and 
malignancy, suggesting that glycine metabolism could in principle be a 
target for the design of innovative therapeutic and diagnostic 
strategies.26,58 
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Figure 5.11. Sagittal PET projections of control and cancer animals resulting 
from averaged images (frames 1-33) obtained after administration of [13N]-
labeled amino acids, [18F]FDG and [11C]choline. The position of the bladder and 
the tumour are indicated with white and red arrows, respectively. Co-registration 
with CT images of the same animal is shown for localization of the radioactivity. 
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Regrettably, high elimination via urine is consistently found for L-
[13N]serine, hampering the visualization of the prostate for the intense 
uptake of the labeled amino acid in the region. This is a non-essential 
amino acid that is biosynthetically linked to glycine, and both together 
provide the essential precursors for the synthesis of both folate and 
methionine. These biosynthetic routes are responsible for the synthesis of 
proteins, nucleic acids, and lipids, which are essential biological processes 
for the uncontrolled growth of cancer cells.26,59-61 Unfortunately, it was not 
possible to make use of L-[13N]serine to assess the metabolism of serine in 
cancer prostate of mice. However, low uptake of L-[13N]serine observed 
in the brain, neck, chest, pelvis, and extremities may open new 
opportunities to explore tumor localization in those areas. Many cancer 
cells are highly dependent on serine62 which can provide novel 
translational opportunities for imaging, drug development, dietary 
intervention, and biomarker identification of human cancers. 
Standard biodistribution of [11C]choline was observed: relatively high 
accumulation in the pancreas, liver and kidneys, and variable uptake in the 
bowel, with insignificant urinary excretion (Figure 5.10). Radiolabeled 
choline PET has been found to be useful in imaging prostate 
cancer.49,51,52,63,64 The biological basis of the radiolabeled choline uptake 
in tumors is the malignancy-induced upregulation of choline kinase, which 
leads to the incorporation and trapping of choline as phosphatidylcholine 
in the tumor cell membranes (Figure 5.10). Unpredictably, tumor uptake 
of [11C]choline in our prostate cancer model was almost inexistent. Hence, 
the low uptake of [11C]choline can be hypothetically explained by the 
hypoxia stage of the cancer cells in our animal model. According to Hara 
et al., hypoxic cells significantly incorporate less [11C]Choline, reflecting 
diverse biochemical responses to hypoxia.65 
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For [18F]FDG, the typical biodistribution pattern for this tracer was 
observed in our studies: high accumulation was detected in the kidneys 
and the bladder due to elimination mainly via urine, while significant 
uptake was also observed in the heart and the brain, organs which are 
known to consume a significant amount of glucose (Figure 5.10). Due to 
its high elimination via urine, [18F]FDG was mainly accumulated in the 
bladder, hampering thus visualizing proper visualization of the prostate 
and eventually the tumor, similarly to what we observed with L-
[13N]serine. 
 
CONCLUSIONS 
In conclusion, we have achieved a fast, efficient, and one-pot synthesis of 
L-[13N]alanine, [13N]glycine, and L-[13N]serine catalyzed by L-AlaDH and 
using NADH as redox cofactor and FDH as recycling enzymatic partner. 
The synthesis of L-[13N]alanine was significantly more efficient than the 
synthesis of [13N]glycine and L-[13N]serine. However, the synthesis of 
[13N]glycine and L-[13N]serine was successfully optimized by increasing 
the biocatalyst load in the reaction mixture. Unfortunately, the synthesis 
of artificial amino acids such as L-[13N]norvaline and L-
[13N]phenylalanine was not achieved under no-carrier-added conditions, 
due to the high Km values for ammonia.  
The synthesis of L-[13N]alanine was optimized by adding FDH to the 
reaction media in order to in situ regenerate NADH using formate as 
scarifying substrates for hydride transfer. This bi-enzyme system enabled 
the 50-fold reduction of NADH concentration in the reaction mixture 
without compromising radiochemical yields.     
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The utilization of the enzyme L-AlaDH shows an innovative synthetic 
strategy to manufacture ready-to-inject 13N-labeled amino acids (L-
[13N]alanine, [13N]glycine, and L-[13N]serine) in sufficient amount and 
purity to approach in vivo studies. Upon intravenous administration, L-
[13N]alanine shows an interesting selective accumulation in the prostate 
which seems to increase in the presence of tumors. On the other hand, 
[13N]glycine shows uptake in the healthy and cancer prostate. 
Unfortunately, L-[13N]serine is eliminated via urine hampering the 
visualization of the tumor progression, similarly to what we observed with 
[18F]FDG.  
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L-Alanine dehydrogenase from Bacillus subtillis has been intensively exploited in 
biocatalysis but its immobilized form is rarely used. In the present work, the 
immobilization of L-Alanine dehydrogenase from Bacillus subtillis on agarose 
microbeads activated with glyoxyl groups (aliphatic aldehydes) and other two carriers is 
presented. These immobilized enzyme preparations were extensively characterized 
towards temperature, pH and kinetic parameters. Finally, we have applied the optimal 
heterogeneous biocatalyst in the synthesis of L-[13N]alanine using pyruvate and 
[13N]NH4OH, as substrates. Herein, we have fabricated a highly stable and active 
heterogeneous biocatalyst for reductive aminations of -ketoacids that has an enormous 
potential in biocatalysis. 
Design and full characterization of L-Alanine 
immobilized on solid and porous materials
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INTRODUCTION 
As already described in Chapter 5, L-alanine dehydrogenase from Bacillus 
subtilis (L-AlaDH) was used for the radiochemical synthesis of a variety 
of L-[13N]amino acids with excellent radiochemical yields and purities.1 
Moreover, L-AlaDH from Bacillus subtilis has been also exploited as an 
auxiliary enzyme to replenish the amine donor (L-alanine) in 
transamination reactions catalyzed by ω-transaminases.2 These examples 
show the usefulness of this enzyme in synthetic chemistry. However, the 
use of enzymes in synthetic applications is frequently limited by their 
solubility and their low stability under operational conditions. 
These limitations underlying the vast majority of the native enzymes have 
been addressed at once by using immobilization techniques.3 Any 
immobilization technique overcomes the solubility problem; nevertheless, 
the immobilization itself does not guarantee the enzyme stabilization and 
sometimes reduces the catalytic activity of the enzymes.3,4 Enzyme 
immobilization is still considered an intuitive technique where the optimal 
immobilization protocol is often found using the trial-and-error approach. 
However, a deep understanding of the molecular structure of enzymes 
combined with spectroscopic tools enable appropriate characterization of 
the interactions between proteins and solid materials, as well as the 
evaluation of the effects that the immobilization causes on both protein 
structure and functionality.5 Such characterization can guide the 
optimization of the immobilization protocols to fabricate the most efficient 
heterogeneous biocatalysts.  
To the best of our knowledge, L-AlaDH has been only successfully 
immobilized on amine surfaces activated with glutaraldehyde6 and on 
sepharose microbeads activated with cyanogen bromide7. In the first 
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system, the immobilized enzyme retained more than 90% of its initial 
activity for weeks under storage conditions at 4°C, while in the second 
case, the enzyme kept 70% of its initial activity after one month at 37°C. 
In this chapter, L-Alanine dehydrogenase from Bacillus subtillis has been 
immobilized through different immobilization chemistries. Structural 
modeling of L-AlaDH supported by kinetic and fluorescence studies was 
also performed to understand how the immobilization reduces the enzyme 
activity but greatly increases the enzyme stability. Finally, to demonstrate 
the potential of this heterogeneous biocatalyst in the context of 
radiochemistry, the radiosynthesis of L-[13N]alanine was carried out. 
 
EXPERIMENTAL SECTION 
Reagents. β-Nicotinamide adenine dinucleotide, reduced disodium salt 
hydrate (β-NADH; purity >97%), pyruvic acid (CH3COCOOH, purity 
≥98%), ammonium chloride (NH4Cl, for molecular biology, purity 
≥99.5%), sodium phosphate dibasic (Na2HPO4, for molecular biology, 
purity ≥98.5%), sodium phosphate monobasic (NaH2PO4, purity ≥99.0%), 
L-alanine (purity ≥98%), SYPRO® Orange Protein Gel Stain and 
cyanogen bromide-activated sepharose 4B (Ag-CB) were purchased from 
Sigma Chemical Co. (St. Louis, IL, USA) and used without further 
purification. TALON resin was purchased from Clontech (Saint-Germain-
en-Laye, France). Bio-Rad Protein Assay Dye Reagent Concentrate was 
purchased from Bio-Rad Laboratories (Madrid, Spain). Agarose 4BCL 
microbeads (ABT, Madrid) activated with aldehyde groups were prepared 
as described elsewhere.8 All other reagents were of analytical grade. 
Chapter 6 
173 
Structural modelling of L-Alanine Dehydrogenase from Bacillus 
subtilis. Three different monomeric structural models of L-AlaDH based 
on sequence homology were built using as templates the alanine 
dehydrogenases from Thermus thermophilus, Mycobacterium 
tubercolosis, and Phormidium lapideum available in protein data bank.9 
The most accurate model was obtained by using the L-AlaDH from 
Phormidium lapideum (PDB: 1SAY) despite having lower sequence 
identity (58.86 %) with L-AlaDH from Bacillus subtilis primary sequence 
than the L-AlaDH from Thermus thermophilus (62.84 %). Finally, the 
hexamer of our L-AlaDH was constructed by using the biological 
assembly of Phormidium lapideum as a template. Protein models were 
visualized and aligned with their template structure by using PyMol 0.99 
developed by DeLano Scientific LLC (San Francisco, CA). The 
electrostatic potential and the local flexibility of the most accurate model 
were calculated by using the Bluues10,11 and COREX/BEST12 servers, 
respectively. 
 
Figure 6.1. Plot showing predicted local similarity of L-AlaDH enzyme model 
by the homology-modeling server from Expasy (predicted local similarity versus 
residue number). 
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Protein and enzyme colorimetric assays. Determination of the protein 
concentration. The protein concentration of soluble L-AlaDH and FDH 
were measured as described in Chapter 4 for eNR. Determination of 
enzyme activity. The enzymatic activities of soluble and immobilized 
preparations were carried as described in Chapter 7. 
Immobilization of L-Alanine Dehydrogenase from Bacillus subtilis. 
The immobilization of L-Alanine Dehydrogenase from Bacillus subtilis 
was performed on three different carriers: 1) porous 4BCL agarose 
microbeads activated with cyanogen bromide groups (Ag-CB); porous 
4BCL agarose microbeads activated with aldehyde (glyoxyl) groups (Ag-
G) and porous 6BCL agarose microbeads activated with cobalt-chelates. 
Ten milliliters of 16g per mL L-AlaDH solution was added to 1 g of the 
carrier (Ag-CB, Ag-G and Ag-Co2+). In the case of Ag-CB and Ag-Co2+, 
the enzyme solution was prepared in 25 mM sodium phosphate buffer at 
pH 8. For Ag-G, the enzyme solution was prepared in 100 mM sodium 
carbonate buffer at pH 10. The mixtures were incubated under gentle 
stirring for 2h at 25°C. Periodically, samples of the supernatants and the 
enzyme-carrier suspensions were withdrawn and analyzed to evaluate the 
progress of the immobilization reaction. After completion of the 
immobilization, the samples with Ag-G were reduced with 1 mg x mL-1 
NaBH4 during 30 minutes at 4°C, whereas the samples with Ag-CB were 
incubated with 100 mM of hydroxylamine for 1 hour at 25°C. All the 
immobilized preparations were filtered, washed with distilled water and 
finally equilibrated with 25 mM phosphate buffer solution at pH 8.  
Thermal Stability. Thermal stability was determined by incubating 
enzyme solutions or suspensions in 10 mM phosphate buffer at pH 8 and 
60°C for 24 h in a thermo-shaker. Samples were taken at 0.5, 1, 2, 4, 6, 
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and 24 h of incubation, and their residual activity was measured as 
described above. The experimental data were fitted to first-kinetic 
equation (A/Ao=e-k*t) using Origin 8.0. In this equation, A is the residual 
activity at different incubation times (t), Ao is the initial activity before 
incubations and k is the inactivation constant. 
Activity-pH profile. The effect of pH on the activity of different enzyme 
preparations was determined by measuring the reductive amination of 
pyruvic acid in the presence of NADH at the different pH values (5-10) at 
25°C. The expressed activity was measured as described before. Different 
10 mM buffer solutions were used to set the right pH value; acetate buffer 
was used for pH 5 and 6; sodium phosphate buffer for pH 7 and 8 and 
sodium bicarbonate buffer for pH 9 and 10.  
Fluorescence assays. Fluorescence Spectra were carried out with a 
Varioskan Flash fluorescence spectrophotometer (Thermo Scientific), 
using an excitation wavelength of 280 nm with excitation and emission 
bandwidths of 5 nm and recording fluorescence emission spectrum 
between 300 and 550 nm. All spectroscopic measurements were 
performed with a solution of 3g x mL-1 of the enzyme (soluble or 
immobilized) in 10 mM sodium phosphate at pH 8 and 25°C.  
Thermal-shift assay. This assay was performed using 3g x mL-1 of the 
enzyme (soluble or immobilized) in 25 mM sodium phosphate buffer and 
0.3% of SYPRO® Orange at pH 7. Then, this mixture was incubated in a 
StepOne-plus RT-PCR (Applied biosystems-ThermoFisher) by using a 
temperature ramp program from 25 to 95°C with a ramp rate of 0.5°C per 
minute.  
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Enzyme kinetic parameters. Michaelis constant value (Km) and 
maximum rate (Vmax) were determined by activity colorimetric assay at 
pH 8 and 25°C as previously described but using 0-1.8M ammonium 
chloride, 0-1mM NADH and 0-0.15M pyruvic acid. The experimental data 
were fitted to the Michaelis-Menten equation using Origin 8.0.  
Production of the radiolabeling agent [13N]NH3. Nitrogen-13 (13N) was 
produced in an IBA Cyclone 18/9 cyclotron via the 16O(p,α)13N nuclear 
reaction as described in chapter 5. Integrated currents around 0.2 μAh were 
used. The resulting solution was transferred to a 10mL vial and the activity 
was measured in a dose calibrator (Capintec CRC®-25 PET, New Jersey, 
USA). 
Synthesis of L-[13N]alanine. The radiosynthesis of L-[13N]alanine was 
carried out by adding 100µL of a mixture containing 0.5mM NADH, 
75mM pyruvic acid and 300mM sodium phosphate buffer solution at pH 
8 (final concentrations in reaction) to a solution or suspension containing 
L-AlaDH (concentration in the range 15-45 µg/mL) and 100µL of 
[13N]NH4OH (35-45 MBq). Reactions were conducted in test-tubes with 
50 KDa cut-off membranes in the case of the soluble enzymes and with 
micrometric filters in the case of immobilized. The corresponding mixture 
was incubated at 25°C under mild stirring for 2.5 to 20 min and 
subsequently filtered under centrifugation during one minute to remove 
the enzyme. 
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RESULTS AND DISCUSSION 
Immobilization of L-AlaDH on porous agarose microbeads activated 
with different reactive groups 
L-Alanine dehydrogenase from Bacillus subtillis was immobilized on 
porous 4BCL agarose microbeads activated with either cyanogen bromide 
groups (Ag-CB) or with aldehyde (glyoxyl) groups (Ag-G) and porous 
6BCL agarose microbeads charged with a tetradentate chelator charged 
with cobalt (AG-Co2+). At pH 8, the cyanogen bromide groups of Ag-CB 
react with the amine from the N-terminus of each subunit forming 
irreversible bonds,13 and the cobalt chelates on the agarose surface of Ag-
Co2+ preferentially interact with the imidazole rings of histidine tags 
located at the N-terminus of each subunit of L-AlaDH, creating reversible 
coordination bonds between the enzyme and the solid surface. On the other 
hand, the immobilization on Ag-G requires alkaline pH to enable the 
protein-carrier interactions. The aldehydes of the carrier form reversible 
imine groups with the primary amine groups of the enzyme (N-terminus 
and -NH2 from the most exposed lysines) that are finally reduced to 
irreversible secondary amines by using a mild reducing agent such as 
sodium borohydride.13  
As it can be seen at Table 6.1, 85-99% of the offered L-AlaDH was 
immobilized on the three carriers herein investigated, but the enzyme 
activity was reduced upon immobilization in all cases. Nevertheless, 
substantial differences were observed between the expressed activities of 
the enzymes immobilized on the different carriers; while the specific 
activity of L-AlaDH immobilized on Ag-CB was 67% of the soluble 
enzyme, L-AlaDH immobilized on Ag-Co2+ was 58% of the soluble 
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enzyme and L-AlaDH immobilized on Ag-G expressed 45% of the activity 
of the soluble one. 
 
Table 6.1. Immobilization parameters of L-Alanine Dehydrogenase from 
Bacillus Subtilis immobilized onto agarose porous microbeads activated with 
different reactive groups. 
CARRIER Reactive group Immobilization chemistry 
Immobiliz
ed Activity 
Ai (U/g)a 
Immobilization 
yield 
 (%)b 
Expressed 
Activity 
Ae (U/g)c/ 
(%)d 
Ag-CB Cyanogen Bromide 
Covalent bond through the primary amine 
group of the N-terminus 
 
55317 973 38587 (67) 
Ag-G Glyoxyl 
Multipoint covalent bond through the -NH2 
of the lysines  56679 8512 
295 4 
(45) 
Ag-Co2+ Cobalt (Co2+) Affinity binding through the His-tags  56411 992 
33920 
(58) 
aAi=The activity immobilized on 1 gram of carrier after the immobilization process. This activity was calculated as the difference 
between the offered activity and the activity in the supernatant after incubation with the carrier for 2h. bImmobilization yield () 
= (immobilized activity/offered activity) x 100. cThe expressed activity (Ae) is defined as the measured activity of the immobilized 
enzyme after washing. dRelative expressed activity (Ae) = (expressed activity/immobilized activity) x 100. 
 
Similarly, previous works have demonstrated that the immobilization of 
two homolog L-AlaDHs from Bacillus stearothermophilus6 and Bacillus 
cereus7 on Ag-CB and aminated glass beads activated with glutaraldehyde, 
respectively, recovered 50-60% of the specific activity. Remarkably, in the 
present work, the L-AlaDH retained 50% of its initial activity upon the 
immobilization on Ag-G under alkaline conditions. Such high activity 
recovery after irreversible covalent attachment using Ag-G carrier has also 
been observed with the glutamate dehydrogenase from Thermus 
thermophilus.14  The high stability of these two enzymes (L-alanine 
dehydrogenase and glutamate dehydrogenase) under alkaline conditions 
avoids their dramatic inactivation during the immobilization process at pH 
10.14,15 In contrast, lactate dehydrogenase from rabbit muscle loses 92% 
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of its initial activity upon immobilization on Ag-G without adding any 
enzyme stabilizers.16 
 
Prediction of L-AlaDH orientation and attachment on the surface of 
different carriers 
To better understand the molecular interaction between the L-AlaDH and 
the carrier, we built a structural model of the hexameric L-AlaDH. The 
model was built by using Swiss-Model Homology modelling server which 
utilizes structure-known proteins deposited in the protein data bank.17,18 
Moreover, we calculated the surface electrostatics10,11 and the residue 
exposure of this model in order to know which are the most exposed 
lysines with the lowest pKa values (-NH2) (Table 6.2).  
 
Table 6.2. Surface exposure and apparent pKa of the lysine residues found in L-
AlaDH from Bacillus subtilis. 
Position Calculated pKa Total Surface area 
32 11.686 188 
35 12.244 166 
87 11.19 226 
97 12.925 3 
99 12.226 50 
111 10.727 234 
132 11.027 123 
134 11.892 7 
174 10.922 347 
176 11.112 173 
179 12.564 124 
193 12.308 109 
208 10.814 155 
239 11.089 261 
268 12.502 214 
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Position Calculated pKa Total Surface area 
279 11.679 210 
282 10.683 230 
314 11.715 178 
351 11.774 142 
355 10.941 291 
The values presented in this table were calculated by Bluues server using the pdb file generated in Swiss-Model 
server. pKa value corresponds to the -NH2 of each lysine. Lysine residues with pKa lower than 11 are 
highlighted in red because they are predicted to be the most reactive ones under the immobilization conditions 
(pH 10) on Ag-G. These lysines are identified in the enzymatic model represented in Figure 5.1. 
 
The hexamer contains 120 lysine residues (20 per subunit) distributed 
along its 3D surface; 5 lysine residues per subunit (K111, K174, K208, 
K282 and K355) present apparent pKa values lower than 11. This means 
that under the alkaline immobilization conditions, those 5 lysines and the 
N-terminus will be the only primary amino groups majorly unprotonated 
and thus ready to react with aldehyde groups on the Ag-G surface. 
Moreover, the N-terminus and the lysines K111, K174, K282 and K355 
are fairly exposed to the solvent, which assures the geometrical 
congruence required for the immobilization reaction to take place.  
After visualizing the 3D-model of L-AlaDH, it was suggested that L-
AlaDH may be immobilized on Ag-G, Ag-CB and Ag-Co2+ through 
mainly one region, Orientation 1, that fairly displays 3 N-terminus and 6 
out of 30 most reactive lysines (3 x K111 and 3 x K351). Ag-CB and Ag-
Co2+ selectively attach the N-terminus, whereas Ag-G establishes bonds 
with the most reactive amine groups including N-terminus, K111 and 
K351. In addition, such region presents a suitable geometrical congruence 
(large flat surface) to attach at least 3 subunits to the solid surface (Figure 
6.2).  
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Figure 6.2. Different planes (orientations) of the L-AlaDH surface. The 
quaternary structure of L-AlaDH is formed by six subunits organized in three 
pairs of symmetrical faces giving rise to three different planar surfaces. None of 
the three faces displays more than three subunits with suitable geometrical and 
chemical congruence to react with the agarose surface. The 6 different subunits 
are colored in red, purple, violet, green, yellow and green, while all the active 
sites are colored in white. The N-terminus (Nt) and the -NH2 from the most 
exposed lysines with the lowest pKa values (calculated by Bluues server) are 
represented as blue spheres. The images were created with Pymol 0.99v.  
 
Kinetics parameters of L-AlaDH immobilized on different carriers 
The kinetics parameters of immobilized enzymes often differ significantly 
from those of the soluble enzymes. In our case, the immobilization of L-
AlaDH on different carriers affected the kinetics parameters of the 
reductive amination of pyruvate in different manners (Table 6.3).  
The catalytic efficiency towards NADH was significantly higher for the 
soluble enzyme than for the immobilized forms, mainly because the latter 
suffered a dramatic affinity loss for the redox cofactor (high Km). The 
higher Km values of the immobilized enzymes for NADH (up to 12.5-fold 
higher than the soluble enzyme) resulted in lower Vmax values for all 
substrates. This effect was less dramatic when the enzyme was 
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immobilized on Ag-CB; in this case, the immobilized enzyme presented a 
3.6 and 2.9-fold lower Km for NADH than the enzyme immobilized on Ag-
G and Ag-Co2+, respectively. Noteworthy, L-AlaDH immobilized on Ag-
G showed 8.5 and 3.4-fold lower Km values for pyruvate and ammonia, 
respectively, than the soluble enzyme. Therefore, the aldehyde chemistry 
seems to enhance the affinity of the immobilized L-AlaDH for both 
ammonia and pyruvate which improves the catalytic efficiency 110 and 
285%, respectively, with respect to the free enzyme. 
 
Table 6.3. Kinetic characterization of free and immobilized L-AlaDH from 
Bacillus Subtilis. 
 
Vmax 
 
Km 
mM 
Kcat 
s-1 
Kcat/Km 
s-1 x M-1 
NADH 
AlaDH soluble 31.05±2.29 0.02±0.008 1.37E+02 6.83E+06 
AlaDH Ag-CB 22.00±1.52 0.07±0.017 9.68E+01 1.38E+06 
AlaDH Ag-Co2+ 17.79±2.69 0.20±0.08 7.82E+01 3.89E+05 
AlaDH Ag-G 17.92±2.5 0.25±0.12 7.88E+01 3.15E+05 
NH4Cl 
AlaDH soluble 44.08±1.77 100.35±15.32 1.94E+02 1.93E+03 
AlaDH Ag-CB 39.45±2.52 120.86±28.02 1.73E+02 1.44E+03 
AlaDH Ag-Co2+ 14.90±0.62 29.91±6.80 6.55E+01 2.19E+03 
AlaDH Ag-G 14.02±1.20 29.16±6.53 6.24E+01 2.14E+03 
Pyruvic 
acid 
AlaDH soluble 55.39±2.20 0.17±0.04 2.44E+02 1.41E+06 
AlaDH CNBr 27.37±1.27 0.17±0.05 1.20E+02 7.10E+05 
AlaDH Ag-Co2+ 19.43±1.47 0.15±0.07 8.55E+01 5.84E+05 
AlaDH Glyoxyl 12.67±1.31 0.02±0.006 6.85E+01 4.03E+06 
 
In all the cases, the immobilization of L-AlaDH driven by either the N-
terminus, the His-tags or the primary amine groups with the lowest pKa 
seems to orient the protein through a region where none of the active sites 
directly contact with the carrier surface (Orientation 1, see Figure 6.2). 
Chapter 6 
183 
Contrarily, the cofactor binding regions of at least three subunits seem to 
interact with the carrier surface, which may hamper the interaction of the 
immobilized enzyme with NADH. This fact may explain the high Km 
values observed for NADH, which ultimately compromise the catalytic 
efficiency of the immobilized enzyme. Furthermore, the valence and the 
nature of the interaction between these protein regions and the carrier 
surface may differently distort tertiary and quaternary structures, thus 
explaining the changes in affinity observed for the other two substrates 
(ammonia and pyruvate). 
 
Protein thermal stability of immobilized L-AlaDH preparations 
The integrity of the protein structure under reaction conditions is 
fundamental to guarantee the protein stability during the operational 
process. L-AlaDH immobilized on different agarose-based microbeads 
was thermally inactivated at 60°C and compared with the soluble enzyme 
(Figure 6.3 and Table 6.4). 
Figure 6.3 shows that L-AlaDH immobilized on Ag-G, Ag-CB and Ag-
Co2+ were 23.8, 3.3 and 1.2-fold more stable than the soluble enzyme, 
respectively. Moreover, at higher temperatures L-AlaDH immobilized on 
Ag-G presented 53% of its initial activity after 30 minutes incubation at 
64°C, while the L-AlaDH immobilized on Ag-Co2+ and the soluble 
enzyme was almost completely inactivated (residual activity < 10%).  
 
 184 
 
Figure 6.3. Thermal inactivation of soluble and immobilized L-AlaDH. The 
different enzymatic preparations were incubated at 60°C and pH 8: Soluble L-
AlaDH (squares); L-AlaDH immobilized on Ag-CB (circles); L-AlaDH 
immobilized on Ag-Co2+ (diamonds); and L-AlaDH immobilized on Ag-G 
(triangles).  
 
Table 6.4. Kinetics parameters of the thermal inactivation of different L-AlaDH 
preparations. The thermal inactivation was carried out at 60°C and pH 8 during 
24h. 
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Carrier a 
Inactivation constant 
(h-1) 
Half-life time 
(h)b 
Stabilization factor c 
Soluble 0.38±0.04 1.82 - 
Ag-CB  0.11±0.02 6.07 3.3 
Ag-Co2+  0.31±0.02 2.22 1.2 
Ag-G  0.016±0.01 43.32 23.8 
a) Experimental data from Figure 5.2 was fitted with a First-order kinetics equation considering total 
inactivation (A/Ao=e-k*t). b) The half-life time was calculated introducing to the corresponding equation 
A/Ao=0.5. c) Stabilization factor means the half-life time of the corresponding immobilization preparation 
divided by the half-life time of the soluble enzyme. 
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To evaluate the effect of the thermal inactivation on the protein structure 
of L-AlaDH immobilized on Ag-G, the intrinsic fluorescence of soluble 
and immobilized enzyme on Ag-G were measured before and after 
incubation at 60°C for 4 hours (Figure 6.4A). 
 
 
Figure 6.4. (A) Intrinsic fluorescence of soluble and immobilized L-AlaDH. The 
intrinsic fluorescence of tryptophan was measured for soluble (black lines) and 
immobilized (grey line) enzymes before (solid line) and after (dash line) sample 
heating at 60°C and pH 8 during 4 hours. (B) The inset figure shows the 
normalized fluorescence of immobilized L-AlaDH before and after the 
inactivation. All fluorescence values were normalized regarding the fluorescence 
at λmax for each sample.  
 
In one hand, the immobilization of L-AlaDH promoted a 20nm blue-shift 
of λmax and 2-fold enhancement of the fluorescence intensity compared to 
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its soluble counterpart before thermal inactivation. These results suggest 
that L-AlaDH has suffered some conformational changes upon the 
immobilization that may explain the lower specific activity of the 
immobilized enzyme. The soluble enzyme presented 6% of its maximum 
fluorescence intensity and its λmax was 45 nm red-shifted after thermal 
incubation, suggesting large structural changes driving the protein to 
unfolded states. On the other hand, the maximum fluorescence intensity of 
L-AlaDH immobilized on Ag-G was reduced to 32% and the λmax red-
shifted 15 nm after the thermal incubation (inset Figure 6.4B). 
 
 
Figure 6.5. In silico representation of L-AlaDH local flexibility using a 
COREX/BEST server. (A) zoomed-in view of the interaction region of one 
subunit showing the highest density of low pKa amine groups. W and F residues 
are coloured in green; (B) rigid and flexible residues are coloured in red and 
yellow, respectively. Gradering between red and yellow (orange) represent 
moderately stable regions. The N-terminus (Nt) and the -NH2 from the most 
exposed lysines with the lowest pKa values (calculated by Bluues server) are 
represented as blue spheres. The images were created with Pymol 0.99v.  
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With the molecular model of L-AlaDH in hand, it was pointed that the 
fluorescence changes induced by thermal incubation may rely on some 
structural rearrangements that affect the protein environment of the unique 
tryptophan residue W90 (Figure 6.4). In the soluble enzyme, the loss of 
fluorescence intensity and the large red-shift of the λmax suggest that W90 
becomes dramatically exposed to the solvent. Contrarily, the 
immobilization of L-AlaDH on Ag-G seems to protect that region, 
alleviating the conformational changes in the vicinity of the W90 and 
resulting in a lower reduction in the fluorescence intensity and a smaller 
red-shift of the λmax.  
Finally, to rationalize why the immobilization on Ag-G through the 
proposed region increases the thermal stability of L-AlaDH, the residue 
stability constant of the L-AlaDH model was calculated by using 
COREX/BEST server.12,19 Figure 6.5B shows that the interaction region 
for Orientation 1 is composed of high, medium and low flexible local 
domains. Although, the most reactive groups (low pKa lysines and N-
terminus) are located in the most rigid domains, additional bonds can 
involve lysines from other domains with medium and high flexibility 
which promote an artificial rigidification of that region. However, since 
the immobilization on Ag-CB is restricted to the interactions with the N-
terminus of the enzyme (located at the rigid domains), further 
rigidification of the most flexible domains is more difficult. In fact, these 
results are supported by the SDS-PAGE analyses (Figure 6.6) that show 
how Ag-G irreversibly attaches the 6 subunits, while Ag-CB can only 
attach 2 out of the 6 subunits. SDS-PAGE studies showed that the 6 
subunits of L-AlaDH were irreversibly attached to Ag-G likely due the 
flexibility of the agarose fibers that may enable a 3D interaction between 
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less accessible and reactive lysines and the aldehyde groups of the carrier 
surface (Figure 6.6). 
 
 
Figure 6.6. (A) SDS-PAGE (14%) of L-AlaDH immobilized on Ag-CB and Ag-
G and their soluble references (Ref) for quantification. (B) Quantification of the 
number of subunits released under denaturing conditions (5 minutes at 99°C in 
presence of SDS-PAGE loading buffer). The quantification was carried out by 
image analysis quantifying the pixel intensity of the regions of interest shown in 
the gel picture. The raw data of each band was subtracted from the raw data of 
the background in order to only quantify the pixel intensity due to the protein 
stain. The reference was considered as the amount of protein corresponding to 6 
subunits.  
These results suggest that the most reactive amine groups can react with 
the carrier when the protein is in the bulk (inter-molecular reaction) 
driving the immobilization, but the less reactive lysines can only react with 
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the aldehydes when the protein surface has landed on the carrier surface 
(intra-molecular reaction). This fact was not observed when the enzyme 
was immobilized on Ag-CB, where only 2 out of 6 subunits were 
irreversibly attached to the surface according to electrophoresis results 
(Figure 6.6). 
Therefore, despite both aldehyde and cyanogen bromide chemistries seem 
to orient the protein through the same region, the immobilization on Ag-G 
may stabilize the quaternary structure and rigidify the most flexible protein 
domains resulting in increased protein stability. In this scenario, it was 
suggested that the valence of the attachment is making the difference in 
terms of protein stability. 
The higher thermal stability of the L-AlaDH immobilized on Ag-G 
compared to the soluble enzyme is also supported by thermodynamic 
denaturalization studies using a thermo-shift assay (Figure 6.7). The 
midpoint temperature where the protein suffers the hydrophobic exposure 
increased 1°C in the immobilized preparation, suggesting that the 
multivalent and irreversible immobilization on Ag-G stabilizes both 
tertiary and quaternary structures of L-AlaDH.  
In previous studies, the stability of L-AlaDH from Bacillus 
stearothermophilus immobilized on aminated glass beads activated with 
glutaraldehyde and the stability of L-AlaDH from Bacillus cereus 
immobilized on Ag-CB have been investigated under moderate 
temperatures (37°C) and storage conditions.6,7 Here, the stability of L-
AlaDH immobilized on Ag-G was stressed under high temperatures, 60°C. 
Our positive results suggest that the valence of the attachment promoted 
by Ag-G is making the difference in terms of protein stability compared to 
the carriers activated with cyanogen bromide and with glutaraldehyde 
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groups. These results agree with different studies using fluorescence and 
force spectroscopy that demonstrate that aldehyde chemistry achieves 
higher protein stabilization than the cyanogen bromide chemistry, as the 
first promotes multivalent interactions through short spacer arms.20,21 
 
 
Figure 6.7. Thermal denaturation of soluble L-AlaDH (black line) and L-AlaDH 
immobilized on Ag-G. The negative first derivative of fluorescence regarding the 
temperature was determined by measuring the fluorescence of the different 
samples in a thermal shift assay using SYPRO Orange dye and a Real-Time PCR 
system. The L-AlaDH preparations were incubated in 10 mM sodium phosphate 
at pH 8 and submitted a gradient of temperatures. 
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The immobilization chemistry affects the activity-pH profile of L-
AlaDH 
The activities of soluble and immobilized enzyme preparations under 
different pH conditions were also measured. It has been reported that the 
immobilization can improve the pH tolerance of enzymes.22 The soluble 
enzyme showed optimal reductive amination activity at pH values in the 
range 8-10 (Figure 6.8); such activity significantly decreased at pH lower 
than 7. The effect of the acidic pH was even more dramatic when L-AlaDH 
was immobilized on Ag-CB; this preparation showed optimal activity at 
pH 9, but its normalized activity considerably decreased at acidic pH 
values. Noteworthy, the immobilization of L-AlaDH on Ag-G yielded a 
highly robust enzyme that presents >75% of its optimal activity from pH 
6 to 10, with a broader optimal pH range (8-10) than the soluble enzyme. 
These data demonstrate that the reductive amination is favoured at alkaline 
pH values likely because of the high stability of the enzyme at high pH 
values. Contrarily, under acidic conditions, the soluble enzyme undergoes 
a dramatic inactivation as reflected in its activity-pH profile. Such 
inactivation can be mitigated by immobilizing L-AlaDH on Ag-G. Overall, 
our results clearly show that the immobilization on Ag-G is able to protect 
L-AlaDH against acidic pH, broadening the pH spectrum where the 
enzyme can be utilized. 
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Figure 6.8. Effect of pH on L-AlaDH activity. The activity of soluble L-AlaDH 
in solution (squares) and immobilized L-AlaDH on Ag-CB (circles) and Ag-G 
(triangles) were assayed at different pH by using the appropriate buffers at 25°C. 
Acetate buffer was used for pH 5 and 6; sodium phosphate buffer for pH 7 and 8 
and sodium bicarbonate buffer for pH 9 and 10.  
 
Biotechnological application of highly stable L-AlaDH immobilized on 
Ag-G in radiochemistry 
The immobilized L-AlaDH on Ag-G has shown an excellent thermal 
stability and acceptable activity for biotechnological purposes. Moreover, 
the 3-fold lower Km value towards ammonia makes this heterogeneous 
biocatalyst highly interesting to be used in the asymmetric reduction of -
ketoacids to synthesize L-[13N]amino acids using [13N]NH4OH as the 
radioactive precursor. In the radiochemical environment, the concentration 
of the radioactive precursor is rather limiting regarding the other 
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substrates, and hence biocatalysts with low Km value for ammonia are 
promising for this application. As a proof of concept, we radiosynthesized 
L-[13N]alanine with different biocatalyst loads in the presence of 75 mM 
pyruvic acid, 0.5 mM NADH and [13N]NH4OH (as a radioactive 
precursor) at pH 8. After 5 min, 45 μg of enzyme immobilized on Ag-G 
per mL of reaction achieved a 65% incorporation of the radionuclide; the 
yield could be increased up to 95% after 20 minutes of reaction. 
 
 
Figure 6.9. Reusing of L-AlaDH immobilized on Ag-G in the radiochemical 
synthesis of L-[13N]-alanine. The reaction was carried out with 45 g x mL-1 of 
immobilized biocatalyst at 25 ºC and pH 8 during 20 minutes. 
 
This immobilized enzyme showed unaltered efficiency in 5 consecutive 
operational batches (Figure 6.9). To the best of our knowledge, this is the 
first time that an immobilized L-alanine dehydrogenase is employed for 
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the one-pot/one-step reductive amination of pyruvate using [13N]NH4OH 
as amine donor and producing L-[13N]alanine. Another L-AlaDH from 
Bacillus species was used in its immobilized form for the selective 
deamination of L-[11C]alanine to synthesize [11C]-pyruvic acid6 and for the 
two-step synthesis of L-[15N]alanine from lactic acid7. Unlike L-AlaDH, a 
plethora of glutamate dehydrogenases from different sources have been 
immobilized on different carriers and applied to a variety of 
biotechnological applications.23,24 In particular, glutamate dehydrogenase 
covalently immobilized on Ag-CB and on silica beads have also been 
utilized for the synthesis L-[13N]amino acids. Depending on the systems 
and the amino acids produced, the radiochemical yield ranged between 35-
70% in short times (<5minutes).25 Our system achieves similar 
radiochemical yields after 5 minutes although performs worse than the 
soluble enzyme that can reach >95% of radiochemical yield in the same 
incubation time and with the same protein cocentration.1 
 
CONCLUSION 
Soluble L-alanine dehydrogenase from Bacillus subtilis has been 
intensively exploited in biocatalysis but rarely used as a heterogeneous 
biocatalyst. The immobilization of L-AlaDH on porous agarose 
microbeads activated with different reactive groups was performed. The 
immobilization of L-AlaDH on Ag-G greatly stabilizes the enzyme at the 
cost of activity reduction. Structural and conformational studies based on 
intrinsic fluorescence of both soluble and immobilized enzyme have 
demonstrated that protein inactivation is due to negative conformational 
changes induced by the temperature. The thermally-driven structural 
distortions are alleviated by the enzyme immobilization through a covalent 
Chapter 6 
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and multivalent attachment. Based on molecular modeling and physic-
chemical calculations, the region that is more prone to react with Ag-G 
was identified. The physic-chemical properties and local flexibility of such 
identified region suggest an excellent chemical and geometrical 
congruence that may rigidify some of the most flexible domains of the 
protein, thus increasing its thermal stability. Finally, a proof of the utility 
and reusability of this robust heterogeneous biocatalyst for the 
radiosynthesis of L-[13N]alanine was carried out showing excellent yields. 
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In this thesis, we have demonstrated that the application of biosynthetic 
methods enables the efficient and selective radiosynthesis of labeled 
compounds that would be hard to address by using chemical methods. The 
excellent results obtained herein rely on the capability of enzymes to 
catalyze a wide variety of chemical reactions and on their high regio-, 
chemo- and stereo-selectivity in the chemical processes. We have 
demonstrated that enzymes can be used either in their free form (in 
solution) or immobilized on a solid carrier. In the context of this PhD 
thesis, the enzymatic processes have been applied in the context of 13N 
radiochemistry. 
The main conclusions of the work conducted are: 
1- The selective radiochemical reduction of [13N]NO3- to [13N]NO2- 
can be achieved by using a NADPH-dependent eukaryotic nitrate 
reductase. Under optimal conditions, such reduction could be 
achieved in >90% radiochemical yield.  
2- By controlling the immobilization chemistry and physicochemical 
properties of the carrier, an optimal heterogeneous biocatalyst 
(Nitrate reductase immobilized in Ag-DEAE) with high potential 
in synthetic chemistry could be fabricated. The immobilized 
enzyme was 12-fold more stable than the soluble enzyme and could 
be re-used for the radiochemical reduction of [13N]NO3- up to 7 
cycles without compromising the efficiency of the reduction. 
3- The 13N-labeled radiotracer [13N]GSNO could be synthesized in 
95% chromatographic yield using the abovementioned 
immobilized enzyme, following a two-step chemo-enzymatic 
process and starting from cyclotron-produced [13N]NO3-. 
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4- A fast, efficient, and one-pot enzymatic synthesis of L-[13N]alanine, 
[13N]glycine, and L-[13N]serine was achieved using a NADH-
dependent L-AlaDH in 5 min reaction. This strategy is not suitable for 
the preparation of L-[13N]norvaline and L-[13N]phenylalanine under 
no-carrier-added conditions, due to the high Km values for ammonia. 
5- For the enzymatic synthesis of L-[13N]alanine, the addition of FDH to 
the reaction media to regenerate NADH enabled a 50-fold decrease in 
the concentration of NADH without compromising radiochemical 
yields  
6- Upon intravenous administration, L-[13N]alanine, [13N]glycine and L-
[13N]serine accumulate in the abdominal region. Contrary to L-
[13N]serine, L-[13N]alanine and [13N]glycine are not eliminated via 
urine and enable proper visualization of the accumulation of the tracer 
in the prostate. Visual inspection of the images suggests increased 
uptake of these amino acids in the prostate of animals with specific 
Pten deletion. 
7- The immobilization of L-AlaDH from Bacillus subtillis on Ag-G 
greatly stabilizes (approx. 24-fold more than soluble enzyme) the 
enzyme at the cost of activity reduction.  
8- Structural and conformational studies based on intrinsic fluorescence 
of both the soluble and immobilized forms of L-AlaDH have 
demonstrated that protein inactivation is due to negative 
conformational changes induced by the temperature.  
9- The thermally-driven structural distortions are alleviated by the 
enzyme immobilization through a covalent and multivalent 
attachment on Ag-G.  
10- This robust heterogeneous biocatalyst enables the radiosynthesis of 
[13N]amino acids with excellent yields (>95%).  
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List of abbreviations 
 
λmax Emission wavelength 
  
2D Two dimension 
3D Three dimension 
  
AADH Amino acid dehydrogenase 
Ag-CB  Cyanogen bromide-activated agarose  
Ag-Co2+ Cobalt agarose 
Ag-DEAE Diethyl-aminoethyl agarose  
Ag-DS Dextran-sulphate agarose 
Ag-G Glyoxyl agarose  
Ag-MANAE Monoaminoethyl-N-aminoethyl agarose  
Ag-PEI Polyethyleneimine agarose 
ATP Adenosine triphosphate 
  
BSA Bovine serum albumin 
  
CoA Coenzyme A 
CT Computerized tomography 
CY Chromatographic yield 
Cys Cystine 
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eNR Eukaryotic nitrate reductase 
  
FAD+ Flavin adenine dinucleotide 
FDA 5’-fluoro-5’-deoxyadenosine 
FDG Fluorodeoxyglucose 
FDH Formate dehydrogenase 
FDI 5'-fluoro-5'-deoxyinosine 
FDR 5´-deoxy-5’-fluoro-D-ribose 
FLPC Fast protein liquid chromatography 
  
GABA Aminobutyric acid 
Glu Glutamate 
GSH Glutathione 
GSNO S-nitrosoglutathione 
  
Hist Histidine 
HPLC High performed liquid chromatography 
HPLC-MS High-performance liquid chromatography-mass 
spectrometry 
HR-MAS 1H high-resolution magic angle spinning 
  
ID Injected dose 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
  
Km Michaelis constant 
KG Ketoglutarate 
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L-AAO L-amino acid oxidase 
L-AlaDH L-Alanine dehydrogenase 
LB Luria-Bertani media 
L-DOPA L-3,4-dihydroxyphenylalanine 
L-FMAU 2´-Fluoro-5-methyl-β-L-arabinofuranosyluracyl 
LOR Lines of response 
Lys Lysine 
  
MOCO Molybdenum cofactor  
MOF Metal organic framework 
MRI Magnetic resonance imaging 
  
NAD+ / NADH Nicotinamide adenine dinucleotide 
NADPH β-Nicotinamide adenine dinucleotide 2′-phosphate  
Nt N-terminus  
  
OD600nm Optical density of 600nm 
  
PDB Protein data bank 
PET Positron emission tomography 
PK Pharmacokinetics  
Pten Phosphatase and tensin homolog 
  
RNA Ribonucleic acid 
RT-PCR Reverse transcription polymerase chain reaction  
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SAM S-adenosyl-L-methionine 
SDS-PAGE Sodium dodecyl sulphate-Polyacrylamide gel 
electrophoresis 
SA Specific activity 
SPECT Single-photon emission computed tomography  
  
TFA Trifluoroacetic acid 
TOF Time of flight  
Trp Tryptophan 
  
UDP Uridine diphosphate 
UPLC Ultra-Performance Liquid Chromatography 
UV Ultraviolet 
  
Vmax Maximum initial velocity  
  
WHO World Health Organization 
  
 
 207 
Acknowledgments 
After more than 3 years in Donosti, now I am in the last stage of my thesis, 
and probably most difficult pages. So, last but not least, I would like to 
express my gratitude to all of you that directly or indirectly made this thesis 
a reality.  
First and foremost, I would like to express my gratitude to Prof. Manuel 
Martín Lomas and Prof. Luis M. Liz Marzán, former and current scientific 
directors of CIC biomaGUNE, respectively, for giving me the opportunity 
to develop the experimental work of this PhD in the outstanding facilities 
of the centre. 
As for you Dr. Jordi Llop and Dra. Vanessa Gomez-Vallejo, for giving me 
the opportunity to conduct this superb international PhD project. I am 
especially grateful to be given the chance to participate in high quality 
international congresses and meetings which opens my mind and sight to 
the world of Radiochemistry and Nuclear Medicine. Also to you, Jordi, as 
supervisor, I would like to thank you for the kindly suggestion of the 
subject of my thesis. Also, I thank you for your priceless support, 
observations, inspiration and valuable suggestions throughout the years of 
the thesis. Without your supervision, guidance, the achievement of this 
thesis would not have been possible. I thank you for providing me the 
opportunity to work with talented researchers. 
Furthermore, I would like to thank Dr. Fernando Lopez, who has been my 
teacher and supervisor in scientific and technical work with enzymes, for 
accepting this challenging collaboration. Fernando, thank you for your 
perseverance, tolerance and daily supervision. I also thank you for your 
excellent and tireless guidance and encouragement during this almost 3 
 208 
years of work together. All your exigent observations, comments and 
suggestions helped me to establish the overall direction of the research. 
You always were there when I need and you always found time for me in 
your busy agenda. 
I take this moment to shower my words of gratitude to all my past and 
present colleagues in the Radiochemistry & Nuclear Imaging Lab, Izaro, 
Ana, Carlos, Maria, Beatriz, Mikel Errasti, Mikel Gonzalez, Zuriñe, Aitor, 
Larraitz, Kiran, Jaya, Sameer, Unai, Xabi, Angel and Luis, it was a 
pleasure for me meeting you all here. Thank you all! 
To Zuriñe, I thank you for your help in all bureaucratic steps of my all my 
PhD, since the beginning to the end. 
Very warm and big thanks for the entire Fernando’s and Valery’s Lab 
colleagues, Susana (Chili girl), Anabel (Transformer), Laura, Ruta, Javi 
and Bea. Thank you for the warm welcome in your lab team!  I am very 
grateful that I made this adventurous journey with your company. I am 
very thankful for all pleasant and FUNtastic days we had in the lab. 
Couldn’t imagine a better place and better colleagues to work with.   
To my office mates, Maria, Dorleta, Unai, Manu, Andrea, Ana, Juan and 
Silvia for all the fun moments, support and exchanged knowledge. Thank 
you for sharing your space, food, brainstorms and thoughts! 
To RADIOMI family, thank you all for the amazing moments that we 
share over theses years during the meetings and schools! 
A special thanks to Ainhoa and Ander for your support during animal 
studies and Bogdan for imaging. Also, thank you all for the amazing 
moments and conversations! 
Acknowledgments 
209 
 
To the incredible people that I have the opportunity to meet in CIC 
biomaGUNE and made my days happier and fun, Ane, Macarena, Nina, 
Ana Percebom, Guocheng, Danijela, Richard, Maria Genua, Ana Sanchez, 
Marek, Luca, Eneko, Marga, Clara, Susana, Sindy, Dani, David, thank 
you!   
Personally, special thanks to Ane, Laura, Sónia, Susana, Anabel, 
Fernando, Maria Sanroman, Ana Sanchez, Aitor, for all the support in my 
down times. 
I would also like to thank all the people of administration (Sheyla, Paula, 
Charo), maintenance and other supporting departments. 
Of course, for you Laura, I have to thank you separately for finding time 
to draw all the calligraphy of this cover. Thank you for your astounding 
work! “Calligraphy is an art form that uses ink and a brush to express the 
very souls of words on paper.” K.A. 
I cannot find words to express my thanks to my right hand, my friend and 
my beloved boyfriend, Gonçalo. Thank you, a lot, for pushing myself to 
apply to this project. I cannot thank you enough for everything that you 
have support me during this walk. All your continuous encouragement, 
understanding, temperance, emotional support and, also, your professional 
appreciations and suggestions, made it possible!  
À minha fabulosa Mamy, gostaria de agradecer todo o incondicional apoio 
e amor ao longo desta aventura.  Por todas as inúmeras vezes que foste o 
meu pilar nesta árdua batalha. Sem ti e sem o teu suporte e amor não teria 
conseguido chegar até aqui. És a minha fonte de admiração e motivação! 
A ti Papy, sei que estás e estarás sempre lá onde quer que seja!  
 210 
O mesmo posso dizer a ti mana, cunhado e sobrinhas quero-vos agradecer 
a vossa amizade e o vosso carinhoso e sempre disponível apoio nesta 
minha etapa. 
A ti mano, futura cunhada e sobrinhos obrigado por toda a motivação e 
admiração. 
A todos os meus amigos que me acompanharam nesta batalha, obrigado 
pelo apoio e amizade, especialmente a ti Tininha, Susana, Rute e Tânia.  
Mila esker! 
Thank you all! 
Muito obrigado! 
Muchas gracias! 
 
 
 
 
Há coisas que nunca se poderão explicar 
por palavras… 
José Saramago 
Eunice Sofia da Silva Fernandes 
E-mail: eunicesofiasilva@gmail.com 
ACADEMICS 
CIC biomaGUNE/University of the Basque Country, UPV-EHU 
       PhD student in Synthetic and Industrial Chemistry; Marie-Curie Fellow within 
the Marie Skłodowska-Curie Innovative Training Network 
       RADIOMI project research- Innovative Radiochemistry to Advance   Molecular 
Imaging, FP7-PEOPLE-2012-ITN (www.radiomi.chem.ox.ac.uk) 
 Supervisor: Jordi Llop Roig, PhD and Fernando Lopez-Gallego, PhD 
San Sebastian, 
Spain,  
2013-2017 
University of Coimbra, Faculty of Pharmacy 
 MSc in Industrial Pharmaceutical Chemistry (grade: 18/20) 
 Supervisor: Prof. Carlos Cavaleiro, PhD 
 Collaboration with Chimie et Biomasse Group - CNRS 6134 of University of 
Corsica Pascal Paoli 
Coimbra, 
Portugal, 
2011-2013
University of Coimbra, Faculty of Pharmacy 
 Post-graduation in Industrial Pharmaceutical Chemistry (grade: 16/20) 
Coimbra, 
Portugal, 
2010-2011 
Health Science Technology School 
BSc in Pharmacy (grade: 17/20) 
Coimbra,  
Portugal 
2006-2010 
PROFESSIONAL SKILLS 
 Pharmacy:
o Laboratory (Techniques incl. analytical, for drug development and identification);
o Industry (GLP, GMP, synthesis, fractioning, quality control, dispensing and packing of
radiopharmaceuticals);
o Hospital (General: Traditional distribution; Replacement for stock levels; Unit Dose;
Pharmacotechnics, Visualization and support the preparation of cytostatics. Paediatric: Reception and
storage of orders; Traditional Distribution; Replacement for stock levels; Unitary Doses; Clinic;
Visualization and support in the preparation of cytostatics and support, and preparation of parenteral
nutrition bags.
o Community (Orders and receipt request; Checking stocks; Dispensing and counselling; Conducting
galenic formulations (Handled); Conducting Blood sugar, Cholesterol, Triglycerides and Blood
Pressure screenings; Prescription conference)
 Radiochemistry/Radiopharmacy: GLP/GMP synthesis, fractioning, quality control and dispensing of [18F]FDG
and others 18F and 11C radiopharmaceuticals; synthesis of radiotracers with PET isotopes; enzymatic catalysis in
the preparation of PET radiotracers; Quality Control (Development of analytical methods and labelling of new
molecules); Cyclotron operation.
 Chemistry: Chemical synthesis; Purification and structural analysis techniques (including but not exclusively,
Analytical and Preparative HPLC, NMR, mass and UV Spectroscopy, Confocal microscopy and Cell observer);
Design and development of new drugs: Scale of synthesis transposition.
 Biochemistry/biotechnology: Analytical techniques involved in natural, biotechnological compounds and
enzymes (Transformation and Expression of proteins; Fluorescence spectroscopy, SDS-page; Protein Thermal
Shift); Functionalization of solid materials for enzyme immobilisation.
 Physiotherapy: Thermotherapy (Paraffin, Parafango, Infrared); Electrotherapy (Ultrasound, Microwave,
Electrophoresis); Mobilization and Massage.
 Software: Microsoft Office, ChemDraw, Origin8, Graphpad, Photoshop, Illustrator CC adobe, Systems
Laboratory Techniques associated with the analysis GC, GC-MS, HPLC, NMR.
TEACHING EXPERIENCE 
Health Science Technology School, Coimbra 
  Invited Auxiliary Professor 
 Lecturer of Pharmacognosy Practice 
Coimbra, 
Portugal 
2012-2013 
PROFISSIONAL EXPERIENCE 
Syncom BV. 
  Chemical and pharmaceutical industry 
 Analytical Scientist 
Groningen, The 
Netherlands 
Since Jan2017 
Farmácia Luz Marques, Lda. 
  Community Pharmacy 
 Pharmacy Technician 
Penacova, Portugal 
2010-2013 
Drug Discovery group, Centre for Pharmaceutical Studies, Faculty of Pharmacy, 
University of Coimbra 
 Research 
       Student Researcher  
Coimbra, Portugal 
2011-2013 
Chimie et Biomasse Group - CNRS 6134 of University of Corsica Pascal Paoli 
 Research 
 Student Researcher 
Corsica, France 
2012 
Hospital Pediátrico de Coimbra 
 Hospital Pharmacy 
       Curricular training 
Coimbra, Portugal 
Nov2009-Jan2010 
Instituto de Ciências Nucleares Aplicadas à Saúde 
 Industry- Radiopharmacy Laboratory 
       Curricular training 
Coimbra, Portugal 
Sept2009-Nov2009 
Laboratório Militar e Produtos Químicos Farmacêuticos, Sucursal de Coimbra 
 Community Pharmacy 
 Curricular training 
Coimbra, Portugal 
Feb2009-April2009 
PUBLICATIONS 
As first author: 
Publication Biocatalysis in Radiochemistry; Enzymatic Incorporation of PET radionuclides into molecules of 
biomedical interest. Eunice S. da Silva, Vanessa Gómez-Vallejo, Fernando López-Gallego, Jordi Llop. Submitted 
Poster Communication: Efficient enzymatic synthesis of 13N-labelled amino acids and evaluation as diagnostic 
tools in a mouse model of prostate cancer. Eunice S. da Silva, Vanessa Gómez-Vallejo, Zuriñe Baz, Amaia 
Zabala, Arkaitz Carracedo, Fernando López-Gallego and Jordi Llop. ISRS 2017. Dresden, Germany 
Publication Structural, kinetic and operational characterization of an immobilized L-aminoacid 
dehydrogenase. Eunice S. da Silva, Vanessa Gómez-Vallejo, Jordi Llop, Fernando López-Gallego. Process 
Biochemistry, Available online 8 March 2017, In press  
Poster Communication: Efficient biosynthetic method for incorporating nitrogen-13 into aminoacids of 
biomedical interest in prostate cancer. Eunice S. da Silva, Vanessa Gómez-Vallejo, Zuriñe Baz, Amaia Zabala, 
Arkaitz Carracedo, Fernando López-Gallego and Jordi Llop. International Symposium: Molecular Imging Agents in 
Medicine, UMCG, The Netherlands. February 2017  
Publication: Efficient Enzymatic Preparation of 13N-labelled amino acids: Towards Multi-Purpose Synthetic 
Systems. Eunice S. da Silva, Vanessa Gómez-Vallejo, Jordi Llop and Fernando López-Gallego. Chemistry - A 
European Journal , 2016, vol.22, 38. 13619–13626 
Publication: Efficient nitrogen-13 radiochemistry catalyzed by a highly stable immobilized biocatalyst. Eunice 
S. da Silva, Vanessa Gómez-Vallejo, Jordi Llop and Fernando López-Gallego. Catal. Sci. Technol., 2015,5, 2705-
2713. 
Oral Communication: Efficient and sustainable synthesis of L-13N-Alanine catalyzed by heterogeneous 
biocatalyst. International Molecular Imaging Workshop 2015. CIC biomaGUNE, San Sebastian-Donostia. 
Oral Communication: Application of biocatalysis in sustainable Nitrogen-13 chemistry. 2nd Workshop UFI-
QOSYC, Pharmacy Faculty, UPV, Vitória-Gasteiz, Spain; 
Poster Communication: Biocatalyzed synthesis of L-13N-Alanine by L-Alanine dehydrogenase from bacillus 
subtilis. November 2015. bioMAPP15, CIC biomaGUNE, San Sebastian-Donostia 
Poster Communication: New advances in Nitrogen-13 chemistry: Preparation of 13N-labelled polysubstituted 
triazoles via Huisgen cycloaddition and biocatalyzed synthesis of L-13N-Alanine by L-Alanine 
dehydrogenase from bacillus subtilis. November 2015. ISAB, CIC biomaGUNE, San Sebastian-Donostia 
Poster Communication: Efficient [13N]nitrate reduction catalyzed by Aspergillus niger nitrate reductase 
immobilized on positively charged carrier. May 2015, University of Missouri, USA, ISRS2015 
Oral Communication: Combination of capillary GC, GC/MS and 13C-NMR for the analysis of the volatile 
extracts of E. dilatatum and E.pandanifolium. CEF2012. Eunice Fernandes, Lígia Salgueiro, Carlos Cavaleiro. 
Coimbra, September 2012. 
Poster Communication: Composition and variability of the volatile oils of Eryngium campestre. L. CEF2012. 
Eunice Fernandes, Lígia Salgueiro, Carlos Cavaleiro. Coimbra, September 2012. 
Poster Communication: Composition of the volatile oils of E. dilatatum Lam. and E. Pandanifolium. Cham. & 
Schltdl. 43rd International Symposium on Essential Oils (ISEO2012), Lisbon, 5-8 September 2012, Abstract Book, 
p. 155
Poster Communication: Composition of the volatile oil of Eryngium dilatatum Lam. 3PYCHEM no Porto. Eunice 
Fernandes, Lígia Salgueiro, Carlos Cavaleiro. Porto, May 2012. 
Publication: Current Radiopharmaceuticals. Positron Emitting Tracers in Pre-Clinical Drug Development. E. 
Fernandes, Z. Barbosa, G. Clemente, F. Alves and A. J. Abrunhosa, Volume 5, Number 2, April 2012. Pp.90-98 
Poster: PET and SPECT in Drug development and discovery of new drugs CEF2010, Faculty of Pharmacy, 
Coimbra. E. Fernandes, Z. Barbosa, G. Clemente.  
Poster: Synthesis of 18F-FDG on Synthera module XII National Congress of Nuclear Medicine, Portuguese 
Society of Nuclear Medicine. E.Fernandes, R.Vitório, J. P Oterelo, G. S. Clemente, M. C. Rodrigues, C. Guerreiro, 
A. Abrunhosa, A. Rodrigues. Mealhada, 2009 
Collaborations:  
Poster Communication: Automated synthesis box based on microfluidics for solid phase supported synthesis: 
application to 18F and 13N. 17th European Symposium on Radiopharmacy and Radiopharmaceuticals-ESRR'14. 
Jorge Elizalde, Javier Berganzo, Jesús M. Ruano-López, Vanessa Gómez-Vallejo, Kiran B. Gona, Beatriz 
Rodríguez, Ana Lima, Eunice Sofia da Silva, Jordi Llop. Pamplona, April 2014. 
AWARD 
MARIE CURIE Fellowship. September 2013 
Best Presentation Award Panel in "Drug Discovery", presented at the Conference CEF2012. September 2012 
LANGUAGES 
 Portuguese: Native.
 English: Pre-advanced level (oral and write communication).
 Spanish: Advanced level (oral and write communication).
 French: Low Intermediate level (oral and write communication).
ADDITIONAL INFORMATION 
Courses & Certificates: 
- RADIOMI School 4, CIC biomaGUNE, Donostia, Spain (2015) 
- RADIOMI School 3, University of Turku, Turku, Finland (2015) 
- RADIOMI School 2, VU University Medical Center, Amsterdam (2014) 
- Positron Emission Tomography: Technology and Application Course by Division  of Imaging Sciences and 
Biomedical Engineering, King’s College London, London, UK.(2014) 
- Training in Technology Transfer Project Management by ISIS Innovation, University of Oxford, Oxford, UK 
(2014) 
- RADIOMI School 1, Department of Chemistry, University of Oxford, Oxford, UK (2014) 
- Radioprotection and Security in radioactive facilities by CIC biomaGUNE, San Sebastian, Spain (2014) 
- Photoshop Course. (2013) 
- Injectable Administration Course by the Associação Portuguesa de Licenciados em Farmácia. (2012) 
- European Basic Life Support Course by Portuguese Red Cross School. (2011) 
- Magisterial Dermatology Formulation Course by Cofanor. (2011) 
- Sifarma 2000 Patients Tracking Course by Post Graduation Scholl of Health and Management. (2011) 
- European Course of First Aids by Portuguese Red Cross School. (2010) 
- Inhalation Therapy Course by Cofanor. (2010) 
- Initial Trainers Teaching Course by Conclusão - Estudos e Formação, Lda. (2010) 
- Veterinary Pharmacy Course by Health Science Technology School, Coimbra. (2010) 
- Homeopathy Course by Health Science Technology School, Porto. (2010) 
- Professional Formation on Recovery Massages by Sindicato Nacional de Massagistas de Recuperação e 
Cinesioterapeutas. (2005-2006) 
Other collaborations: 
- Collaboration in Pharmacy Introduction signature (Pharmacy graduation) with the lecture: “New job 
opportunities in Pharmacy”, November 2014 
- Member of the evaluation panel for the subject “Estágio II”, on ESTeS de Coimbra. 2011-2013 
- Organizing Committee of I Jornadas do Departamento de Farmácia da ESTeSC (Theme: "Community 
Pharmacy - Counselling and Health Care Provision"), position of secretary. 2009-2010 
- Organising Committee of Semana das Ciências Aplicadas na Saúde 2009 (SCAS 2009). 
